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1 
Head and neck cancer 
Epidemiology 
The mucosa of the head and neck region may undergo malignant 
transformation which will lead to head and neck squamous cell carcinoma 
(HNSCC). Most cancers that develop from the head and neck mucosa are 
squamous cell carcinomas (SCC), which account for 90% of all head and neck 
malignancies. Other encountered types of cancer include adenocarcinomas, 
sarcomas, malignant lymphomas, salivary gland tumors and bony and 
cartilaginous tumors. In this thesis the focus will be on HNSCC that may evolve 
from premalignant precursor lesions, detectable on the vocal cords and oral 
cavity because of early symptoms (e.g. hoarseness and macroscopically 
detectable mucosal patches such as leukoplakia). 
HNSCC is the sixth most common cancer type worldwide, with approximately  
686.000 new cases and 376.000 cancer deaths annually.1,2 A subdivision is 
made according to the anatomical site of the tumor, and includes amongst 
others the larynx, pharynx and oral cavity, including lip-tumors. Most frequently 
encountered is cancer of the oral cavity and lip with an estimated 300,000 new 
cases worldwide, followed by laryngeal cancer (157,000 new cases) and 
pharyngeal cancer (nasopharynx excluded, 142,000 new cases) in 2012.2 
HNSCC is encountered predominantly in men. Established risk-factors include 
tobacco use and alcohol consumption, which show a synergistic carcinogenic 
effect. Another risk factor is infection with oncogenic viruses, such as Human 
Papilloma Viruses (HPV) predominantly in oropharyngeal cancer and Epstein 
Barr Virus (EBV) in nasopharyngeal carcinoma.3,4 HPV positive HNSCC show 
in general a favorable survival compared to HPV negative tumors and should 
be considered as a separate biological entity of HNSCC.5,6 Also inherited 
mutations may lead to the development of HNSCC, such as those in the genes 
FANC, CDKN2A and p53 related to Fanconi anemia and Li Fraumeni.7-9 
Finally, an association between periodontal disease and HNSCC has been 
reported.10 
Anatomy of the head and neck 
The head and neck mucosa consists of squamous cell epithelium. It is part of 
the aero-digestive tract and is divided in different anatomical regions consisting 
of the larynx (including the vocal cords), the naso-, oro- and hypopharynx, oral 
cavity and nose and paranasal sinuses, which can be further divided in 
anatomical subregions. 
The larynx consists of three anatomical sub-regions: 1) the glottis containing 
the vocal cords and comprising the area up to 1 cm under the level of the free 
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edge of the vocal cords, 2) the supraglottis, including the valse vocal cords and 
the sinus of Morgagni, and 3) the subglottis existing of the region downwards of 
the cauda; border of the glottis to the level of the lower border of the cricoid 
cartilage, Figure 1.1A. 
The oral cavity comprises the lips, oral vestibule, alveolar processes, the teeth, 
cheeks, tongue, floor of the mouth, soft and hard palate and is dorsally 
bordered by oropharyngeal isthmus, Figure 1.1B. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1A Sagittal section of the neck with the main anatomical structures and subregions 
displayed.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1B The anatomical structures of the oral cavity and oropharynx. 
 
General introduction 
11 
1 
The head and neck region is characterized by different functionalities including 
breathing, chewing, swallowing, speaking and humidification and clearance of 
respired air, tasting and hearing. Based on the lymphogenic drainage of the 
head and neck different regions ranging from I to VI are defined, which reflect 
the lymph node metastasis pattern of malignancies per mucosal region, Figure 
1.2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2 Division of the neck in anatomical subregions I-VI, which is relevant for the metastasis 
pattern and the surgical treatment of locoregional neck metastases.  
 Source: Roodenburg JLN, Witjes MJH, Schepman KP. Oncologie. In: MKA Chirurgie. 
Ed. Stegenga et al. Van Gorcum, Assen, 2013 
 
Clinical presentation and prognosis 
Patients with HNSCC may present with a visible alteration of the mucosa, 
dysphagia, referred pain to the ear, a sore throat and hoarseness. Tumor 
spread in HNSCC generally occurs through lymphogenic metastasis to the 
adjacent neck lymph nodes, resulting in a mass in the neck of the patient, 
which may also be the first and only symptom of the disease. Lymph node 
metastasis may occur more easily if the tumor is localized in a region of the 
head and neck mucosa with an extensive lymphatic drainage, such as the 
(hypo)pharynx and supraglottic larynx (Figure 1.2). The prognosis of HNSCC 
patients depends largely on tumor localization and spread and the presence of 
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locoregional lymph node or distant metastasis, which is defined by the TNM 
classification and staging of the disease. Early stage HNSCC patients have in 
general a 60-95% overall survival rate in contrast with patients with stage III 
and IV disease which have a much worse survival rate of 25-30%.11-13 
Recently, it has been shown that HPV positive (oropharyngeal) tumors in 
general have a more favorable prognosis than HPV negative tumors with a 
comparable TNM classification, which implicates that the traditional TNM 
classification might not always provide adequate prognostic information in this 
HPV positive subgroup of patients.14 
Treatment options and factors influencing prognosis 
Treatment modalities for HNSCC include surgery, radiation therapy, 
chemotherapy, and targeted therapy, or a combination of these.5,6 In the last 
decades treatment morbidity of HNSCC could be reduced significantly because 
of medical progress, however, the 5-year survival rate of HNSCC could not be 
improved and still remains approximately 50%.1,15 Once a tumor has developed 
treatment results are rather disappointing. This might be explained by 1) late 
presentation of patients due to a late onset of complaints, which results in the 
majority of patients presenting with stage III or IV disease and locoregional 
metastasis at primary presentation,16 2) locoregional tumor recurrence after 
surgery or radiation therapy in up to 30%, due to minimal residual disease in 
tumor resection margins and/or the presence of premalignant lesions as a 
result of field cancerization,17,18 3) limitations of surgical resection and radiation 
therapy, taking into account functional organ preservation and individual patient 
factors and 4) disappointing results using the targeted therapeutic anti-EGFR 
agent cetuximab. Furthermore, approximately 15% of patients with HNSCC will 
develop a second or third primary tumor in the aero-digestive tract due to 
carcinogenic exposition by tobacco and alcohol consumption and field 
cancerization.19-22 Therefore recent health policies focus on primary prevention 
of HNSCC by an improvement of the awareness of the carcinogenic effect of 
especially tobacco and alcohol, which led to a decrease of non-HPV induced 
HNSCC in the USA. However, an increase of HPV-positive HNSCC is 
observed in the USA and Western Europe.23 Furthermore, effects of primary 
prevention need decennia to occur and only a part of all cancers can be 
prevented.  
Therefore, secondary prevention will always be of utmost importance. It 
consists of the prevention of malignant outgrowth of symptomatic premalignant 
head and neck lesions by their early detection and if necessary treatment. 
However, although many morphological alterations of the mucosa are 
macroscopically detectable, it is difficult to predict their risk of malignant 
transformation on the basis of histology.  
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Tertiary prevention should prevent the development of tumor recurrences after 
treatment of the primary tumor. Markers and methods to reliably differentiate 
between normal or non-progressive lesions and lesions at risk for malignant 
progression and/ or recurrence remain scarce.5,15,24-27 This thesis focuses on 
secondary prevention which is particularly useful in head and neck lesions 
because of the characteristics of head and neck carcinogenesis which will be 
described in the following section. 
Head and neck carcinogenesis- clinical and histopathological aspects 
It is assumed that HNSCC, in general, develop out of pre-existing precursor 
lesions, which can be present for many years before malignant transformation 
takes place. Precancerous lesions may clinically present as leukoplakia (“white 
patches”) or erythroplakia (“red patches”), of which the former are encountered 
much more frequently than the latter.28,29 Furthermore, oral submucous fibrosis 
may be distinguished as a precursor lesion.27 These clinical descriptions of 
lesions, have no direct correlation to histopathological features. Erythroplakias 
are most at risk for malignant transformation with risk-rates up to 90%28-30 
compared to 5-30% in leukoplakias.31-33 Nevertheless, the clinical impact of 
leukoplakia is larger because it is encountered far more often than 
erythroplakia. 
The gold standard for the classification of premalignant head and neck lesions 
is histopathological assessment of hematoxylin & eosin-stained tissue sections 
by light microscopic examination. Changes in the cell morphology and tissue 
architecture are generally referred to as dysplasia, which can be subdivided in 
different degrees according to the classification system used. The three most 
commonly used histopathological classification systems for head and neck 
precursor lesions are the WHO, SIN and Ljubljana system. 
WHO classification system  
The WHO classification system is worldwide the most applied classification 
system for (pre)malignant head and neck lesions. It comprises the 
morphological identification of hyperplasia, mild, moderate and severe 
dysplasia and carcinoma in situ (CIS) (Figure 1.3A-C). Reported malignant 
transformation risk for hyperplasia range from 0-3%, for mild dysplasia 0-30%, 
for moderate dysplasia 0-44%, for severe dysplasia 20-57% and CIS 0-80% for 
laryngeal lesions.34,35 For oral lesions a meta-analysis showed an estimated 
transformation rate of 10.3% for mild and moderate dysplasia and 24.1% for 
severe dysplasia and CIS, with a broad range of rates reported in the studies 
which were included.36  
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Squamous Intraepithelial Neoplasia (SIN) classification 
The SIN classification is mainly used for laryngeal lesions. It consists of three 
classes, i.e. SIN 1, 2 and 3, in which SIN 1 and 2 are comparable to, 
respectively, mild and moderate dysplasia of the WHO classification system 
and SIN 3 to both severe dysplasia and CIS (Figure 1.3A-C). A similar 
classification system is also used for uterine cervical intraepithelial lesions.34,37 
The reported malignant progression risk for laryngeal lesions varies from 5% 
(SIN 1) to 25% (SIN 2) and 11-25% (SIN 3).34,38  
Ljubljana Classification of Squamous Intraepithelial Lesions (SIL) 
This classification system is also mainly applied for laryngeal lesions and 
consists of 1) “simple” squamous cell hyperplasia without atypical cytologic 
changes, 2) “abnormal” basal/ parabasal cell hyperplasia, 3) “atypical” 
hyperplasia and 4) CIS, which requires treatment.34,39 The reported malignant 
transformation risk in laryngeal lesions varies from respectively 1.1% for basal/ 
parabasal cell hyperplasia to 9.5% for atypical hyperplasia.39 In oral lesions 0% 
is reported for simple or abnormal hyperplasia and 18.2% for atypical 
hyperplasia.40 Recently a modified Ljubljana 3-grade classification system for 
laryngeal lesions has been proposed.41 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3A Mild dysplasia (WHO classification) or parabasal hyperplasia (Ljubljana classification), 
characterized by an increased thickness of the epithelium and hyperkeratosis 
(Fleskens et al. Head Neck Oncol 2009 May 11;1:11). 
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Figure 1.3B Moderate dysplasia (WHO classification) or atypical hyperplasia (Ljubljana 
classification), characterized by blunt and elongated epithelial ridges and nuclear 
atypia confined to the lower epithelial half (Fleskens et al. Head Neck Oncol 2009 
May 11;1:11). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3C Severe dysplasia (WHO classification) or atypical hyperplasia (Ljubljana 
classification), characterized by morphological alterations involving the entire 
epithelial layer (Fleskens et al. Head Neck Oncol 2009 May 11;1:11). 
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Inter and intraobserver variability of histopathological assessment 
Existing classification systems do not allow for a reliable risk estimation of 
malignant progression and thus for an evidence based indication for treatment. 
Depending on classification system used a very broad range of malignant 
transformation risks for the different grades of dysplasia is found in literature. 
Furthermore, the comparison between studies remains difficult due to different 
study designs and inclusion criteria. Based on available data in the literature 
Fleskens et al.34 reported high interobserver variabilities, i.e. an overall kappa 
value of 0.32 for the reproducibility of the WHO classification in laryngeal 
lesions and kappa-values varying from 0.15-0.59 for lesions of the oral cavity 
and oropharynx. For the modified Ljubljana classification applied on 
premalignant laryngeal lesions Gale and colleagues (9 pathologists) reported 
kappa-values, varying from 0.68-0.81. Thus far, no kappa values are available 
for the SIN classification.   
A study performed on oral dysplastic lesions using the WHO classification 
criteria reported very poor kappa-values for intraobserver variability, ranging 
from 0.15-0.40 for exact agreement on the subclassification of dysplasia.42 
No studies on intraobserver variability in the histopathological assessment of 
laryngeal lesions are reported in literature.  
 
Thus, independent of the classification system used, the prediction of the 
malignant transformation risk of premalignant head and neck lesions on the 
basis of histopathological diagnosis alone remains a major challenge. 
Therefore, new indicators to reliably predict malignant progression are urgently 
needed. A better knowledge of the molecular mechanisms underlying the 
tumorigenesis of the head and neck mucosa is required to identify putative 
molecular biomarkers for this purpose. This will be described in the following 
section. 
Head and neck carcinogenesis - molecular biology 
Carcinogenesis is a complex process in which exposure to environmental 
carcinogens promotes the accumulation of changes on the gene and protein 
level of cells, generally leading to loss of cell cycle control (and induction of 
unlimited proliferation), loss of the capability to induce programmed cell death 
(apoptosis) and immortalization. In addition, processes such as angiogenesis, 
tumor invasion and metastasis may be induced. Underlying these tumor 
characteristics is the development of multiple molecular alterations that 
frequently lead to aneuploidy or chromosome instability, which is an increasing 
rate of losing or gaining whole (or large parts of) chromosomes during cell 
division.  
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Acquired molecular alterations, however, may not always lead to 
histomorphological changes and thus can remain unnoticed by 
histopathological assessment,43 while histomorphological changes may occur 
without molecular alterations. Additional hallmarks of cancer include the 
reprogramming of energy metabolism, evasion for immune mediated 
destruction and the participation of the tumor microenvironment including e.g. 
inflammatory cells.  
Many molecular genetic and gene expression studies have analyzed 
(pre)malignant lesions of the head and neck mucosa in order to identify 
molecular alterations underlying HNSCC pathogenesis and correlate them with 
clinical data, treatment outcome and patient survival.2,3,5,15,27,44-48 Although the 
exact sequence of molecular changes during carcinogenesis may vary in 
individual lesions, several recurrent molecular changes in (pre)malignant head 
and neck lesions have been identified. Figure 1.4 summarizes these molecular 
alterations underlying multistep tumor development and progression.15,49,50 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4 Summary of the genetic alterations that are observed at the different histopathological 
stages of head and neck carcinogenesis. (Dionne et al. Int J Cancer 2015 Feb 
1;136(3):503-15, with permission). 
 
 
Tobacco smoking and alcohol related HNSCC demonstrate near universal 
loss-of-function TP53 mutations and CDKN2A inactivation accompanied by 
frequent chromosome instability, including 3p and 9p loss and amplification of 
11q13 and 3q.47 In contrast, HNSCC infected with High-Risk HPV (HR-HPV, 
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predominantly HPV 16) are considered as a separate biological entity with a 
better overall prognosis and a different genetic profile compared to HPV 
negative tumors.14,51 These tumors inactivate p53 and pRb by expressing the 
viral oncoproteins E6 and E7, respectively, and show recurrent PIK3CA 
mutations, loss of TRAF3 and amplification of the cell cycle gene E2F1.47 
Because the emphasis of this thesis is particularly on the carcinogenesis of the 
larynx and oral cavity, in which HR-HPV does not play a prominent role,52,53 a 
summary is given below of the most frequently used detection methods and 
reported recurrent molecular changes in HNSCC tumorigenesis induced by 
smoking and alcohol consumption. 
Recurrent molecular changes in premalignant head and neck lesions 
Microsatellite analysis of chromosome loci 
With the use of microsatellite analysis, clonal changes (loss of heterozygosity 
(LOH), allelic imbalance, microsatellite instability) can be detected in extracted 
genomic DNA from (pre)malignant cells. LOH for alleles at chromosome 3p and 
9p21 are the most early and frequent events in head and neck lesions, and 
have already been detected in hyperplasia, mild dysplasia and even in normal-
appearing epithelial cells.54 These regions harbor well-known tumor suppressor 
genes, such as FHIT at 3p14, RASSF1A at 3p21 and p16INK4A and p14INK4B at 
9p21, indicating involvement of these genes in malignant transformation of 
cells. Indeed, precursor lesions with LOH at one of both loci showed cancer 
development in half of the cases in a retrospective study and, together with 
LOH at additional loci found to be involved in HNSCC development (at 4q, 8p, 
11q, 13q, 14q and/or 17p), these lesions showed 33-fold increases in relative 
cancer risk.49 These results were confirmed in a subsequent prospective study 
by Rosin et al. (2012).50 
Whole genome array CGH 
Genomic DNA from oral (pre)malignant lesions has also been used for  DNA 
profiling by means of array comparative genomic hybridization (CGH). Garnis 
et al.55 analyzed 86 oral (pre)malignant lesions and found a clear difference in 
the number of genetic alterations between low grade dysplasias that 
progressed into invasive disease and those that did not. Progressive low grade 
dysplasias showed complex patterns of genome alterations, including whole 
chromosome (arm) gains/amplifications and deletions as well as intra-
chromosomal segmental gains and losses, as was also observed in the higher 
grade dysplastic lesions. This study confirms the conclusions of earlier studies, 
that there are multiple genetic mechanisms involved in progression to invasive 
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oral cancer,26,46,50,56 and that markers for aneuploidy/chromosome instability 
should be effective to identify progressive head and neck precursor lesions. 
DNA cytometry - quantitative DNA analysis 
An alternative for using genomic DNA analysis for the assessment of 
aneuploidy/chromosome instability is the application of image-or flow cytometry 
to measure DNA content in cells of oral leukoplakia. These studies have also 
shown that DNA cytometry may be of value to detect aneuploidy as a risk 
marker for malignant progression.57-60 
Limitations of above mentioned techniques 
The use of microsatellite (LOH) analysis, array CGH and DNA cytometry, 
however, has limitations, e.g. failure to recognize cells at risk in DNA diploid 
lesions, in tissues with a high number of infiltrating lymphocytes or in tissues 
heterogeneous for aneuploid cells. Furthermore, the relatively large amount of 
cells (and tissue material) required for reliable detection of 
aneuploidy/chromosome instability can be a limiting factor in small formalin-
fixed, paraffin-embedded tissue samples. Therefore, alternative approaches 
have been utilized to study molecular alterations directly in morphologically 
preserved tissue. 
FISH analysis of chromosome copy numbers  
We and others have shown that numerical chromosomal aberrations as 
detected by Fluorescence In Situ Hybridization (FISH) in head and neck 
precursor lesions may have a predictive value for progression to carcinoma.61-
64 Numerical aberrations for chromosomes 1 and 7 are often detected in dysplasia 
and carcinoma in situ (CIS), whereas histologically normal mucosa and the 
majority of hyperplastic lesions do not contain these alterations.61 A ten-year 
translational study showed that besides LOH for 3p and 9p loci, as well as 
overexpression of the p53 protein, also polysomy for chromosomes 9 and 17 
strongly predicted cancer development.65 Poh et al.66 confirmed the reported 
value of chromosome 7 alterations for this purpose, and also showed that 
polysomy for chromosome 9 was less suitable due to the loss of chromosome 9 
sequences in many of these lesions. 
Immunostaining of p53 
The most frequent mutations that promote the development of chromosome 
instability in HNSCC are those in the TP53 tumor suppressor gene.67,68 P53 
gene mutations are present in up to 70% of HNSCC45,46,57 and can already be 
detected as an early genetic event in precursor lesions.22,69,70 P53 protein 
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overexpression in cell nuclei, as detected by immunohistochemistry (IHC), is 
frequently used as a biomarker predicting the presence of a TP53 gene 
mutation in the tissue. The presence of TP53 mutations and p53 
overexpression have also been proposed as markers to predict the risk of local 
relapse in head and neck precursor lesions as well as local recurrence in tumor 
adjacent mucosa.25,71,72 However, discrepancies have been reported 
concerning the value of p53 dysregulation in the detection of precursor lesions 
at risk for progression, because p53 accumulation may also be the result of 
cellular stress due to for example DNA damage or viral infection.5,46,69 
Furthermore, p53-negative lesions may exhibit undetectable truncated TP53 or 
p53-independent mechanisms leading to chromosome instability.67,70 Thus, the 
reliability of p53 overexpression as a single marker to identify a progressive 
premalignant lesion remains unclear as is the time a p53 mutation occurs 
within the sequence of genetic changes in head and neck 
carcinogenesis.15,22,26,69,73 
Other recurrent alterations 
Other proposed markers of malignant progression include 11q13 amplification, 
corresponding with the cell cycle regulation protein cyclin D1 (CCND1)74,75 and 
Fas-associated Death Domain (FADD), an adaptor protein for the cell death 
receptor,76,77 7p gain and amplification related to overexpression of Epidermal 
Growth Factor Receptor (EGFR),5,78 which plays an extensive role in cell 
signaling and growth79 and 18q21 loss associated with the tumor suppressor 
gene SMAD4.56 
Finally, during tumorigenesis telomerase is reactivated prolonging survival of 
cells, and is centrosome amplification observed in cells with aneuploidy/CI with 
genetic abnormalities and making accumulation of multiple genetic alterations 
possible.80,81 
In this thesis, the emphasis will be on analysis by FISH, which is ideal for small 
tissue sections such as laryngeal biopsies and does not influence the 
histomorphological appearance of the tissue and facilitates histopathological 
assessment. Other approaches, such as CGH and DNA ploidy analysis, which 
require larger tissue amounts are less suitable for laryngeal lesions. 
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Scope of this thesis 
Based on the previous overview on the currently available knowledge on 
histopathological and molecular changes found in premalignant head and neck 
lesions, the main aim of the studies of this thesis was to identify molecular 
markers in combination with routine histopathological assessment as potential 
prognosticators in the risk-counseling of premalignant head and neck lesions. 
Above all, the applicability in the clinical setting was taken into account. First, 
we applied a double target FISH approach using centromere probes for 
chromosomes 1 and 7 in order to detect numerical aberrations of one or both 
chromosomes. This technique gives a quick impression on the presence of 
chromosome instability and leaves the tissue morphology unchanged. 
Furthermore, it does not require large tissue samples. Second, DNA ploidy 
analysis using image cytometry was applied on oral lesions in order to assess 
the general ploidy status of a lesion and to compare the results with the results 
of our FISH analysis. Third, we applied IHC for the detection of different protein 
markers in premalignant laryngeal and oral lesions as well as in resection 
margins of Oral Squamous Cell Carcinomas (OSCC) in order to evaluate the 
association of overexpression with malignant progression as well as tumor 
relapse. The role of the gold standard of histopathological assessment of 
lesions was outlined and a suggestion for a progression model was posed. 
 
The following questions were addressed: 
1. Which histopathological classification method for premalignant laryngeal 
lesions gives the most uniform diagnosis, and which level of uniformity can 
be reached (interobserver variability)? 
 Three worldwide applied histopathological classification systems for 
premalignant head and neck lesions were compared with each other in 
terms of interobserver variability. Clinical consequences related to a 
different diagnosis of a lesion were high-lighted. 
2. Which biomarker(s) can reliably predict malignant progression in 
premalignant laryngeal lesions?  
 Chromosome 1 and 7 copy number analysis by FISH was compared with 
immunohistochemical analysis of p53, FADD, pFADD and CyclinD1 
expression. 
3. Which biomarker(s) can reliably predict malignant progression in 
premalignant oral lesions?  
 Chromosome 1 and 7 copy number analysis by FISH was compared with 
DNA ploidy detection using image cytometry. 
4. Can CI detection predict tumor recurrence in histopathologically tumor-free 
resection margins in oral squamous cell carcinoma (OSCC)? 
 
 
22 
 CI detection by FISH (copy number analysis of chromosomes 1 and 7) was 
compared with p53 immunostaining on resection margins of 
histopathologically radically resected OSCC and related to clinical 
outcome. 
5. Which evaluation method for CI detection by FISH is preferred to predict 
malignant progression of premalignant laryngeal lesions? 
 Two evaluation methods for CI detection by FISH (copy number analysis of 
chromosomes 1 and 7) were compared with each other and with 
histopathological classification to predict the progression of laryngeal 
precursor lesions to CIS/ cancer.  
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Abstract 
The objective of this study is to measure interobserver variability in the classification of 
laryngeal mucosal premalignant lesions by reassessing the histopathology of previously 
diagnosed cases and to determine the possible therapeutic consequences of 
disagreement among observers. Histopathological assessment of 110 laryngeal 
mucosal premalignant lesions was done by three pathologists. Each slide had to be 
classified according to the World Health Organization, Squamous Intraepithelial 
Neoplasia, and the Ljubljana Squamous Intraepithelial Lesions systems. After the 
independent assessment, a joint meeting took place. To assess the relation between 
histopathological grading and subsequent clinical management, we created a two- and 
a three-grade system besides one comprising all options. For all analyses, the 
SAS/STAT statistical software was used. The highest unweighted κ-values concerning 
the all-options system are observed for the Squamous Intraepithelial Neoplasia 
classification (0.28, 95% confidence interval 0.23–0.33), followed by the World Health 
Organization and Ljubljana classifications. For the two-grade system the Ljubljana 
classification shows the highest unweighted κ-values (0.50, 95%, 0.39–0.61), followed 
by the World Health Organization and Squamous Intraepithelial Neoplasia 
classifications. For the three-grade system, the unweighted j-values are similar. The 
implementation of weighted κ-values led to higher scores within all three classification 
systems, although these did not exceed 0.55 (moderate agreement). Given the high 
level of consensus, simultaneous pathological assessment may be said to provide 
added value in comparison with independent assessment. In the current study, no clear 
tendency is observed in favor of any one classification system. The proposed three-
grade system could be an improved histopathological tool because it is easier to 
correlate with clinical decision making and because it yields better unweighted κ-values 
and proportions of concordance than the all options system. Furthermore, clinical 
management could benefit from assessment by more than one pathologist in suspected 
cases of dysplasia or carcinoma. 
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Introduction 
Laryngeal mucosal premalignant lesions are seen frequently in clinical practice. 
They are defined as an altered epithelium with an increased likelihood of 
progression to laryngeal squamous cell carcinoma. The altered epithelium 
shows a variety of cytological and architectural changes that have traditionally 
been brought under the common denominator of dysplasia.1,2 Grading of 
dysplasia, including that of laryngeal lesions, continues to be a topic of debate. 
It is subjective and has been shown to lack intra- and inter-observer 
reproducibility, which may have significant therapeutic implications.3–7 To 
minimize both morbidity and mortality, it is highly important to detect the lesions 
at risk for malignancy in its earliest stage.8–10 Unfortunately, there is no 
universally accepted histopathological classification system. Moreover, there is 
no consensus on the diagnostic criteria for the various entities, particularly on 
criteria to differentiate severe dysplasia from carcinoma in situ. This is 
illustrated by the fact that during the last decades, more than 20 classification 
systems have been described for laryngeal mucosal premalignant lesions.3,11–15 
In the current literature and clinical practice, the 2005 World Health 
Organization, Squamous Intraepithelial Neoplasia, and the Ljubljana 
Classification of Squamous Intraepithelial Lesions systems are the most widely 
used and are considered the most relevant. So far, the reproducibility of one of 
these systems, the World Health Organization classification, has been 
evaluated for laryngeal lesions in just one published study.6 Thus, for the 
Squamous Intraepithelial Neoplasia and Ljubljana systems, no data are 
available on reproducibility for laryngeal lesions.  
The objective of the present study is to reassess the histopathology of 
previously diagnosed laryngeal mucosal premalignant lesions in order to 
measure the interobserver variability of the World Health Organization, 
Squamous Intraepithelial Neoplasia, and Ljubljana classification systems and 
to determine the possible therapeutic consequences of disagreement among 
observers. Moreover, a proposal to compensate for this variability is made to 
facilitate the use for clinical purposes. 
Materials and methods 
To set up an interobserver study on the histopathological assessment of 
laryngeal mucosal premalignant lesions, three pathologists with head and neck 
pathology as a field of interest (Marie-Louise van Velthuysen, Freek Bot, and 
Piet Slootweg) reviewed laryngeal mucosal premalignant lesions cases. 
Sections stained with hematoxylin and eosin (H&E) were obtained from the 
files of the Departments of Pathology at the Radboud University Nijmegen 
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Medical Center (n=60) and the Maastricht University Medical Center (n=50). 
The sections represented a range of diagnoses along the spectrum of laryngeal 
mucosal premalignant lesions. Table 2.1 gives an overview of the original 
histopathological diagnoses made according to the World Health Organization 
classification system.1 The 110 slides were selected by two investigators (Stijn 
Fleskens and Ewa Bergshoeff) who did not participate as one of the reviewing 
pathologists. Each pathologist independently reviewed the anonymized 110 
microscopic slides without any previous discussion and was completely blinded 
to the initial diagnosis and grade. No clinical information was provided with the 
cases. Each slide had to be classified according to the 2005 World Health 
Organization classification, the Squamous Intraepithelial Neoplasia 
classification, and the Ljubljana classification. The criteria they used were 
derived from the WHO-IARC blue book.1 
 
Table 2.1 An overview of the cases according to the original histopathological diagnosis. 
Original histopathological diagnosis Study population 
Number of cases 
Hyperkeratosis     3 
Inflammation     6 
Squamous cell hyperplasia   17 
Mild dysplasia   23 
Moderate dysplasia   32 
Severe dysplasia   16 
Carcinoma in situ   13 
Total 110 
 
 
The World Health Organization classification provides the following options: 
normal histopathology (hyperkeratosis); inflammation; hyperplasia; mild 
dysplasia; moderate dysplasia; severe dysplasia; carcinoma in situ; and 
squamous cell carcinoma. The Squamous Intraepithelial Neoplasia 
classification is slightly different: normal histopathology (hyperkeratosis); 
inflammation; SIN 1; SIN 2; SIN 3; and squamous cell carcinoma. The options 
in the Ljubljana classification are different again: normal histopathology; 
inflammation; squamous cell (simple) hyperplasia; basal/parabasal cell 
hyperplasia; atypical hyperplasia; carcinoma in situ; and squamous cell 
carcinoma. 
To calibrate the categories across the three systems and thus be able to 
compare the classification systems (Table 2.2), we used the proposal made in 
the WHO-IARC blue book and by Gale et al.1,16 All three pathologists were 
familiar with the different classification systems. The microscopic slides 
examined by the reviewers were those on which the initial diagnoses had been 
made. After the independent assessment, cases with different independent 
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diagnoses were randomly selected on the basis of the all-options system. At a 
joint meeting, this random selection was assessed by the three pathologists 
together in order to determine the degree of consensus, which serves as an 
indicator of the implications of having lesions reviewed by more than one 
pathologist simultaneously. 
Besides comparing all separate options of each system, we designed a two- 
and a three-grade system (see Table 2.2) to include clinical management in the 
histopathological grading.1,17 The two- and three-grade systems are based on 
the risk of malignant progression and its consequences for clinical practice: a 
‘low-risk’ group, not needing treatment based on grading, and a ‘high-risk’ 
group, requiring treatment, usually consisting of (laser) surgery or 
radiotherapy.4,18,19 In the ‘high-risk’ group, the three-grade system additionally 
distinguishes mild and moderate dysplasia from severe dysplasia, carcinoma in 
situ, and squamous cell carcinoma (World Health Organization); it also 
distinguishes SIN 1 and 2 from SIN 3 and squamous cell carcinoma 
(Squamous Intraepithelial Neoplasia), and it differentiates (atypical hyperplasia) 
dysplasia from carcinoma in situ and squamous cell carcinoma (Ljubljana). This 
further differentiation was made because in daily practice normal histology, 
inflammation, and hyperplasia (green segment in Table 2.2) are generally 
considered to require no periodic observation. In contrast, the other 
histopathological diagnoses do require at least periodic observation (yellow 
segment in Table 2.2) and treatment (pink segment in Table 2.2), respectively. 
 
Table 2.2 Overview of the scoring form and definition of a two- and three-grade system. 
WHO SIN SIL 
normal  normal  normal  
inflammation  inflammation  inflammation  
hyperplasia    squamous cell (simple) hyperplasia  
basal/parabasal cell hyperplasia  
mild dysplasia  SIN 1  
moderate dysplasia  SIN 2  atypical hyperplasia (dysplasia)  
severe dysplasia  
carcinoma in situ  
SIN 3  carcinoma in situ  
squamous cell carcinoma squamous cell carcinoma squamous cell carcinoma  
Two-grade system: 1) green 2) yellow + pink 
 
Statistical analysis 
The κ-statistics were calculated to assess the degree of interobserver 
agreement in the reporting of all options for each of the three classification 
systems and the derived two- and three-grade systems. The statistics describe 
the extent to which observers concur on a diagnosis, adjusted for levels of 
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agreement that are expected to occur by chance alone. The interpretation of κ-
values could not rely on any absolute definitions. According to Altman (slightly 
adapted from Landis and Koch20,21), κ-values <0.20 indicate poor agreement; 
0.21–0.4 fair agreement; 0.41–0.6 moderate agreement; 0.61–0.8 good 
agreement; and values 0.81–1.00 very good agreement. Standard weighted 
and unweighted κ-values and their 95% confidence intervals were calculated 
for each pair-wise comparison of the three pathologists. Weighted κ-values 
take into account the amount of disagreement between two raters when a 
scoring system has three or more categories, which means that more weight is 
given to a difference of more than one category than to a difference between 
raters of only one category.22 
All analyses were performed with SAS/STAT statistical software (SAS system 
8.2, SAS Institute, Cary, NC, USA). Generalized, unweighted κ-values for the 
three raters and their 95% confidence intervals were calculated using the SAS 
macro MAGREE. Finally, the proportion of total concordance among the three 
raters was calculated for each of the three scoring systems and the derived two 
and three-grade systems. 
Results 
Two cases were excluded from analysis because of insufficient quality of the 
H&E-stained sections. Two other cases were excluded because of insufficient 
laryngeal tissue in the H&E-stained sections. 
Unweighted and Weighted κ-Values 
Table 2.3 gives an overview of the unweighted and weighted κ-values with 95% 
confidence intervals. * Only unweighted κ-values are applicable for the two-
grade system. 
All options 
Comparison of the results using all grading options of the World Health 
Organization, Squamous Intraepithelial Neoplasia, and Ljubljana classification 
systems yielded the following overall unweighted κ-values: 0.21 (95% 
confidence interval 0.17–0.26); 0.28 (95% confidence interval 0.23–0.33); and 
0.19 (95% confidence interval 0.14–0.24), respectively. Weighted and 
unweighted κ-values for the pair-wise comparisons of the three are presented 
in Table 2.3. 
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Two-grade system 
Comparison of the results for the two-grade system for the World Health 
Organization, Squamous Intraepithelial Neoplasia, and Ljubljana classification 
systems gave the following overall unweighted κ-values: 0.44 (95% confidence 
interval 0.33–0. 55); 0.43 (95% confidence interval 0.32–0.54); and 0.50 (95% 
confidence interval 0.39–0.61), respectively. Weighted κ-values for the pair-
wise comparisons of the three observers are presented in Table 2.3. 
 
Table 2.3 Overview of the unweighted and weighted κ-values with 95% confidence intervals. 
 All options All options Two-grade* Three-grade Three-grade 
 unweighted weighted unweighted unweighted weighted 
WHO      
  Observer 1 vs. 2 0.25 
(0.14-0.36) 
0.50 
(0.39-0.60) 
0.47 
(0.29-0.64) 
0.37 
(0.22-0.51) 
0.50 
(0.37-0.62) 
  Observer 1 vs. 3 0.20 
(0.10-0.30) 
0.49 
(0.39-0.59) 
0.40 
(0.23-0.58) 
0.38 
(0.23-0.52) 
0.47 
(0.33-0.60) 
  Observer 2 vs. 3 0.21 
(0.11-0.31) 
0.48 
(0.37-0.58) 
0.45 
(0.28-0.63) 
0.42 
(0.28-0.57) 
0.53 
(0.40-0.66) 
  Overall 0.21 
(0.17-0.26) 
 0.44 
(0.33-0.55) 
0.39 
(0.31-0.47) 
 
SIN      
  Observer 1 vs. 2 0.24 
(0.13-0.35) 
0.45 
(0.34-0.57) 
0.41 
(0.23-0.59) 
0.35 
(0.20-0.50) 
0.48 
(0.35-0.61) 
  Observer 1 vs. 3 0.29 
(0.17-0.40) 
0.51 
(0.40-0.62) 
0.42 
(0.24-0.59) 
0.39 
(0.24-0.54) 
0.48 
(0.34-0.61) 
  Observer 2 vs. 3 0.33 
(0.21-0.44) 
0.52 
(0.41-0.63) 
0.46 
(0.29-0.63) 
0.45 
(0.31-0.59) 
0.55 
(0.42-0.68) 
  Overall 0.28 
(0.23-0.33) 
 0.43 
(0.32-0.54) 
0.40 
(0.32-0.48) 
 
Ljubljana      
  Observer 1 vs. 2 0.19 
(0.07-0.30) 
0.41 
(0.29-0.52) 
0.43 
(0.26-0.61) 
0.32 
(0.17-0.47) 
0.43 
(0.29-0.57) 
  Observer 1 vs. 3 0.23 
(0.12-0.34) 
0.43 
(0.32-0.55) 
0.49 
(0.32-0.66) 
0.46 
(0.32-0.61) 
0.54 
(0.40-0.68) 
  Observer 2 vs. 3 0.18 
(0.08-0.28) 
0.40 
(0.30-0.50) 
0.56 
(0.41-0.72) 
0.40 
(0.26-0.54) 
0.50 
(0.37-0.63) 
  Overall 0.19 
(0.14-0.24) 
 0.50 
(0.39-0.61) 
0.39 
(0.31-0.47) 
 
* Only unweighted κ-values are applicable for the two-grade system. 
 
Three-grade system 
Comparison of the results using the three-grade system for the World Health 
Organization, Squamous Intraepithelial Neoplasia, and Ljubljana classification 
systems gave overall unweighted κ-values of: 0.39 (95% confidence interval 
0.31–0.47); 0.40 (95% confidence interval 0.32–0.48); and 0.39 (95% 
confidence interval 0.31–0.47), respectively. Weighted and unweighted 
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κ-values of the pair-wise comparisons of the three observers are presented in 
Table 2.3. 
Proportion of Concordance 
Table 2.4 shows the proportion of concordance among the pathologists for the 
three classification systems. The proportions using all grading options of the 
World Health Organization, Squamous Intraepithelial Neoplasia, and Ljubljana 
classification systems were 13% (95% confidence interval 7–20), 24% (95% 
confidence interval 16–32), and 17% (95% confidence interval 10–24), 
respectively. Using the two-grade version of the World Health Organization, 
Squamous Intraepithelial Neoplasia, and Ljubljana classification systems, the 
proportions of concordance were 60% (95% confidence interval 51–70), 60% 
(95% confidence interval 51–70), and 62% (95% confidence interval 53–72), 
respectively. The proportions for the three-grade version of the World Health 
Organization, Squamous Intraepithelial Neoplasia, and Ljubljana classification 
systems were 42% (95% confidence interval 33–52), 43% (95% confidence 
interval 34–53), and 47% (95% confidence interval 38–57), respectively. 
 
Table 2.4 Proportion of concordance among the three pathologists and 95% confidence 
intervals. 
 All options Two-grade Three-grade 
WHO  13% (7-20) 60% (51-70) 42% (33-52) 
SIN   24% (16-32) 60% (51-70) 43% (34-53) 
Ljubljana   17% (10-24) 62% (53-72) 47% (38-57) 
Simultaneous Pathological Assessment at the Joint Meeting 
World Health Organization 
A total of 45 cases with different independent diagnoses that had been made 
on the basis of the all-options system were selected randomly. Consensus 
could be achieved in 37/45 (82%) of the cases. 
Squamous Intraepithelial Neoplasia 
A total of 47 cases with different independent diagnoses based on the all-
options system were selected randomly. Consensus could be achieved in 
37/47 (79%) of the cases. 
Ljubljana 
A total of 40 cases with different independent diagnoses made on the basis of 
the all-options system were selected randomly. Consensus could be achieved 
in 28/40 (70%) of the cases. Regarding the World Health Organization and 
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Squamous Intraepithelial Neoplasia classifications, the clinically relevant 
differentiation between moderate and severe dysplasia (SIN 2 or 3) was the 
main source of disagreement. Consensus could not always be reached in 
these cases, as illustrated in Figure 2.1. For the Ljubljana classification, the 
clinically relevant differentiation between (para)basal and atypical hyperplasia 
turned out to be the most difficult for the raters, as illustrated in Figure 2.2. 
Discussion 
In this report, the histopathology of previously diagnosed laryngeal mucosal 
premalignant lesions was reassessed by three experienced head and neck 
pathologists. The purpose was to measure the interobserver variability of the 
three most frequently used classification systems. In this study, these systems 
have been assessed using all their original categories. Alternatively, a two- or 
three-grade system has been used, clustering the categories according to the 
clinical consequences each one would have. When comparing the results of 
the current study with the literature, we noted that the only available similar 
study—by McLaren et al,6 based on 100 laryngeal biopsies—published a κ-
value of 0.32 using all grading options and 0.52 for a two-grade system using 
the World Health Organization classification. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1 Photomicrograph showing a mucosal lesion for which no consensus could be reached, 
opinions differing between moderate or severe dysplasia/SIN 2 or 3 (World Health 
Organization and Squamous Intraepithelial Neoplasia classifications). 
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Figure 2.2 Photomicrograph showing a mucosal lesion for which no consensus could be reached, 
opinions differing between atypical versus basal cell hyperplasia (Ljubljana 
classification). 
 
 
No 95% confidence intervals were given in that study. In comparison, when we 
used the World Health Organization classification, we found an overall 
unweighted κ-value for all options of 0.21 (95% confidence interval 0.17–0.26). 
Our weighted κ-values ranged from 0.48 (95% confidence interval 0.37–0.58) 
to 0.50 (0.39–0.60). Using the two- or three-grade system gave an overall κ-
value of 0.44 (95% confidence interval 0.33–0.55) and 0.39 (95% confidence 
interval 0.31–0.47), respectively. The implementation of weighted κ-values led 
to higher values for all three classification systems. However, they did not 
exceed 0.55, corresponding with moderate agreement by Altman’s criteria.20,21 
Concerning the proportion of concordance for the two- and three-grade system, 
it should be noted that in 38–40% and 53–58% of the cases, respectively, the 
three pathologists disagreed. The proposed two or three-grade system is 
based on the presumed chance of malignant progression and its implications 
for clinical practice: ‘low risk’ with mainly periodic observation in comparison 
with ‘high risk’ requiring (laser) surgery or radiotherapy. By extension, the 
clinical consequences would be either overtreatment (i.e., surgery or 
radiotherapy instead of periodic observation) or undertreatment (i.e., periodic 
observation instead of surgery or radiotherapy). Either way, the therapeutic 
implications would be significant. In that light, there is a need for additional 
tools to identify which lesions would and which would not become malignant if 
left untreated. 
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In our review of the literature, we noted that other authors have also proposed 
or investigated a binary or two-grade system to classify head and neck 
mucosal premalignant lesions.4,6,16,23 Gale et al.16 concluded that the results of 
a long-term follow-up study of 1268 patients once again justify the proposal of 
the Ljubljana classification. It entails dividing the morphological criteria into two 
basic groups: benign (squamous hyperplasia and basal/ parabasal hyperplasia) 
and potentially malignant (atypical hyperplasia). It has been customary to use 
relatively few categories (three or two) and to assess accuracy by measuring 
interobserver agreement with κ-statistics. The extent of interobserver 
agreement is often less than anticipated when carefully controlled studies are 
undertaken, and there has been a tendency to recommend the use of fewer 
categories.6,23–26 However, according to Deolekar and Morris,24 the policy to 
lower the degree of inter- and intra-observer disagreement by reducing the 
number of subjective categories is misleading. Although acknowledging the 
importance of grading pathological continua, they concluded that information is 
lost when too few categories are used. The judgment should be cited along 
with a confidence interval so as not to imply a degree of accuracy that cannot 
be achieved. Some have argued that it would be logical to use more categories 
and to give the clinician a range of values within which the true value will lie (a 
90, 95, or 99% confidence interval).24,27 Shannon28 measured information on a 
binary system. One bit of information reduces uncertainty by one-half, two bits 
reduce it to one-quarter of the initial level, and three bits reduce uncertainty to 
one-eighth. 
We prefer a three-grade system because of the correlation with daily clinical 
practice (no periodic observation, periodic observation, and treatment ((laser) 
surgery or radiotherapy). We would rather avoid the use of only two categories. 
Furthermore, our current study shows higher unweighted κ-values and 
proportions of concordance than found with the all-options system. 
Comparison of the categories within the different systems has prompted 
discussion on the position of atypical hyperplasia in the Ljubljana classification. 
This category showed an overlap with moderate as well as severe dysplasia. 
Therefore, no optimal discrimination is possible between grades 2 and 3 
(yellow and pink segment in Table 2.2). 
In the current study, the highest κ-values for the all-options system are found 
for the Squamous Intraepithelial Neoplasia classification, followed by the World 
Health Organization and Ljubljana classifications. For the two-grade system, 
the Ljubljana classification has the highest κ-values, followed by the World 
Health Organization and Squamous Intraepithelial Neoplasia classifications. 
The κ-values are similar for the three-grade system. As the 95% confidence 
intervals show some overlap, as seen in Table 2.3, no statistically significant 
(P<0.05) differences are found among the three classification systems. In the 
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future, a similar study based on more cases might demonstrate statistically 
significant differences. 
Furthermore, because of a high level of consensus, the simultaneous 
pathological assessment had added value in comparison with independent 
assessment. A consequence could be to advise assessment by more than one 
pathologist for suspected cases of dysplasia or carcinoma. Similar proposals 
are found in current guidelines for esophageal and colonic premalignant 
lesions.29–31 
Montgomery32 suggested that we should look beyond the problem of 
interobserver variability in the diagnosis of esophageal dysplasia. He thinks 
that sampling error on the part of endoscopists is probably more serious a 
problem than observer variation among the pathologists who are reviewing 
patient samples. However, this possibility would only make the diagnosis of 
premalignant lesions even less reliable and offers no excuse for the observer 
variation. In our opinion, the identification of patients with intermediate-level 
laryngeal dysplasia and high risk of malignancy is a multidisciplinary challenge 
for both clinician and pathologist, a claim that has been made before.6 The 
necessity or urgency to treat a laryngeal mucosal premalignant lesion is 
dependent on several factors: the (voice) complaints of the patient and the risk 
of progression to invasive cancer or the risk that the sample is not 
representative for the entire lesion. In the absence of reliable biological 
markers, the grade of dysplasia is still the most often used parameter to guide 
the treatment decision. Realizing that clinicians should be aware of the fact that 
sampling errors may occur and that the determination of the grade of dysplasia 
is variable. In case of suspicion of a sampling error, a re-biopsy or more 
extensive surgery should be considered. 
Conclusion 
In the current study, we have observed no clear tendency in favor of one 
particular system for classifying laryngeal mucosal premalignant lesions. The 
weighted κ-values did not exceed 0.55, indicating only moderate agreement 
and underscoring the assertion that current clinical management is in need of 
additional tools to identify lesions that would or would not become malignant if 
left untreated. The proposed three-grade system could be useful because of its 
correlation with daily clinical practice (no periodic observation, periodic 
observation, and treatment). Another advantage is that it yields better 
unweighted κ-values and a higher proportion of concordance in comparison 
with the all-options system. Moreover, because of a high level of consensus, 
simultaneous pathological assessment provides added value in comparison 
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with independent assessment. Therefore, assessment by more than one 
pathologist might be advisable for suspected cases of dysplasia or carcinoma. 
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Abstract 
Aims 
Because the histopathology of premalignant laryngeal lesions does not provide reliable 
information on the risk of malignant transformation we examined new molecular markers 
which can easily be implemented in clinical practice.  
 
Methods 
Dual-target Fluorescence In Situ Hybridization (FISH) for chromosome 1 and 7 
centromeres was performed on tissue sections of laryngeal premalignancies of 69 
patients. Chromosome Instability (CI) was indicated by numerical imbalances and/or 
polysomy for chromosomes 1 and 7. Additionally, immunostainings for p53, Cyclin D1 
and (p)FADD expression were evaluated. Malignant progression was recorded. 
Eighteen patients with carcinoma in situ (CIS) were treated after diagnosis and excluded 
from follow-up.  
 
Results 
CI was strongly associated with a high risk of malignant transformation, especially in 
lower-grade lesions (hyperplasia, mild and moderate dysplasia; Odds Ratio = 8.4, 
P=0.004). Patients with CI-containing lesions showed a significantly worse 5-year 
progression-free survival than those with premalignancies without CI (P=0.002). Neither 
histopathology nor the protein markers predicted progression in univariate analysis, 
although histopathological diagnosis, p53 and FADD contributed positively to CI in 
multivariate analysis.  
 
Conclusions 
CI is associated with malignant progression of laryngeal premalignancies, especially in 
lower-grade lesions. These results may contribute to better risk-counselling, provided 
that they can be validated in a larger patient-set. 
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Introduction 
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common 
cancer in the world with an estimated 500,000 new cases annually and has a 
poor 5-years survival rate of approximately 50 percent.1 The predominant 
etiological risk factors for HNSCC are alcohol consumption and tobacco 
smoking.1-3 Important factors which influence prognosis are locoregional 
recurrence in up to 30% of patients, originating from minimal residual disease,4,5 
and the development of new or progression of existing precursor lesions.5,6 
Furthermore, molecularly targeted therapies are directed toward activated 
oncogenes and do not influence inactivated tumor suppressor genes, which are 
frequently found in HNSCC.7 This makes early detection of potentially malignant 
head and neck precursor lesions extremely important.  
A diagnostic dilemma is to decide which precursor lesions are potentially 
malignant. However, histopathological examination is troubled by inter-observer 
variability.8-10 Therefore, we need more reliable, sensitive, fast, and easily to 
interpret molecularly based detection-methods to identify potentially malignant 
precursor lesions, which can be easily implemented in clinical diagnostics. 
The histomorphological transition from normal mucosa to cancer is driven by 
the accumulation of genetic changes, resulting in chromosome instability 
(CI),1,5,11 which can already be detected in premalignant lesions using different 
molecular biological approaches. The relationship of CI with cancer 
development has been extensively studied in oral lesions. First, loss of 
heterozygosity (LOH) on chromosome 9p21 (p16INK4A and p14 ARF locus) 
and possibly also 3p correlates with cancer development in half of the cases, 
and is associated with a 11 to 52-fold increase in relative cancer risk if detected 
together with LOH at 4q, 8p, 11q, 13q, 14q and/or 17p.12-15 Second, DNA flow- 
and image cytometry demonstrated an association between aneuploidy and 
malignant outgrowth of oral premalignant lesions.16,17 Third, array CGH also 
showed accumulation of chromosomal alterations in association with disease 
progression.18 Fourth, in situ hybridization (ISH) analyses revealed that 
numerical chromosomal aberrations can predict progression.4,19,20 Numerical 
aberrations for chromosomes 1 and 7 were detected in dysplasia and 
carcinoma in situ (CIS) and not in histologically normal mucosa and the 
majority of hyperplastic lesions.21 A ten-year translational study showed that 
LOH for 3p and 9p, p53 protein overexpression and polysomy for 
chromosomes 9 and 17 strongly predicted cancer development in oral 
leukoplakia.12 The use of chromosome 7 alterations to assess the 
aggressiveness of potentially malignant oral lesions has been demonstrated by 
Poh et al..22 This study also showed that polysomy for chromosome 9 seems 
less suitable for this purpose due to loss of chromosome 9 sequences.  
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Relatively few studies have assessed the clinical value of CI to predict 
malignant development of laryngeal precursor lesions. DNA ploidy analysis 
showed that 77% of the lesions which preceded carcinoma (in situ) showed 
aberrant DNA ploidy results.23 Furthermore, microsatellite and single-target 
brightfield ISH-analysis showed that LOH at 9p21, 17p13 and 18q23 correlated 
with numerical abnormalities for chromosomes 1, 7, 9, 17 and 18 in high risk 
premalignant lesions.24 Because of the limited size of laryngeal biopsies, 
variations in the number of (pre)malignant cells and loss of tissue architecture 
during processing, microsatellite-, array CGH- and DNA content analyses are 
not ideal. Therefore, we applied ISH in an earlier retrospective study on CI 
detection (indicated by the presence of imbalances in chromosome 1 and 7 
centromere copy numbers and/or polyploidization). This study showed that CI 
predicted malignant progression in premalignant laryngeal lesions.25 
Other potential molecular markers of progression include the cell cycle proteins 
p53, Cyclin D1, Fas-associated Death Domain (FADD) and its phosphorylated 
isoform pFADD. Multiple studies have shown that accumulation of p53 occurs 
more often in high-grade than in low-grade precursor lesions, although a strong 
association with malignant progression has not been identified.12,26,27 
Amplification of the 11q13 region, including the Cyclin D1 and FADD genes, is 
frequently found in HNSCC.28,29 Particularly Cyclin D1 and FADD proteins are 
accumulated in tumor cells which is indicative of a worse cancer free 
survival.30,31 Furthermore, dysregulated Cyclin D1 expression has been 
associated with progression in premalignant head and neck lesions.29,32 High 
levels of FADD and pFADD have been associated with a poor disease-specific 
survival in laryngeal and pharyngeal carcinomas, and pFADD overexpression 
with a better response to taxol-based chemotherapy.30,33 Its value as a 
predictor for progression of premalignant laryngeal lesions has not as yet been 
investigated. 
In this study we examined a new collection of premalignant laryngeal lesions for 
the presence of CI as well as p53, Cyclin D1, FADD and pFADD and analyzed 
their value to predict malignant progression. 
Materials and methods 
Patient data and tissue material 
Out of 180 patients with laryngeal dysplasia that had undergone a laryngeal 
biopsy during microlaryngeal surgery between 1986 and 2001 in the Maastricht 
University Medical Centre, we included 69 premalignant laryngeal (5 supraglottic, 
64 glottic) lesions of 69 patients (57 male, 12 female) in this study (referred to 
as group 1). The other patients were excluded in case of 1) a follow-up time 
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shorter than 6 months prior to malignant progression, 2) a lack of sufficient 
patient material 3) a radically performed biopsy e.g. vocal cord “stripping” or 4) 
previous inclusion in a previous study from our institute.25 In case of multiple 
available biopsies the last biopsy preceding SCC or CIS was chosen, taking 
into account the 6-months period as a minimum. The material was treated 
according to the Code for Proper Secondary Use of Human Tissue (Federation 
of Medical Scientific Societies, The Netherlands; 2003) and the study protocol 
was approved by the institutional ethical committee.  
The histopathological assessment of the lesions was performed using the 
WHO classification system and thoroughly reviewed (F.J.B). Eighteen cases 
diagnosed as CIS were treated by radiotherapy or (laser-assisted) 
microlaryngeal surgery after diagnosis and therefore excluded from follow-up 
and survival analyses, resulting in a follow-up group of n=51 (referred to as 
group 2). Because of the current discussion whether a distinction between 
severe dysplasia and CIS can be made, possibly resulting in the treatment of 
these lesions we also defined a third group (referred to as group 3): lesions 
with hyperplasia, mild or moderate dysplasia only, severe dysplasia excluded. 
Follow-up information of the 69 patients was collected from the medical 
records. Lesions were classified as “progressive” in case of development of 
carcinoma in situ (CIS) or squamous cell carcinoma (SSC) at the same 
localisation as the primary biopsy site. 
Four-µm thick formalin-fixed, paraffin embedded tissue sections of all 69 
specimens (further referred to as group 1) were subjected to dual-colour FISH 
analysis using centromere-specific DNA probes for chromosomes 1 and 7. A 
control group consisting of 10 tissue samples of normal squamous head and 
neck epithelium was also subjected to FISH analysis. On subsequent tissue 
sections of the 51 cases which were submitted to follow-up and survival 
analyses (group 2) immunostainings were performed for p53, Cyclin D1, FADD 
and pFADD in 50, 50, 48 and 48 specimens respectively. Missing cases were 
due to insufficient patient material.  
Data concerning tobacco smoking and alcohol consumption were available in 
52 of the 69 patients. Patients were divided into 1) non-smokers (never smoked 
or ceased smoking for at least 20 years) and 2) smokers (current smokers or 
ceased smoking for less than 20 years). Alcohol consumption was categorized 
as 1) non-user, i.e. ≤2 Alcohol Units (AU) /day) and 2) user i.e. >2 AU/day).  
Detection of chromosome 1 and 7 alterations by FISH  
FISH was performed on 4 μm thick tissue sections as described previously.4,34 
Briefly, sections were deparaffinized, pretreated with 85% formic acid / 0.3% 
H2O2, 1 M NaSCN and 4 mg/ml pepsin in 0.01M HCl, post-fixed in 1% 
formaldehyde in phosphate-buffered saline (PBS), dehydrated in an ethanol 
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series and hybridized with a mixture of digoxigenin-labeled human centromere 
1-specific and biotin-labeled centromere 7-specific DNA probes [1 ng/μl 60% 
formamide, 2x sodium-saline citrate (SSC), 10% dextran sulphate and 50x 
excess salmon sperm carrier DNA]. After hybridization the preparations were 
washed stringently in 2x SSC at 42 ˚C (two times for 5 min) and 0.1x SSC at 
60˚ C (two times for 5 min). The probes were detected by application of (i) 
mouse anti-digoxin (Sigma) / avidin fluorescein (Vector Laboratories, 
Burlingame, CA, USA), (ii) rabbit anti-mouse rhodamin (Dako, Glostrup, 
Denmark) / biotinylated goat anti-avidin (Vector) and (iii) swine anti-rabbit 
rhodamin (Dako) / avidin fluorescein. Preparations were mounted in 
Vectashield (Vector Laboratories) containing 4,6-diamidino-2-phenyl indole 
(Sigma; 0.2 μg/ml).  
Microscope images were recorded with the Metasystems Image Pro System 
(black and white charge coupled device camera; Metasystems, Sandhausen, 
Germany) mounted on top of a Leica DM-RE fluorescence microscope (Leica, 
Wetzler, Germany) equipped with fluorescein-, rhodamine- and DAPI-specific 
filter sets for single-colour analysis and a double bandpass filter set 
(fluorescein, rhodamine) for simultaneous dual-colour analysis. 
Controls and evaluation of FISH results 
Hybridizations on tissue sections with proven aneusomies (monosomy, disomy, 
trisomy, and tetrasomy) as well as on 10 normal squamous tissue sections 
were used as a control group to exclude hybridization artefacts and 
interpretation problems. Evaluation of the FISH results was carried out by two 
investigators (AH and EJMS) according to our earlier described and validated 
protocol.25,34 FISH signals were scored per colour and nucleus for the presence 
of aberrant copy numbers of chromosomes 1 and 7. The highest copy number 
per nucleus was determined and set if ≥20% of the nuclei (with a minimum of 
50 nuclei and a maximum of 500 nuclei, depending on the size of the lesion) 
showed this number of FISH signals. Based on this evaluation, the lesions 
were categorized as either monosomic, disomic, trisomic, tetrasomic or 
polysomic (>4 signals per nucleus) for the respective probe targets.  
After this evaluation, the lesions were divided into 1) a group of lesions without 
CI, i.e. no evidence of numerical chromosomal alterations (diploid) or an 
altered but balanced chromosome 1 and 7 status (trisomy or tetrasomy for both 
chromosomes, indicating tri- or tetraploidization), and 2) a group of lesions 
containing CI, i.e. showing chromosome 1/7 copy number imbalances and/or 
chromosome polysomy (>4 signals per nucleus).  
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Immunohistochemistry 
Immunohistochemical staining was performed for p53 (clone DO-7; Dako), 
Cyclin D1 (clone SP4; Labvision, Fremont, USA), FADD (clone A66-2; BD 
Biosciences, Breda, NL) and Ser194 pFADD (polyclonal; Cell Signaling, 
Danvers, USA) expression on 4-μm thick formaldehyde fixed, paraffin-
embedded tissue sections as described earlier.30,35 Evaluation was performed 
by VEB, SGHL, AH, and EJMS for p53 staining and ES, JW, and EJMS for 
Cyclin D1, FADD and pFADD.  
p53: Lesions were classified as negative when no or only few cells with nuclear 
staining were observed, or positive when either multiple cells with nuclear 
staining were present above the basal cell layer or tissue areas showed ≥10% 
stained cell nuclei.35  
Cyclin D1:  Lesions were evaluated using a cut-off value for strong nuclear 
staining in >10% of cells based on earlier reports.29 
FADD and pFADD: The stainings of both proteins are morphologically different 
in head and neck carcinomas30 and therefore have been evaluated separately. 
FADD staining was mostly cytoplasmic and categorized as low (no or weak 
expression) or high (intermediate or strong expression). When normal 
epithelium was present in the tissue section, cytoplasmic staining of the 
suprabasal layer was used as the reference.30 pFADD expression was 
assessed as the percentage of cells with strong nuclear staining. For statistical 
analysis the cut-off value for was set at ≥60% positivity, based on the 
population mean staining percentage. 
Statistical analysis 
All data were analyzed using SAS (version 8.02, SAS Institute Inc., Cary, NC, 
USA) and SPSS 18.0. Patients with non-progressive lesions were censored at 
the date of last follow-up (with a minimum of 5 years of follow-up from the date 
of biopsy) or date of death, provided that death was not related to laryngeal 
malignancy. Differences in patient characteristics between subgroups in the 
study population were evaluated with a two-tailed T-test for continuous 
variables and the Chi-square test or Fisher’s Exact test for categorical 
variables. Univariate logistic regression analysis was performed to identify 
potential predictive markers for malignant progression and to assess their Odds 
Ratios (ORs). Based on these results and taking into account the influence of 
possible confounders, multivariate logistic regression analysis was carried out, 
which resulted in a risk model based on the combination of different prognostic 
markers, including ROC curves. These analyses were also performed on group 
3 (i.e. hyperplasia, mild and moderate dysplasia only (n=39) in order to exclude 
a potential bias by the severe dysplastic cases. Progression-free survival 
analysis was calculated using the Kaplan-Meier method. A log rank test was 
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performed to compare the progression-free survival of subgroups, classified 
according to histopathology, CI, and protein expression. In all analyses the P-
value for significance was set at 0.05. 
Results 
CI analysis 
FISH analysis performed on group 1 resulted in 42 (60%) lesions with CI. All 27 
lesions without CI exhibited a diploid chromosome status, except for one case 
of hyperplasia and one case of moderate dysplasia, which harboured a 
balanced tetrasomy for chromosomes 1 and 7. Representative images of FISH 
analyses on tissue sections of premalignant laryngeal lesions are displayed in 
Figure 3.1A and 3.1B, and an example of a FISH 1c/7c counting in a lesion 
with CI is shown in Figure 3.1C. The percentage of lesions with CI increased 
with advancing histopathological stage (Figure 3.1D). The 10 cases of normal 
squamous epithelium showed a disomy for both chromosomes.  
A significantly higher mean age at biopsy, i.e. 64 yrs (range 43-79) was found 
in the group of patients with CI compared to the group without CI (56 yrs, range 
23-77; P=0.0001), which may reflect the effect of longer carcinogenic 
exposure. No significant differences were observed between the patients with 
CI and without CI with respect to the other potential confounders (gender and 
alcohol consumption/tobacco smoking). Thirty patients (58%) of group 2 
showed progression to CIS or SCC. Six lesions harboured CI, but were non-
progressive, 9 lesions did not harbour CI but developed SCC in 4, and CIS in 5 
patients. Interestingly, in these cases also the developed SCC or CIS showed 
no CI. Univariate logistic regression analysis on group 2 indicated that CI is a 
strong individual marker of progression (OR=5.8, P=0.005), corresponding with 
a sensitivity of 70% and specificity of 71%. Also in group 3 CI was strongly 
associated with malignant outcome (OR=8.4, P=0.004); sensitivity 75%, 
specificity 74%).  
p53, Cyclin D1, FADD and pFADD expression analyses 
P53 immunostaining resulted in 23 (46%) p53-positive cases (group 2). 
Representative images of a p53 positive lesion are depicted in Figure 3.1E and 
3.1F. Patients with P53-positive lesions did not differ significantly from patients 
with P53-negative lesions with respect to age, gender and tobacco smoking 
and alcohol consumption or CI status. P53 did not appear to be a reliable 
prognosticator in univariate logistic regression (OR=2.29 Confidence Interval 
(0.72-7.27); Table 3.1).  
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Nuclear Cyclin D1 overexpression was found in 16 (32%) lesions (group 2). A 
representative case with Cyclin D1 overexpression is depicted in Fig. 1G. No 
significant differences were found for CI status or potential confounders (age, 
gender, tobacco smoking and alcohol consumption) when comparing the Cyclin 
D1-positive and -negative patients. In univariate logistic regression analysis 
Cyclin D1 overexpression did not appear to be a prognosticator (OR= 1.0, 
Confidence Interval (0.50-6.10); Table 3.1).  
Seven samples (15%) were categorized as “high FADD”. Six of these lesions 
displayed CI and were progressive, although no statistically significant 
association with outcome was found. FADD showed a high OR in univariate 
logistic regression analysis, which however was not statistically significant 
(OR=5.71, Confidence Interval (0.63-51.77), Table 3.1). A nuclear pFADD 
staining was identified in 45 (93%) lesions (range 10-90% positive nuclei) and 
pFADD positivity was not significantly associated with progression in univariate 
logistic regression analysis (OR=0.94, Confidence Interval (0.30-2.99), Table 
3.1). Representative images of cases with high FADD and pFADD 
overexpression can be found in Figure 3.1H and 3.1I respectively.  
Histopathology  
Histopathological examination resulted in 4 cases of hyperplasia, 14 mild 
dysplasias, 21 moderate dysplasias, 12 severe dysplasias and 18 cases of 
CIS. Univariate logistic regression analysis on group 2 showed that only severe 
dysplasia predicted progression (OR=15.0, Confidence Interval (0.98-228.90), 
P=0.05), (Table 3.1). Neither pooling of hyperplasia and mild dysplasia versus 
moderate and severe dysplasia nor severe dysplasia versus the 3 combined 
lower histopathological classifications improved the prognostic value of 
histopathology (Table 3.1).  
All analyses as described above were also performed in group 3. Univariate 
analyses showed that also in this group, which contained only low-grade 
dysplasia, only CI was significantly associated with malignant outcome (OR= 
8.4, Confidence Interval (1.96-35.37), (P=0.004); (Table 3.1). 
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Figure 3.1 Representative images of tissue sections of premalignant laryngeal lesions, analyzed 
by FISH for CI detection, and immunohistochemistry; 
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A, B)FISH analyses, showing (A) disomy for chromosomes 1 (green) and 7 (red) (no 
CI), and (B) trisomy for chromosome 1 and polysomy for chromosome 7 (CI). C) 
Example of a chromosome 1 and 7 counting of 200 nuclei in a tissue section 
containing CI. Trisomy, tetrasomy and polysomy is encountered. D) Enhanced 
percentage of chromosome instability (CI) in premalignant laryngeal lesions ranging 
from hyperplasia, mild, moderate to severe dysplasia/CIS as determined by FISH 
1c/7c. E, F) P53 immunostaining, showing (E) p53 overexpression, displaying nuclear 
staining of the (para)basal cell layer in “patches” (indicated by arrows), and (F) detail 
of this tissue section. G, H, I) Immunostaining images for overexpression of (G) Cyclin 
D1: nuclear staining 10%, (H) FADD: mostly cytoplasmic staining categorized as 
“high”, (I) pFADD: 80% nuclear staining. 
 
 
Table 3.1 Odds Ratios for individual markers to predict malignant progression of premalignant 
lesions.  
Marker   OR (95% Confidence Interval) P-value 
 Group 2 Group3 Group 2/Group 3 
CI 5.83 (1.71-19.90) 8.4 (1.96-35.37) 0.005*/0.004* 
P53 2.29 (0.72-7.27) 2.29 (0.60-8.83) 0.16/0.228 
FADD 5.71 (0.63-51.77) 3.96 (0.361-41.20) 0.12/0.26 
pFADD (>60% nuclear staining) 0.94 (0.30-2.99) 1.00 (0.28-3.57) 0.92/1.00 
Cyclin D1 (>10%) 1.74 (0.50-6.10) 1.73 (0.44-6.79) 0.39/0.43 
Histopathology:    
   Mild dysplasia (MD) 3.00 (025-36.33) 3.00 (0.25-36.33) 0.39/0.39 
   Moderate dysplasia (MDD) 4.00 (0.36-45.10) 4.00 (0.36-45.10) 0.26/0.26 
   Severe dysplasia (SD) 15.00 (0.98-228.90)  0.05 
HP + MD vs. MDD+SD 2.50 (0.77-8.12)  0.13 
HP + MD + MDD vs. SD 4.75 (0.92-24.56)  0.06 
HP +MD vs. MDD  1.67 (0.47-5.93) 0.43 
HP vs. MD + MDD  1.05 (0.34-37.69) 0.87 
* significant P-value. OR, Odds Ratio; CI, Chromosome Instability; HP, hyperplasia; MD, mild 
dysplasia; MDD, moderate dysplasia; SD, severe dysplasia. Group 2: n=51. Group 3: n=39, cases 
with severe dysplasia excluded. 
 
Progression-free survival analysis   
Of the 51 patients 20 developed SCC and 10 developed CIS on the site of 
primary biopsy. The 5-year progression-free survival of group 2 was 45% (95% 
Confidence Interval: 30.2-59.8). Survival analysis showed a significantly 
shortened progression-free survival time for patients with CI compared with 
patients without CI (P=0.0022), Figure 3.2A. This finding was even more 
pronounced in group 3 (P=0.0006), Figure 3.2B.  
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Figure 3.2 Kaplan-Meier survival analyses for histopathology and molecular markers. 
A) Progression-free survival, according to the presence of CI (CIS excluded): lesions 
with CI versus lesions without CI. Lesions with CI show a significantly increased risk 
for malignant progression (P=0.0022). B) Progression-free survival according to the 
presence of CI (in hyperplasia, mild and moderate dysplasia only); lesions with CI 
versus lesions without CI. Lesions with CI are strongly at risk for malignant 
progression (P=0.0006). C) Progression-free survival according to p53-status (CIS 
lesions excluded). Lesions with p53-overexpression (p53+) versus lesions without p53 
overexpression (p53-). P53+ shows a tendency towards a worse progression-free 
survival, however non-significant (P=0.063). D) Progression-free survival according to 
p53-status (in hyperplasia, mild and moderate dysplasia only). Lesions with p53-
overexpression (p53+) versus lesions without p53-overexpression (p53-), difference 
between groups is not significant (P=0.149). E) Progression-free survival according to 
histopathological diagnosis (CIS excluded), non- significant difference between groups 
(P=0.13). F) Progression-free survival for severe dysplasia versus the joined group of 
hyperplasia, mild and moderate dysplasia. Severe dysplasia has a significantly 
increased risk for malignant progression (P=0.038). 
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A (non-significant) trend towards a worse progression-free survival for p53-
positive versus p53-negative lesions was found in group 2 (P=0.063, Figure 
3.2C), which was not observed in group 3 (Figure 3.2D). In group 2 the CI-
positive patients with p53-overexpression showed a significantly shortened 
progression-free survival (P=0.0344) compared with the p53-negative patients 
(results not shown).  
Progression-free survival analysis according to histopathological classification 
revealed no significant difference between the concomitant histopathological 
subgroups, as shown in Figure 3.2E. However, a significantly shortened 
progression-free survival was found for severe dysplasia as compared to the 
combined group of hyperplasia, mild and moderate dysplasia (P=0.038) (Figure 
3.2F). In group 3 no significant association with malignant outcome was found. 
Cyclin D1, FADD or pFADD did not significantly influence progression-free 
survival (results not shown). 
A summary of clinical and molecular patient data is shown in Table 3.2. 
 
Table 3.2 Summary of clinical and molecular data of 51 patients with premalignant lesions of the 
larynx. 
Patient- 
number 
Age at biopsy 
(yrs) 
Follow-up 
time (yrs) 
Histopathology CI* p53† FADD‡ pFADD§ 
(%) 
Cyclin D1∞ 
(%) 
Outcome 
1 45  16.3 HP - - - 20  NED 
2 66  14.9 HP - - - 60 10 NED 
3 44    5.1 HP - + - 90 5 NED 
4 65    1.1 HP + + - 40 10 SCC 
5 47  20.1 MD - - - 20 30 NED 
6 23  14 MD - - - 40 10 NED 
7 52    6.1 MD - - - 60 10 SCC 
8 74    8.9 MD - - - 70 30 NED 
9 35    3.9 MD - - - 50 5 NED 
10 71    5.8 MD - - - 80 10 NED 
11 58  17.1 MD - + - 80 0 NED 
12 78  13.8 MD - + - 60 10 NED 
13 65    3.4 MD - + - 80 15 SCC 
14 61  17.4 MD + - - 60 0 SCC 
15 50    3 MD + -  80 20 SCC 
16 54    2.2 MD + - - 70 5 SCC 
17 80    2 MD + - + 90 20 SCC 
18 56    1.8 MD + + - 90 30 SCC 
19 55    4.2 MDD - - - 40 1 CIS 
20 76    5.5 MDD - - -  30 NED 
21 63    5 MDD - - - 80 50 NED 
22 72  17.5 MDD - + - 60 2 NED 
23 25    5.2 MDD - + - 70 10 NED 
24 51    4.5 MDD - + - 90 10 CIS 
25 75    1.2 MDD - +  60 10 SCC 
26 79    0.9 MDD + - - 35 20 SCC 
27 55  16.4 MDD + - - 80 20 SCC 
28 69  18.8 MDD + - - 70 1 NED 
29 67    9.7 MDD + - - 70 30 NED 
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Table 3.2 (continued) 
Patient- 
number 
Age at biopsy 
(yrs) 
Follow-up 
time 
(yrs) 
Histopathology CI* p53† FADD‡ pFADD§ 
(%) 
Cyclin D1∞ 
(%) 
Outcome 
30 57  16 MDD + - - 60 0 NED 
31 51    1.8 MDD + - - 80 10 SCC 
32 70    0.9 MDD + - - 70 0 SCC 
33 78    2.1 MDD + - - 20 5 NED 
34 70    3.9 MDD + - + 80 10 CIS 
35 43    3.1 MDD + - + 90 5 NED 
36 57    1.1 MDD + + - 30 30 SCC 
37 62    2.3 MDD + + - 10 0 SCC 
38 73    2.5 MDD + + + 60 0 SCC 
39 66    0.9 MDD + +  0 60 CIS 
40 73    5 SD + + - 70 0 CIS 
41 66    0.7 SD + + - 20 10 SCC 
42 62    0.8 SD - - +  10 CIS 
43 70    1.1 SD - + - 70 10 CIS 
44 64    1.2 SD + + - 70 30 SCC 
45 46    1.2 SD + + +  20 SCC 
46 75    2.3 SD + + - 40 20 CIS 
47 39    2.4 SD - - - 0 5 CIS 
48 65    3.2 SD - + - 70 0 NED 
49 69    3.5 SD + - + 80 10 CIS 
50 79    4.5 SD + + - 80 5 NED 
51 49    9.5 SD - + - 90 0 SCC 
HP, hyperplasia; MD, mild dysplasia; MDD, moderate dysplasia; SD, severe dysplasia; NED, No 
evidence of disease; SCC, squamous cell carcinoma; CIS, carcinoma in situ. * CI  (-), balanced 
chromosome 1 and 7 copy numbers and (+), imbalances chromosome 1 and 7 copy numbers. † 
p53(-), no or only few cells with nuclear staining and (+), either multiple cells with nuclear staining 
above the basal cell layer, or tissue areas with ≥10% stained cell nuclei. ‡ FADD: (-) no or weak 
expression and (+) intermediate or strong expression. § pFADD: the percentage of cells with strong 
nuclear staining. ∞ Cyclin D1: (-) nuclear staining in ≤10% of cells, and (+) nuclear staining in >10% 
of cells. 
 
Multivariate progression model for combined markers 
Based on the results of the univariate logistic regression analysis in group 2, 
multivariate model was obtained including CI and other markers with predictive 
value i.e. p53, FADD and histopathological diagnosis. This resulted in the best 
prognostic tool with a sensitivity of 80% and a specificity of 71% and a 
Receiver Operating Characteristic (ROC) curve with an Area Under the Curve 
(AUC) of 0.82, which represents a good predicting model (Figure 3.3.). For 
group 3, only p53 contributed positively to the model based on CI, resulting in a 
sensitivity op 90% and specificity of 74%; AUC=0.81 (Figure 3.3).  
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Multivariate progression model for combined markers 
Based on the results of the univariate logistic regression analysis in group 2, 
multivariate model was obtained including CI and other markers with predictive 
value i.e. p53, FADD and histopathological diagnosis. This resulted in the best 
prognostic tool with a sensitivity of 80% and a specificity of 71% and a 
Receiver Operating Characteristic (ROC) curve with an Area Under the Curve 
(AUC) of 0.82, which represents a good predicting model (Figure 3.3.). For 
group 3, only p53 contributed positively to the model based on CI, resulting in a 
sensitivity op 90% and specificity of 74%; AUC=0.81 (Figure 3.3).  
Confounders 
The influence of the potential confounders gender, age, tobacco smoking and 
alcohol consumption was also analyzed. Non-alcohol-users had a significantly 
better prognosis than alcohol users (P=0.02), however, in multivariate analysis 
with CI alcohol use did not contribute to outcome prediction. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3 Receiver operating characteristic (ROC) curves for the progression model of CI, CI 
with the following additional markers: histopathological assessment, p53 and FADD 
(Area Under the Curve (AUC) =0.82) and also for CI + p53 in group 3 (n=39, severe 
dysplasia cases excluded); AUC=0.81). 
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Discussion 
Early detection of potentially malignant precursor lesions is a key-issue in 
reducing patient morbidity and mortality of HNSCC. As routine 
histopathological assessment does not provide reliable information on the risk 
of malignant outgrowth of these lesions, as is also shown in this study, there is 
a need for other markers to predict progression. Such a diagnostic method 
should not only be reliable but also easy implementable in daily clinical 
practice. Therefore, in this study we have investigated the value of CI, p53, 
Cyclin D1, FADD and pFADD protein overexpression as potential 
prognosticators in premalignant laryngeal lesions in relation to histopathological 
classification. We found an increasing level of CI with advancing 
histopathological grade. This is in line with the current molecular progression 
models showing CI development early in head and neck tumorigenesis.1,3,11 CI 
proved to be significantly associated with malignant progression (OR=5.8), and 
this association was even stronger in low-grade lesions including hyperplasia, 
mild and moderate dysplasia (OR=8.4). Patients with CI containing lesions 
showed a significantly shorter progression-free survival. None of the other 
individually tested markers was clearly able to predict progression in univariate 
analysis. The best multivariate risk-model consisted of CI, histopathological 
assessment, p53 and FADD with a sensitivity of 80% and a specificity of 71%. 
In low-grade lesions only p53 contributed positively to CI in the risk-model 
(sensitivity 90%, specificity 75%). The fact that Cyclin D1 and pFADD 
immunostainings are of less importance in this model might be explained by 
the fact that strong cyclin D1 and pFADD expression is observed both in 
lesions with and without CI, reflecting a disruption of the balance between cell 
proliferation and apoptosis in tumorigenesis without association with malignant 
outgrowth. We found high FADD expression in only 15% of cases, 6 of which 
were progressive and harboured CI. Therefore, FADD overexpression seems 
not to be an early event in carcinogenesis but rather indicates later molecular 
changes associated with progression. Six of the CI-containing cases did not 
show malignant progression, which may be explained by the radical excision of 
potentially malignant cells during biopsy. On the other hand, 9 of the remaining 
24 lesions without CI showed progression nevertheless. This interesting finding 
suggests that a certain group of premalignant lesions without CI may progress 
to a diploid tumor.5 Four of the CI-negative and progressive lesions showed 
p53 overexpression and one of these was classified as high-FADD, indicating 
that p53 analysis could possibly contribute to a reduction of false-negative 
cases in this specific group of CI-negative lesions.  
Carcinogenic mechanisms that can be involved in CI-negative lesions include 
infection with high risk-HPV viruses35-37 (although this is usually confined to the 
oropharynx), microsatellite instability,38,39 narrow amplicons e.g. on 
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chromosomes 8q or 11q13,40,41 or inactivation of tumor suppressor genes by 
promotor hypermethylation or truncation of its gene product.42,43 
This study confirms and extends the results of our previous analyses25 and is in 
agreement with earlier reported FISH results on oral premalignant lesions and 
histologically tumor free resection margins, showing numerical aberrations of 
chromosomes 1 and 7 as indicators for malignant progression or tumor 
recurrence, respectively.4,21,22 This assay is easily applicable in routine 
molecular diagnostics, and the use of only one 4-µm paraffin tissue section for 
analysis of CI makes the approach extremely useful for laryngeal biopsies that 
are often small in size.  
In conclusion, this study shows that CI as an individual marker can predict 
malignant progression in premalignant laryngeal lesions, especially in lower-
grade premalignancies, in which histopathological examination does not 
provide reliable information on malignant potential. CI analysis by FISH can, in 
contrast to other molecular diagnostic techniques, easily be incorporated in the 
standard clinical routine of risk-counselling of premalignant head and neck 
lesions, which may eventually minimize patient morbidity. Validation of our 
results in a larger patient population is however required. 
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Abstract 
Objectives 
One of the main problems in reducing the incidence of oral squamous cell carcinoma 
(OSCC) is the inability to appropriately deal with leukoplakia. Accurately identifying 
lesions which will progress to malignancy is currently not possible. The present study 
aims to establish the value of chromosome instability (CI) detection by DNA image 
cytometry and FISH analysis for prognosis and monitoring of oral leukoplakia 
 
Materials and methods 
For this purpose, we included from our archives 102 oral leukoplakia cases, which had 
been diagnosed between 1991 and 2008. Patient follow-up data were collected and the 
histopathological diagnosis was revised. CI assessment was carried out on paraffin-
embedded tissue sections using both DNA image cytometry (ICM) and dual target FISH 
for chromosomes 1 and 7.  
 
Results 
16 of 102 patients developed carcinoma in situ or OSCC. Both detection methods were 
found to yield prognostic information independent of the histopathological diagnosis. CI 
was a strong individual marker of progression, with Hazard Ratios (HR) of 7.2 and 6.8 
for ICM and FISH respectively. Moreover, this approach seems suitable for monitoring 
lesions over time, (especially ICM). Combining histopathology and CI enables 
subdivision of patients into three risk groups, with different probabilities of malignant 
progression.  
 
Conclusion 
CI detection seems a reliable method for risk assessment of oral premalignancies and 
its application may contribute to a better risk-counselling and appropriate treatment 
regimen or watchful-waiting approach of patients. 
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Introduction 
Oral cancer is the sixth most common malignancy worldwide, with a yearly 
incidence of about 274.000 cases.1 Most oral tumours are squamous cell 
carcinomas (SCCs) with smoking and alcohol consumption as major risk 
factors.1,2 In contrast to cancers of the breast, colon, prostate and melanoma 
that are showing a significantly better prognosis due to improvements in early 
detection and therapy3, the survival rate of patients with oral squamous cell 
carcinomas (OSCC) has not increased substantially over the last decades.2,4 
The oral cavity and oropharynx are easily accessible for visualization, which 
may facilitate early diagnosis of (pre)malignant lesions. Nevertheless, in spite 
of advances in surgical and other treatment modalities, the 5-year survival rate 
of OSCC remains only approximately 50%.2,3 This lack of progress can partially 
be explained by our inability to adequately recognize early developed OSCC as 
well as precursor lesions at risk for progression.3  
Oral leukoplakia and, to a lesser degree, erythroplakia are relatively common 
lesions of the oral mucosa, some of which are at risk for malignant 
transformation.5 In particular, the borders of the tongue and the floor of the 
mouth have been mentioned as high-risk sites.6 Whereas oral erythroplakia 
show malignant transformation in almost all cases, oral leukoplakia eventually 
progress to malignancy in an estimated 1.1-17.5%.7 Therefore, especially 
discrimination between potentially malignant leukoplakias and non-harmful 
lesions is of key importance.  
Unfortunately, current histopathological examination of precursor lesions (i.e. 
dysplastic and non-dysplastic) is insufficiently accurate to predict their 
malignant potential.8 In addition, histopathological classification is hampered by 
observer variability9,10 and sampling variability.11 Therefore, more effective 
methods for the assessment of the malignant potential of oral leukoplakia are 
urgently needed.12 It is widely believed that instability of the genome is the 
driving force behind the development of the majority of human epithelial 
cancers.13 CI may be detected by different molecular biological approaches. 
DNA content analysis using image cytometry (ICM) or flow cytometry (FCM) 
are frequently used techniques.4,14,15,16,17 Three recently published 
retrospective studies have shown that ICM is able to identify patients with 
dysplasias that are more likely to progress to OSCC.14,16,17 FCM displays an 
increasing degree of aneuploidy in the spectrum of lesions ranging from 
healthy oral mucosa, non-dysplastic and dysplastic leukoplakia to OSCC. 15 
Alternatively, copy number alterations of individual chromosome loci can be 
studied using fluorescence in situ hybridization (FISH) analysis.18,19,20,21 Several 
studies on FISH for chromosomes 1 and 7 revealed that numerical 
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chromosome aberrations have a predictive value in the progression of oral 
precursor lesions to SCC.18,19,22  
The aim of the present study was to establish the value of CI detection by 
means of both ICM and FISH in comparison with routine histopathological 
assessment for the risk assessment of oral precursor lesions in a series of 102 
leukoplakia. In addition, we evaluated both essays for their reliability to monitor 
possible progression of premalignant lesions over time. 
Materials and methods 
Patient selection  
This retrospective study included patients who were admitted to the department 
of Oral and Maxillofacial Surgery at the Radboud University Nijmegen Medical 
Centre (RUNMC), The Netherlands, between 1991 and 2008 for evaluation of 
suspicious lesions of the oral mucosa. The minimal follow-up time was 6 
months. Patients with oral hyperplastic or dysplastic lesions were identified 
using the Dutch Pathology diagnosis and registration system (PALGA). 
Patients who had been previously treated for malignancy as well as patients 
with a histologically confirmed carcinoma in situ at first biopsy were excluded. 
Clinical data including age, etiological factors, localization, type of treatment 
(surgery, laser ablation or expectative policy) were obtained from the patients’ 
medical charts. Only patients with a complete data-set were included, resulting 
in 102 specimens (of 102 patients). Data collection was performed in 
accordance with local ethical guidelines. 
ICM and FISH analyses were performed on biopsy specimens obtained at the 
time of the first diagnosis of leukoplakia and on specimens from eventually 
developed carcinoma (carcinoma in situ or invasive carcinoma). The time 
between consecutive lesions was set at a minimum of six months in order to 
exclude synchronous lesions. To assess the value of ICM and FISH for the 
monitoring of lesions over time, subsequent premalignant lesions and recurrent 
malignancies were analysed.  
For each case of leukoplakia and SCC first a 4μm thick slide was cut from a 
paraffin-embedded specimen for Haematoxylin-eosin (HE) analysis followed by 
three 50μm and two 4μm sections for ICM and FISH respectively and ending 
again with one 4μm slide for HE analysis. The first and last slides of the initial 
leukoplakia were haematoxylin-eosin stained and revised by an experienced 
pathologist (PJS). In this manner it could be assured that both ICM and FISH 
analysis were performed on representative areas, to enhance the accuracy of 
the test. 
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DNA ploidy measurement of isolated nuclei from tissue sections 
Two to four 50μm thick paraffin-embedded sections were used to isolate cell 
nuclei according to well-established procedures.10 A thickness of 50μm was 
shown to minimize the number of artefacts in DNA histograms.23 Sections were 
deparaffinised and rehydrated as follows: xylene (three times 15 minutes), 
100% ethanol (twice), 96% ethanol (twice), 70% ethanol, 40% ethanol, distilled 
water and phosphate-buffered saline (PBS) at least ten minutes in each 
solution. The tissue sections were transferred into a centrifuge tube and 
incubated with 0.5% pepsin (Sigma Aldrich, St Louis, MO, USA) in PBS (pH 
1.50) at 37 degree Celsius, for 60 minutes. After enzymatic digestion, 4ml of 
ice-cold PBS was added to stop the reaction. Next the tissue suspension was 
filtered through a CellTrics filter with 50μm pore size to separate nuclei from 
tissue debris. After centrifugation (1000 rpm, 10 min), 2 ml PBS was added and 
the amount of nuclei was counted with a cell-counting device (Z1 Coulter 
Particle Counter®, Beckman Coulter Inc., Woerden, The Netherlands). The cell 
suspension was diluted until the right concentration, (20 000 cells) was 
reached, to form a monolayer in a cytospin-centrifuge (10 minutes 700rpm), air 
dried, and fixed in Böhm fixative for 1 hour, hence a mixture of 85% methanol 
absolute, 10% formaldehyde (37%), and 5% acetic acid (96%). Slides were air 
dried after twice rinsing in methanol absolute. 
Feulgen staining 
First the cell preparations were hydrolysed in 5M HCl under controlled 
temperature at 25˚C for one hour, after which the process was stopped using 
distilled water. Thereupon the isolated nuclei were stained by the Schiff 
method10 (Merck®, Darmstadt, Germany) for 1 hour at room temperature. Next 
the slides were rinsed in streaming tap water for 20 minutes, dehydrated in 
increasing concentrations of ethanol, xylol and mounted in Permount® (Thermo 
Fisher Scientific, Landsmeer, The Netherlands).  
Measurement of DNA content 
All measurements were performed using the Leica QPath Image Cytometry 
Workstation (Leica Microsystems GmbH, Wetzlar, Germany) according to an 
established protocol.10 Slides of stained cell nuclei were analysed using a 
microscope equipped with a 550-nm green filter and a computer controlled 
stage. Each monolayer contained at least 1500 sampled nuclei. The QPath 
software measures the Feulgen integrated optical density (IOD) of individual 
nuclei while avoiding the measurement of overlapping, folded, or clumped cells. 
ICM analysis of all histological specimens was performed in a blinded fashion 
at the RUNMC. DNA ploidy histograms were visually classified independently 
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by two experienced observers (JvdL; IOH). In all cases of discrepancy, a 
consensus classification was reached by the same two observers. 
In the present study, a diploid histogram is defined by a single dominant 2c 
peak (representing G0/G1 phase cells) and possibly a 4c peak (G2 phase cells) 
not exceeding 10 percent of the total number of nuclei (Figure 4.1A). If the 
number of nuclei with a DNA content >5c exceeded 1 percent of the total 
number of cells, the histogram was classified as aneuploid. Also, a histogram 
was classified as aneuploid if there was a clear and distinct peak outside the 
2c/4c regions (Figure 4.1B). A lesion was defined as tetraploid if the number of 
4c nuclei exceeded 10 percent of the total number of epithelial cells and a 8c 
peak was observed. The measurements were performed according to previous 
published guidelines.24 Because in some cases the coefficient of variation (CV: 
standard deviation of the 2c peak divided by the mean, given in percent) 
slightly exceeded the advised threshold of 5%, CVs up to 6% were allowed in 
the present study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1 Examples of ICM ploidy histograms A) diploid pattern, B) typical aneuploidy pattern. 
C, D. Representative examples of FISH results using centromere probes specific for 
chromosome 1 (green) and 7 (red) in cell nuclei (blue) of head and neck oral mucosa 
epithelium. C) Nuclei showing disomy for both chromosomes. D) Nuclei showing an 
imbalance between the copy number of chromosomes 1 (maximal 4 copies) and 7 
(maximal 6 copies). 
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Double-target fluorescence in situ hybridisation (FISH) on tissue 
specimens 
FISH was performed at the University of Maastricht Medical Centre, 
Department of Molecular Cell Biology. The procedure was performed as 
described previously.10,25 Briefly, 4 μm thick paraffin-embedded tissue 
specimens were first deparaffinised and pretreated with 85% formic acid/0.3% 
H2O2 at room temperature 1 M sodium thiocyanate (NaSCN) at 80˚C and 0.4 g 
pepsin (800 to 1200 U/mg protein porcine stomach mucosa (Sigma Aldrich, St 
Louis, MO, USA) per ml 0.02 NHCl at 37˚C. Slides were post-fixed with 1% 
formaldehyde in PBS and dehydrated with an ascending series of ethanol. The 
probes for chromosome 1 and 7 were prepared by labelling with biotin- and 
digoxigenin-dUTPs and dissolved at a concentration of 1 ng/μl in 60% 
formamide, 2x standard saline citrate (SSC, pH 7.0), 10% dextran sulphate, 
and 50 times excess of carrier DNA (salmon testis DNA; Sigma Chemical Co, 
St Louis, MO). After denaturation of probe and tissue at 80˚C for 5 min and 
overnight hybridization the tissue specimens were washed stringently in 2x 
SSC containing 0.05% Tween-20 (Acros Organics, Geel, Belgium) two times 
for 5 min at 42˚C, followed by 0.1xSSC two times for 5 min at 60˚C and 
4xSSC/0.05% Tween-20 at room temperature.  
Detection of the hybridised probes was established with the following antibody 
combinations diluted in 4xSSC containing 5% non-fat dry milk powder: FITC-
labeled avidin (Vector, 1:100)/ anti-digoxigenin monoclonal antibody (1:200, 
Mannheim); Biotinylated Goat Anti-Avidin (Vector, 1:100)/ rabbit anti mouse 
TRITC (Vector, 1:1000) and FITC-labeled avidin (1:100)/ swine anti rabbit 
TRITC (Vector, 1:100). Following the final wash and dehydration, slides were 
mounted in Tris glycerol, containing 2% DACO Antifade (Glostrup, Denmark) 
and 0.5 μg/ml of the nuclear DNA counterstain DAPI. An example of FISH 
results is shown in Figures 1C and D. Evaluation of the FISH results was 
carried out as described in our previous studies.10,22,25 
Data analysis 
Clinical data, histopathological characteristics and ICM and FISH scores of all 
lesions were statistically analysed using SPSS version 17.0.1 software (SPSS 
Inc., Chicago, USA). The progression into carcinoma was analysed using uni- 
and multivariate Cox regression analyses and hazard ratios (HR) including its 
95% confidence intervals (CI) and associated p-values were calculated. 
Cumulative progression towards malignancy analysis was performed by means 
of the Kaplan Meier method. In all analyses the p-value for significance was set 
at 0.05. To assess the degree of agreement between ICM and FISH к-statistics 
were calculated. 
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Results 
Patient characteristics and outcome 
Of the 102 patients diagnosed with leukoplakia, 48 (47%) were female and 54 
(53%) were male (Table 4.1). The duration of follow-up after the first biopsy 
ranged from 6 to 246 months (median 91.5). Malignant progression occurred in 
16 patients (5 developed carcinoma in situ and 11 invasive carcinoma). The 
median follow-up time of these patients was 27.0 months (range: 7-151). 
Progressive lesions were located on the floor of mouth (n=2), tongue (n=10), 
buccal mucosa (n=3) and inferior alveolar rim (n=1). Carcinomas developed at 
the same location as the preceding leukoplakias (n=13), or within a range of 2 
centimetres of the initial lesion (n=3) (Warren and Gates criteria).26 
Clinical parameters 
Table 4.3 gives an overview of the HRs of different clinical parameters. 
Location was associated with risk of malignant development: leukoplakia of the 
floor of mouth or tongue had a significantly higher risk of malignant progression 
(HR=3.2; P=0.047). Older patients were slightly more susceptible to malignant 
transformation with a HR of 1.1 (P=0.025). No correlation was found between 
the type of treatment and developed SCC (data not shown).  
 
Table 4.1 Patient characteristics based upon primary premalignancies. 
Patient data  Malignant Transformation 
  No Yes 
Number of patients  86 16 
Age Mean (years) 51.9 57.8 
 CI (95%)  (49.6-54.2) (50.9-64.7) 
Sex Female 41 7 
 Male 45 9 
Smoking Yes 54 9 
 No 32 5 
 In history    9 1 
 Data NA   2 1 
Alcohol Yes 39 7 
 No 40 8 
 Data NA   4 1 
Follow-up Median (months) 98.0 27.0 
 CI (95%)  (84.8-104.6) (23.7-70.8) 
 
Histopathology 
An overview of the histological diagnosis for each case of leukoplakia related to 
malignant progression can be found in Table 4.2 (first two columns). Because 
of the low number of severe dysplasias (n=3), in the present study these 
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lesions were pooled with moderate dysplasias for further analyses. This is in 
accordance with the review by Warnakulasuriya et al.27 In univariate Cox 
regression, histopathological diagnosis was associated with malignant 
transformation with a hazard ration (HR) of 6.3 (CI: 2.3-17.3; P<0.001; Table 
4.3) comparing the combination of hyperplasia and mild dysplasia with 
moderate and severe dysplasia. Figure 4.2 shows the corresponding survival 
curves. 
 
Table 4.2 Fraction of hyperplastic and dysplastic lesions transformed into malignancies 
Histopathology Number of 
SCC after 
leukoplakia 
Number of 
SCC after 
diploid 
leukoplakia 
(ICM) 
Number of SCC 
after aneuploid 
leukoplakia 
(ICM) 
Number of 
SCC after 
diploid 
leukoplakia 
(FISH) 
Number of SCC 
after aneuploid 
leukoplakia  
(FISH) 
All 16 / 102 
(15.7%) 
6 / 79 (7.6%) 10 / 23 (43.5%) 8 / 85 (9.4%) 8 / 17 (47.1%) 
   HP  5 / 66 (7.6%) 4 / 59 (6.8%) 1 / 7 (14.3%) 4 / 63 (6.3%) 1 / 3 (33.3%) 
   D+ 3 / 16 (18.8%) 0 / 11 (0.0%) 3 / 5 (60.0%) 0 / 11 (0.0%) 3 / 5 (60.0%) 
   D++ 7 / 17 (41.2%) 2 / 9 (22.2%) 5 / 8 (62.5%) 3 / 10 (30.0%) 4 / 7 (57.1%) 
   D+++ 1 / 3 (33.3%) 0 / 0 (0.0%) 1 / 3 (33.3%) 1 / 1 (100.0%) 0 / 2 (0.0%) 
HP=hyperplastic, D+=mild dysplasia, D++=moderate dysplasia, D+++=severe dysplasia. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2 Outcome of patients with leukoplakia of the oral cavity, based upon histopathology. 
Comparing the combination of hyperplasia and mild dysplasia with moderate dysplasia 
and severe dysplasia results in HR=6.3 (CI: 2.32-17.25) (P<0.001). 
 
 
 
72 
Table 4.3 Progression-free period and different assays as well as clinical parameters determined 
by uni- and multivariate Cox regression analyses. Floor of mouth and tongue were 
considered to be high-risk locations, all other sites low-grade. 
 Univariate Cox regression 
Analysis 
Multivariate Cox regression analysis 
 
Variable Hazard Ratio p-Value  Hazard Ratio  
   Corrected for: 
   Histopath. ICM FISH 
Histopathology 6.3 
(2.32-17.25) 
<0.001 - 4.1 
(1.42-11.80) 
(P=0.009) 
3.9 
(1.31-11.50) 
(P=0.014) 
DNA image 
cytometry 
7.2 
(2.61-20.03) 
<0.001 5.4 
(1.82-15.77) 
(P=0.002) 
- 4.2 
(0.99-17.59) 
(P=0.052 
FISH 6.8 
(2.53-18.30) 
<0.001 4.4 
(1.50-13.08) 
(P=0.007) 
2.3 
(0.57-9.27) 
(P=0.24) 
- 
Age 1.1 
(1.01-1.10) 
0.025 
Sex 1.2 
(0.42-3.11) 
0.79 
Location 3.2 
(1.02-9.82) 
0.047 
Treatment 0.9 
(0.29-2.93) 
0.88 
Alcohol 1.1 
(0.98-1.23) 
0.098 
Tobacco 0.9 
(0.32-2.73) 
0.74 
Pack Years 1.0 
(0.94-1.02) 
0.29 
 
CI=95% confidence interval 
 
Chromosome instability  
As tetraploid lesions (n=3 for both ICM and FISH) harbour an abnormal DNA 
content,28,29,30 these lesions were included in the aneuploid group. ICM analysis 
revealed 23 aneuploid vs. 79 diploid lesions (23%) and FISH showed 17 
aneuploid vs. 85 diploid lesions (16%). Comparison of FISH and ICM revealed 
an identical outcome in 90 out of 102 leukoplakia (Table 4.4). The kappa 
statistic for this comparison was 0.63, which indicates a substantial agreement 
between both methods. (CI: 0.44-0.82). The percentage of aneuploidy 
increased with advancing histopathological classification. Of the aneuploid 
lesions detected by respectively ICM and FISH, 10 of 23 (43.5%) and 8 of 17 
(47.1%) showed malignant progression. In contrast, only 6 out of 79 (7.6%) and 
8 of 85 (9.4%) of diploid leukoplakia showed malignant progression for ICM 
and FISH, respectively (Table 4.2). Univariate Cox regression analysis 
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revealed an increased risk of malignant progression for aneuploid lesions (both 
ICM (HR=7.2; P<0.001) and FISH (HR=6.8; P<0.001); Table 4.3). This is also 
reflected in the progression-free survival curves based on CI detection, 
showing a significantly shorter survival for aneuploid lesions (Figure 4.3-4.4). 
Including both FISH and ICM in multivariate Cox regression analysis showed 
decrease of the HR for both techniques (ICM: HR=4.2; P=0.052 respectively 
FISH: HR=2.3; P=0.240; Table 4.3) for ICM and FISH, respectively), indicating 
that both techniques yield comparable information.  
 
Table 4.4 Correlation-table ICM and FISH.  
  FISH 
  Diploid Aneuploid Total 
ICM Diploid 76 3 79 
 Aneuploid 9 14 23 
 Total 85 17 102 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3 Kaplan-Meier curve of the progression free proportion of based upon ICM. HR=7.2 
(CI: 2.61-20.03) (P<0.001). 
 
Combining histopathology and CI 
In multivariate Cox regression analysis, ICM adjusted for histopathology 
showed a HR of 5.4 (CI: 1.82-15.8; P=0.002; Table 4.3). In this analysis 
histopathology and ICM appeared to be rather independent, complementary 
factors. Therefore, multivariate analysis was also performed by comparing 4 
combined classes i.e.: low-grade diploid, high-grade diploid, low-grade 
aneuploid and high-grade aneuploid lesions (high grade being defined as 
moderate or severe dysplasia, low grade encompassing the other 
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histopathological categories). Taking diploid low grade lesions as the reference 
category, the HR of aneuploid high-grade lesions was found to be as high as 
22.0 (CI: 5.78-83.45); P<0.001), with lesions being either high-grade diploid or 
low-grade aneuploid showing HR of 4.3 (CI: 0.76-23.92; P=0.101) and 5.5 
(CI: 1.37-21.96; P=0.016), respectively (Table 4.5). Because the latter two 
groups showed comparable HRs they were combined in progression-free 
survival analysis (Figure 4.5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4 Kaplan-Meier curve of the progression free proportion of based upon FISH. HR=6.8 
(CI: 2.53-18.30) (P<0.001). 
 
 
FISH adjusted for histopathology showed a HR of 4.4 (CI: 1.5-13.1; P<0.01; 
Table 4.3). Combining histopathology and FISH in multivariate Cox regression 
in a manner comparable to that described above for ICM and histopathology, 
similar results were obtained (Table 4.5). Aneuploid high-grade lesions show a 
HR of 16.3 (CI: 3.90-68.18; p<0.001) compared to low grade diploid lesions, 
with lesions being either high-grade diploid or low-grade aneuploidy showing 
HR of 9.0 (CI: 2.21-36.9; P=0.002) and 10.1 (CI: 2.52-40.4; P=0.001). When 
the latter two groups were combined a HR of 9.5 (CI: 2.85-32.00; P<0.001) was 
found in progression-free survival analysis as compared to low grade diploid 
lesions, but was not significantly different from aneuploid high-grade lesions 
(HR 1.71 with CI: 0.49-6.0; P=0.40). 
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Figure 4.5 Outcome of the ICM combined with histopathological subclasses. Aneuploid low-grade 
combined with diploid high-grade: HR: 5.0 (CI: 1.41-17.89) (P=0.013) ( adjusted to 
diploid low-grade) . Aneuploid high-grade HR: 21.9 (CI: 5.78-83.18) (P<0.001) 
(adjusted to diploid low-grade). Aneuploid high-grade: HR: 4.4 (CI: 1.29-14.70) 
(P=0.018) (adjusted to aneuploid low-grade + diploid high-grade). 
 
 
Table 4.5 Level of association of ICM/FISH and different histopathological classes with 
progression free survival. 
Histopathology 
DNA Image Cytometry Low-grade (HP and D+) High-grade (D++ and D+++) 
   Diploid Reference N=70 HR: 4.3 
(CI: 0.76-23.92) 
(P=0.101) 
N=9 
   Aneuploid HR: 5.5 
(CI: 1.37-21.96) 
(P=0.016) 
N=12 HR: 22.0 
(CI: 5.78-83.45) 
(P<0.001) 
N=11 
FISH analysis     
   Diploid Reference 
 
N=74 HR: 9.04 
(CI: 2.21-36.9) 
(P=0.002) 
N=11 
 
   Aneuploid HR: 10.1 
(CI: 2.52-40.4) 
(P=0.001) 
N=8 HR: 16.3 
(CI: 3.90-68.18) 
(P<0.001) 
N=9 
 
Low-grade: combination of hyperplasia and mild dysplasia. High-grade: combination of moderate 
and severe dysplasia. 
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Monitoring 
ICM revealed that almost all aneuploid malignancies resulted from aneuploid 
precursor lesions (9 out of 10) and almost all diploid carcinoma had a diploid 
precursor lesion (5 out of 6; FISH showed more variability: 4/8 respectively 
5/8). Interestingly, two aneuploid leukoplakias developed after 9.3 and 12.6 
years into an aneuploid SCC (based on ICM). 
Also analysis of intermediate precursor lesions and recurrent SCC was 
performed (Tables 4.6 and 4.7). From seven initial premalignancies showing 
progression to SCC, subsequent biopsies were available. Leukoplakia and 
subsequent malignancies were considered to be related if they were found at 
the same mucosal location.  
Six of seven cases (ICM-based) showed that the ploidy status of the 
successive lesions (both premalignant lesions and SCC) was identical to the 
status of the initial lesion. Only one initial aneuploid leukoplakia was followed 
by both a diploid leukoplakia and a diploid SCC (patient 1; Table 4.6). 
Interestingly, three initially aneuploid lesions without malignant progression for 
which subsequent leukoplakia specimens were available, showed transition 
from aneuploid to diploid lesions (ICM-based) (Table 4.7). Additionally, 6 (ICM-
based) diploid initial leukoplakia without malignant progression were followed 
by diploid leukoplakia on the same location (FISH: 4 diploid; 2 not available). 
(data not shown). Five patients treated for SCC developed new leukoplakia at 
the same location (Table 4.6). 
 
Table 4.6 Sequential ploidy scores represent mucosal disorders developed subsequently. 
Patient Initial 
premalignancy 
Intermediate 
premalignancies 
SCC Intermediate 
premalignancies 
Recurrent 
SCC(s) 
1 A D D A A 
2 A AA A  A 
3 A A Aa D AaAA Ab 
4 A A A  Aa 
5 D D D   
6 D  D DbDb  
7 A A A A AA 
8 A A Aa   
9 D  D D  
A=aneuploid lesion; D=diploid lesion. All values represent the same scores for ICM and FISH 
except the cases marked with a (ICM is aneuploid and FISH diploid). bFISH data not available. 
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Table 4.7 Monitoring of three patients with multiple leukoplakia without malignant transformation. 
Patient Biopsy 
year 
Biopsy Site Histopathology ICM FISH Treatment 
10 1999 
2000 
2002 
FOM front 
FOM front 
FOM front 
D+++ 
D+++ 
D+++ 
A 
D 
D 
A 
A 
D 
Laser 
Laser 
Laser 
 2006 End of follow-up 
11 2004 
2007 
2010 
Buccal mucosa left 
Buccal mucosa left 
End of follow up 
D+++ 
D+++ 
A 
D 
 
A 
D 
 
Surgery 
Expectative 
 
12 1997 
1997 
Trig. Retromolare right 
Trig. Retromolare right 
D++ 
HP 
A 
D 
D 
A 
Expectative 
Expectative 
 2001 Patient died because of heart failure   
FOM=floor of mouth; Trig=trigonum; HP =hyperplasia; D++=moderate dysplasia; D+++=severe 
dysplasia; D=diploid; A=aneuploid). Precursor lesions described in bold is the first biopsied lesion. 
 
Discussion 
In this study we analysed the added value of CI for the assessment of the 
malignant potential of oral leukoplakia, using two techniques (ICM and dual 
target FISH for chromosomes 1 and 7). Previous studies established that 
histopathology is only partly successful in predicting future behaviour of 
premalignant oral lesions.8,9,11,12 Data of the present study show that CI 
assessed by the two different approaches is an independent prognosticator, 
providing valuable information in addition to the histopathological diagnosis. 
Combining these sources of information, three groups of leukoplakia 
possessing respectively low, intermediate and high risk for malignant 
transformation may be discriminated. Moreover, it was found that CI detected 
by ICM might be a useful tool to monitor lesions over time. Generally, 
successive aneuploid premalignancies ultimately resulted in (aneuploid) 
tumours, whereas a shift from an aneuploid to a diploid status suggested a 
favourable prognosis.  
Our data concerning the prognostic value of the ploidy status of oral 
leukoplakia are largely concordant with existing literature.14,16,17 In the present 
study, aneuploid oral lesions showed malignant progression in 43.5% to 47.1% 
(detected by ICM and FISH, respectively). Similar percentages are found in 
other studies.14,16,17 Also in line with these studies, not all aneuploid leukoplakia 
transformed into malignancies. The results might be explained by the fact that 
these studies (including the present study) are based upon retrospective data, 
harbouring different intervention modalities (both radical and irradical) which 
ranged from watchful waiting to surgical excision or laser ablation. As reported 
by Torres-Rendon et al,14 we observed that aneuploid premalignancies are 
able to transform into SCC after a long time span (in this study one case even 
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after 12.6 years). Also, the fact that diploid lesions may progress to SCC was 
repeatedly found14,16,17 
In this study, 37.5% of the developed SCC were found to be diploid (FISH 
56.3%), which may (at least partly) be explained by the assessment method 
used. Previous studies found a large variability in the percentage of diploid oral 
SCC (8-70%).14,15,31,32 The lowest number of diploid SCC (8%) was found using 
a very sensitive method (CV values as low as 1%) applying FCM.15 In the 
present study using ICM, CV values of approximately 5% were found, making 
distinction between diploid and near-diploid populations hazardous. Okafuji et 
al concluded that sensitive techniques such as comparative genomic 
hybridisation showed that all oral carcinomas were aneuploid, but that many 
are not detected as such by techniques as FCM or ICM because of their 
detection limit.33,35 Another factor to consider when assessing ploidy status is 
heterogeneity within oral lesions as reported before.33,34  
Baretton et al. showed increased sensitivity for ICM based ploidy assessment, 
measuring ‘in situ’ in histological sections, rather than isolating whole nuclei 
from paraffin blocks.32 Apparently, the possibility of selective sampling of nuclei 
in suspicious regions enables detection of small aneuploid subpopulations, 
even when applying a less sensitive measurement procedure. In the present 
study, three of the initial premalignancies were diploid in ICM but aneuploid in 
FISH. Besides sampling error an explanation might be the inability of ICM 
(on whole nuclei) to detect small aneuploid subpopulations in the biopsy 
specimen. In this study, FISH analysis, which is also applied to selective tissue 
section areas, identified in general less aneuploid cases compared to ICM, 
resulting in decreased sensitivity for predicting progression (with a 
corresponding increase in specificity). This may be explained by sampling bias 
or by the fact that FISH only assesses copy number variations of two 
centromere probes. 
The results of Baretton et al.32 are in accordance with our previously published 
data, in which ploidy assessment in tissue sections was combined with 
assessment of expression of biomarkers Ki67, p53 and yH2AX.10 Despite a 
sufficiently high sensitivity of ICM and FISH also diploid precursor lesions as 
well as their subsequent tumours may be found. It has been shown previously 
that a minority of oral lesions follow an alternative genetic pathway, ultimately 
resulting in an invasive phenotype not harbouring large copy number 
alterations or chromosome instability.36 This phenomenon may also explain the 
results found in the present study. Further study is therefore recommended. 
Combining ploidy data with analysis of biomarkers relevant for this alternative 
pathway even may yield additional information and increase sensitivity.10 
Subdivision of leukoplakia into three risk levels, based on the combined 
histopathology and CI analysis may lead to a more appropriate patient 
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treatment. Both ICM as well as FISH are suitable for this approach. In this 
study, aneuploid high grade dysplasia (comprising 11% of cases) had a 
progression free survival of approximately 40% after 4 years (HR of 22.0 
compared to low histological grade diploid cases). Similar results were 
published previously (HR of 19.3 for aneuploid high grade dysplasias, which 
constituted 8% of the population).17 In comparison, 37.5% of OSCC patients 
showed recurrence in a comparable time interval after treatment.37 Therefore, 
considering these lesions to be similar to OSCC in terms of treatment options 
may be considered. On the other end, diploid low grade leukoplakia are largely 
devoid of malignant transformation (<3% after 6 years), justifying a ‘wait and 
see’ policy. Especially for cases of mild and moderate dysplasia, CI analysis 
may be used to tune clinical management. Results from this study suggest that 
an aneuploid mild dysplasia is comparable to a diploid moderate dysplasia in 
terms of progression free survival. On the other hand, a diploid mild dysplasia 
may be eligible for a ‘wait and see’ policy whereas an aneuploid moderate 
dysplasia may demand treatment comparable to an OSCC. In this way, CI 
analysis may greatly reduce the number of cases of intermediate malignant 
potential, which are inherently difficult to manage.  
With regard to the option of using CI analysis for monitoring patients over time, 
promising results were obtained. Considering the low number of cases for 
which data were available, however, a prospective study is required to confirm 
this hypothesis. 
In conclusion, assessment of CI in oral leukoplakia yields independent 
prognostic information, which may contribute to individual patient management. 
Different assays may be applied to establish the CI status, having their own 
merits and weaknesses. In the present study the combination of histopathology 
and CI (both ICM and FISH) improved the assessment of the malignant 
potential and may enable the monitoring of (treated) oral leukoplakia over time. 
CI analysis can help to select patients with a high risk of malignant progression 
and therefore may identify a subset of leukoplakia suited for stricter follow-up 
as well as a group of leukoplakia eligible for more aggressive treatment. 
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Oral squamous cell carcinoma (OSCC) has a poor prognosis with a 5-years 
survival of approximately 50%, partly due to the development of (loco)regional 
recurrences in 10-30% of surgically treated patients.1,2 These recurrences may 
arise from histopathologically undetected residual cancer cells and precursor 
lesions (minimal residual disease) in resection margins. The presence of 
(pre)malignant cells in resection margins that were apparently tumor-free after 
histopathological examination  can be demonstrated by the use of various 
molecular and cytochemical assays, including p53 mutation and expression 
analysis as well as chromosome 1 and 7 copy number detection by the use of  
in situ hybridization (ISH).3,4 Mutations in  p53 and chromosome 1 and 7 
alterations are common in (pre)malignant head and neck lesions and have 
been used successfully for risk-assessment of premalignancies.1,5-7 
In 2001 we have reported  on the molecular detection of residual 
(pre)malignant cells in the resection margins  of 20 oral cancers that were 
radically resected between 1994 and 1997.4 None of these patients did receive 
any additional treatment and no follow-up data were reported at that time. 
Resection margins were examined by ISH for chromosome instability (CI), 
defined as the presence of chromosome 1 and 7 copy number imbalances 
and/or polysomy, and by immunohistochemistry for nuclear p53 overexpression 
in squamous epithelial cells. Table 5.1 summarizes these molecular data, 
showing 8 out of 19 cases with (pre)malignant cell nuclei harboring CI (see 
Figure 5.1) and 8 cases with nuclear p53 immunostaining (with 6 cases 
overlapping). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1 Representative image of a FISH analysis on an OSCC resection margin of patient 17, 
showing A) blue DAPI-stained nuclei, B) 3-4 fluorescein-stained copies of the 
chromosome 7 centromere per nucleus (green), and C) 1-2 rhodamine-stained copies 
of the chromosome 1 centromere per nucleus (red). 
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In order to examine the predictive value of these molecular markers, we have 
now re-evaluated the histopathological and clinical patient files and collected 
follow-up data of these 19 patients over a period of 10-13 years (see Table 
5.1). One patient is excluded from the current study because of a 
retrospectively proven irradical resection of the primary tumor. Our study 
revealed that all 11 patients without CI in their resection margins showed no 
evidence of disease during follow-up. In contrast, 4 out of 8 patients with CI 
developed disease during follow-up, two showing local recurrence within 
5 years, and two additional patients developed local/locoregional tumours after 
10 and 11 years. Four patients remained tumour-free. 
 
Table 5.1 Clinical follow-up data of 19 patients with OSCC, whose primary tumour resection 
margins were histopathologically tumour-free and analysed for CI and p53 
overexpression. 
Molecular results 
in 
resection margins 
Follow-up 
time 
(years) 
Progression Patient 
number 
Location of primary tumour TNM* 
CI p53   
1 Trigonum retromolare (right) T2N0M0 - -  12.5 - 
2 Lateral tongue (left) T1N0M0 - -  11 - 
3 Floor of mouth (left) T1N0M0 - -  12 - 
4 Floor of mouth anteromedial T2N0M0 - -  12.5 - 
5 Lateral tongue (right) T2N0M0 - -  12 - 
6 Floor of mouth anteromedial T2N0M0 - -  10 ** - 
7 Lateral tongue (left)  T1N0M0 - -  11.5 - 
8 Inferior alveolar proc. (left) T1N0M0 - -  11 - 
9 Lateral tongue (left) T1N0M0 - -  11.5 - 
10 Lateral tongue (left) T2N0M0 - +    2 ** - 
11 Lateral tongue (left) T3N0M0 - +    8 ** - 
12 Lateral tongue (left) T2N0M0 + -  12 - 
13 Floor of mouth (right) T1N0M0 + +  10.5 - 
14 Floor of  mouth (left) T1N0M0 + +  12 - 
15 Floor of mouth (right) T2N0M0 + +  11.5 - 
16 Lateral tongue (right) T1N0M0 + -    1.5 + (LT) 
17 Lateral tongue (right) T1N0M0 + +    2 + (LT) 
18 Floor of mouth (left) T1N0M0 + +  10 + (LT) 
19 Lateral tongue (right) T1N0M0 + +  11 + (LRT+DM) 
*Tumors were classified according to the TNM-classification criteria of malignant tumors (UICC). 
**These patients died during follow-up due to a non-OSCC related cause. CI: Chromosome 
Instability measured by ISH for chromosomes 1 and 7, defined as the presence of chromosome 1 
and 7 copy number imbalances and/or polysomy. p53: Lesions were classified as either p53-
negative, when no or only a few cells with positive nuclear staining were observed, or p53-positive, 
when multiple cells with positive nuclear staining were present21. LT: Local tumor growth. LRT: 
Locoregional tumor growth. DM: Distant metastasis. 
 
 
While all 4 recurrent cases showed CI, only 3 of these were positive for p53. As 
a result CI detection is strongly associated with (loco)regional tumor outgrowth 
during follow-up as indicated by a P-value of 0.018 in the Fisher’s exact test, 
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whereas p53 immunostaining does not significantly correlate with recurrence of 
OSCC. We therefore advise to perform a CI analysis in histopathologically 
radical resection margins of OSCC. A re-resection or additional treatment 
should be considered in case of CI detection. 
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Abstract 
Chromosome instability (CI) detected by Fluorescence in Situ Hybridization (FISH) for 
chromosome 1 and 7 centromeres predicts malignant progression in premalignant head 
and neck lesions in which routine histopathological evaluation does not provide 
sufficient information. The aim of this study was to determine objective, clinically 
applicable evaluation criteria for CI detection. We performed dual-target FISH for 
chromosome 1 and 7 centromeres on 4 µm formalin-fixed, paraffin embedded tissue 
sections of 87 laryngeal premalignancies (severe dysplasia and carcinoma in situ (CIS) 
excluded) to detect copy number variations (CNVs). Thirty-five randomly selected, 
normal head and neck squamous cell samples were used as a control. The 
chromosome 7:1 ratio (CR) and percentage of aberrant nuclei (PAN) were established 
in each lesion. The normal range of CRs (≥0.84≤1.16) was based on the mean CR +/- 3 
x SD found in the normal population, the cut-off value for PAN was set at ≥10%. PAN 
showed a stronger correlation with malignant progression than CR (resp. OR 5.6, 
P=0.001 and OR 3.8, P=0.009). PAN combined with dichotomized histopathological 
diagnosis (HP) resulted in a prognostic model with an area under the ROC curve (AUC) 
of 0.75 (s.e. 0.061, sensitivity 71%, specificity 70%). Evaluation criteria for FISH 1c/7c 
based on PAN ≥10% provide the best prognostic information in the risk-management of 
premalignant laryngeal lesions. 
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Introduction 
Head and neck squamous cell carcinoma (HNSCC) belongs to the 10 most 
common cancers worldwide.1 Well-established oncogenic risk factors include 
alcohol and tobacco consumption as well as infection with Human Papilloma 
Virus (HPV) especially in oropharyngeal cancer.2-6 Curative treatment consists 
of surgical excision, radiation therapy with or without chemotherapy and/or 
targeted therapy. Approximately 25% of all HNSCC are located in the larynx.1 
Despite medical oncological progress HNSCC is associated with a poor 5-year 
survival of approximately 50%, which can partially be explained by 1) a late 
onset of symptoms and thus presentation at late-stage disease 2) association 
of HNSCC with second (or thirth) primary malignancies in the digestive or 
respiratory tract 3) tumor recurrence due to minimal residual disease (MRD) in 
resection margins and/ or locoregional recurrence and  4) poor results of 
chemotherapy by a lack of therapeutic (onco)target genes. Furthermore, 
difficulties in the differentiation between potentially harmful (progressive) and 
non-harmful (non-progressive) premalignant head and neck lesions make the 
choice for appropriate treatment difficult.7-10 The current gold standard is 
histopathological examination of the epithelium and underlying stroma, in most 
cases on tissue biopsy material. However, it has been shown that 
histopathological classification, especially in low-grade lesions, is hampered by 
a high inter- and intra-observer variability, which has implications on clinical 
decision making and the prognosis of patients.11,12 The oncogenic molecular 
changes which lead to an increased rate of chromosome mis-segregation in 
mitosis, failure to maintain a correct chromosomal content (euploidy) and the 
status of chromosome instability (CI) and thus to malignant progression of a 
lesion do not always lead to histomorphological changes that can be detected 
by the pathologist.13-16 This makes the application of other, objective and more 
reliable molecular markers, which can detect CI in an early stage necessary.  
Our previous studies on CI detection showed that the assessment of numerical 
aberrations of chromosome 1 and 7 using dual target centromere FISH probes 
for chromosomes 1 and 7 can predict malignant progression in oral and 
laryngeal premalignant lesions.17,18 These chromosomes were chosen because 
in HNSCC chromosome 1 copy numbers in general reflect the ploidy status of 
the nucleus whereas chromosome 7 shows very frequently gain, also in 
relation to chromosome 1 copy number.18,19 Recent genomic studies on head 
and neck lesions also report extensive CI with frequent gain of chromosome 
7.16,20 This FISH approach requires only small tissue amounts, which is an 
advantage in e.g. laryngeal lesions, in contrast to other molecular diagnostics 
(loss of heterozygosity analysis (LOH), DNA flow- and image cytometry and 
array comparative genomic hybridization). Furthermore, the tissue architecture 
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remains unaffected which allows a thorough impression of an often 
heterogeneous lesion. Moreover, this technique is relatively easy to perform 
with low costs, in comparison to e.g. more complex approaches such as 
microarray analysis  or next-generation sequencing (NGS).16,21-25  
The fact that in premalignant head and neck lesions with CI predominantly 
chromosome gain for one or both chromosomes is found (especially for 
chromosome 7), generally allows easy visualization of aberrant nuclei and 
gives a quick impression of the presence of CI in a lesion.17,18 Until now the 
evaluation of our FISH results was carried out by two independent investigators 
who performed a global screening of a lesion and assessed the presence of 
aberrant copy numbers of chromosomes 1 and 7. In this way a lesion could be 
labeled as disomic, trisomic, tetrasomic or polysomic (>4 signals per nucleus) 
for one or both chromosomes, based on the highest copy number of both 
chromosomes per nucleus present in ≥20% of nuclei (with a minimum of 50 
nuclei and a maximum of 500 nuclei, depending on the size of the lesion), and 
categorization as either “stable” (configuration 2/2) or “instable” (configuration 
other than 2/2, including a “balanced” chromosome 7/1 status e.g. 4/4 or 
tetrasomy). However, FISH analysis on tissue sections for the assessment of 
the number of signals per nucleus is hampered by 1) cutting artifacts, which 
can lead to loss of signals and 2) fortuitous overlap of nuclei, which could both 
lead to misinterpretation of the correct number of signals per nucleus.26 Taking 
into account these technical limitations we intended in this study to define 
stricter and reproducible evaluation criteria for the assessment of FISH lesions 
in order to obtain a maximum of objectivity. These new evaluation criteria 
should also be implementable in future computerized tissue analysis.  
 
Based on FISH analyses in tumor diagnostics for other entities than HNSCC, 
which detect numerical chromosomal aberrations or copy number variations 
(CNV), chromosome re-arrangements, amplifications or deletions in a certain 
number of analyzed nuclei27-30 (Table 6.1), and our previous results8,14,15,17,18,23 
we compared in this study: 1) the Chromosome Ratio (CR) between 
chromosomes 7 and 1, and 2) the percentage of aberrant nuclei (PAN) based 
on the absolute number of nuclei per 100 with >2 signals for one or both 
chromosomes. We compared both criteria in terms of reliability in the 
assessment of malignant progression-risk and clinical applicability in a series of 
87 premalignant laryngeal lesions. Furthermore, we used a normal control 
population as a reference in order to reduce the possible influence of cutting 
and overlap of nuclei on the interpretation of data. 
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Table 6.1 Evaluation criteria currently used for routine FISH analysis of tumors.  
Tumor entity DNA 
Probe(s) for   
Tissue Evaluation 
criterium 
Cut-off value N=nuclei 
to be 
scored 
References 
Lung cancer ALK   FFPE& 
cyto 
rearrangment PAN≥50%  
PAN≥15% 
n=50 
n=100 
Jurmeister et al.27 
 ROS1 FFPE& 
cyto 
rearrangment PAN≥50%  
PAN≥15% 
n=50 
n=100 
Jurmeister et al.27 
 RET FFPE& 
cyto 
rearrangment  PAN≥20%, 
PAN≥4% 
n=50 Tsuta et al.35 
 MET FFPE&  
cyto 
amplification MET/ CEP7-  
ratio ≥2 
 Jurmeister et al.27 
Different types of 
lymphomas 
Bcl2 FFPE& 
cyto 
translocation PAN≥10%,  
staining intensity  
n=200 Haralanbieva et al. 
 Bcl6 FFPE& 
cyto 
translocation PAN≥10%   Haralanbieva et al. 
 Myc FFPE 
cyto 
translocation PAN≥10%,  
staining intensity 
 Haralanbieva et al. 
Breast cancer ERBB2/ 
CEP17 
FFPE& 
cyto 
amplification/ 
CNG† 
ERBB2/ CEP 17 
Copy Ratio ≥2.0  
or <2 
n=20 Orsaria et al.36 
ASCO/ CAP 
guidelines37 
Melanoma  11q13/ 
6q23/6p25/C
EP6 
FFPE& loss/ CNG† PAN ≥ (29-55%)/ 
multiparameter 
model/ CR&& 
n=30 Gerami et al.38 
Bladder cancer Urovysion 
(chrom. 
3,7,9p21,17)  
Urine 
cytology 
CNV§ CNG* for 
chromosomes 
3,7,17 (≥4); 9p21 
loss in ≥12  
n=25 Huysentruyt et al.39 
 
Liposarcoma MDMD2/CD
K4/CEP12 
FFPE& amplification MDMD2/ CEP12- 
ratio ≥2; 
CDK4/CEP12  
ratio ≥2 
n=20 Sirvent et al.40 
Different sarcoma 
types 
DDIT3, 
EWSR1, 
FOXO1, 
FUS SS18, 
MDM2 
FFPE& rearrangement PAN ≥10-13% n=100 Horn et al. 2014 
 
Oligodendroglioma 1p/19q FFPE& Loss/ CNG 1p/1q and 19q/ 
19p ratio ≤0.8 
PAN≥30% 
n=20 Van der Bent et al. 
&FFPE: Formalin Fixed Paraffin Embedded. *GCN: Gene copy numbers, †CNG: Copy Number Gain,  §CNV: 
Copy Number Variation, &CEPX: centromere probe for chromosome x, &&CR Chromosome Ratio 
Materials and methods 
Patient data and tissue material  
Formalin-fixed, paraffin-embedded (FFPE) tissue biopsies from glottic 
premalignant lesions were obtained from the Radboud University Medical 
Center Nijmegen, the Netherlands, Zuyderland Medical Center Heerlen, the 
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Netherlands and The Netherlands Cancer Institute, Amsterdam, the 
Netherlands. 
Patient material was obtained by microlarynx-surgery between 1984 and 2007. 
87 out of 220 lesions were eligible for this study. We excluded 1) lesions 
harboring severe dysplasia or carcinoma in situ (CIS), 2) patients that had 
previously undergone radiation therapy of the larynx, 3) patients that had 
undergone a radical excision biopsy or vocal cord “stripping” (chordectomy type 
I), 4) laryngeal lesions other than glottic and 5) patients with a follow-up time 
from initial biopsy until malignant progression shorter than 6 months. None of 
the patients were included in previous studies of our department. N=33 patients 
could not be included because of a lack of representative patient material. 
Thirty-five at random selected, head and neck squamous cell tissue samples 
from 35 healthy, non-cancer related patients were used as a control population. 
The patient material was treated according to the Code for Proper Secondary 
Use of Human Tissue (Federation of Medical Scientific Societies, The 
Netherlands; 2003) and the study protocol was approved by the institutional 
ethical committee. In case of multiple available biopsies the last biopsy 
preceding SCC or CIS was chosen, taking into account a 6-months follow-up 
period as a minimum. Patient information including the follow-up data on 
malignant progression was collected from the medical records. Lesions were 
classified “progressive” in case of the development of carcinoma in situ (CIS) or 
squamous cell carcinoma (SSC) at the same localization site as the primary 
biopsy site within five years of follow-up.  
Histopathological assessment 
4 µm thick haematoxylin-eosin stained tissue sections of all lesions were 
thoroughly histopathologically classified according to the WHO classification 
system.  
Detection of chromosome 1 and 7 alterations by FISH analysis 
All lesions were submitted to FISH on 4 μm thick tissue sections, using 
centromere-specific probes for chromosomes 1 and 7 according to our earlier 
described protocol.17 Briefly, sections were deparaffinized, pretreated with 85% 
formic acid ⁄ 0.3% H2O2, 1 M NaSCN and 4 mg ⁄ml pepsin in 0.01M HCl, post-
fixed in 1% formaldehyde in phosphate-buffered saline (PBS), dehydrated in an 
ethanol series and hybridized with a mixture of digoxigenin-labeled human 
centromere 1-specific and biotin-labeled centromere 7-specific DNA probes [1 
ng⁄μl 60% formamide, 2x sodium-saline citrate (SSC), 10% dextran sulphate 
and 50x excess salmon sperm carrier DNA]. After hybridization the 
preparations were washed stringently in 2x SSC at 42˚C (two times for 5 min) 
and 0.1x SSC at 60˚ C (two times for 5 min). The probes were detected by 
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application of (i) mouse anti-digoxin (Sigma) ⁄ avidin fluorescein (Vector 
Laboratories, Burlingame, CA, USA), (ii) rabbit anti-mouse rhodamin (Dako, 
Glostrup, Denmark) ⁄ biotinylated goat anti-avidin (Vector) and (iii) swine anti-
rabbit rhodamin (Dako) ⁄ avidin fluorescein. Preparations were mounted in 
Vectashield (Vector Laboratories) containing 4,6-diamidino-2-phenyl indole 
(Sigma; 0.2 μg⁄ml). Microscope images were recorded with the Leica DC 300 
Fx camera (Leica, Wetzlar, Germany) mounted on top of a Leica DM 500 B 
fluorescence microscope (Leica), equipped with fluorescein-, rhodamine- and 
DAPI-specific filter sets for single-color analysis and a double bandpass filter 
set (fluorescein, rhodamine) for simultaneous dual-color analysis. 
Evaluation of FISH results 
All FISH stained lesions were examined independently, by two observers (VEB 
and MB). FISH signals in 100 nuclei were counted per color to determine 
chromosome 1 and 7 copy numbers. Nuclei containing other than 0,1 or 2 
signals per chromosome (e.g. tri-, tetra-, or polysomy) were considered 
aberrant. In all cases the entire tissue section was thoroughly screened for 
aberrant nuclei and counts were performed in a region which showed most 
aberrant nuclei. In order to discriminate between premalignant laryngeal 
lesions with or without CI, the following two approaches were applied and 
compared: 
1) the assessment of the chromosome 7/1 ratio (CR-FISH), based on the 
absolute amount of signals of both chromosomes in 100 nuclei. Cut-off 
values for CI were defined as CR-FISH≤0.84 or ≥1.16, based on the ratios 
found in the normal control population (further description in the Results 
section). 
2) the assessment of the amount of aberrant nuclei, counted in a total of 100, 
defined as the percentage of aberrant nuclei (PAN-FISH). The PAN cut-off 
value for CI in premalignant laryngeal lesions was set at ≥10% based on 
the optimal sensitivity and specificity in relation to prediction of malignant 
progression. 
Statistical analysis 
All data were analyzed using SPSS 22.0. Patients with non-progressive lesions 
were censored at the date of last follow-up (with a minimum of 5 years of 
follow-up from the date of biopsy) or date of death, provided that death was not 
related to laryngeal malignancy. Differences in patient characteristics between 
subgroups in the study population were evaluated with a two-tailed T-test for 
continuous variables and the Chi-square test or Fisher’s Exact test for 
categorical variables.  
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Logistic regression analysis was performed for histopathological diagnosis, CR 
and PAN. Taking into account the influence of possible confounders, 
multivariate logistic regression analysis was carried out, which resulted in a 
predictive model based on the combination of the different prognostic markers, 
including ROC curves. Progression-free survival analysis was calculated using 
the Kaplan-Meier method. A log rank test was performed to compare the 
progression-free survival of subgroups, classified according to histopathology, 
CR and PAN. In all analyses the P-value for significance was set at 0.05. 
Results 
Patient characteristics 
The patient group consisted of 34 females and 53 males. The lesions were 
histopathologically classified as 27 hyperplasias, 38 mild dysplasias and 22 
moderate dysplasias. Twenty-four out of 87 (27.3%) lesions showed malignant 
progression with a mean malignant progression time of 23.9 months (range 6-
54). Patient characteristics are found in Table 6.2. 
 
Table 6.2 Clinicopathological characteristics of the patient group. 
Patient population Histopathology CR PAN 
 HP+MD MDD P-value Normal Aberrant P-value <10% ≥10% P-value 
    N=62 N=25  N=51 N=36  
Gender   P NS   P=NS   P=NS 
   Male (n=53) 39 14  36 17  30 23  
   Female (n=34) 26 8  25 9  24 10  
Age (mean, (SD)  57.7 
(11.8) 
60.7 
(11.9) 
P NS 57.6 
(11,18) 
61.35 
(12.96) 
P=NS 57.8 
(12.4) 
59.9 
(10.8) 
P=NS 
Histopathology     P=NS   P=0.02* 
   Hyperplasia (n=27)    19 
(67%) 
8 
(33%) 
 17 
(67%) 
10 
(33%) 
 
  Mild dysplasia (n=38)    29 
(76%) 
9 
(24%) 
 26 
(74%) 
12 
(26%) 
 
   Moderate dysplasia 
(n=22) 
   14 
(64%) 
8 
(36%) 
 8 (36%) 14 
(64%) 
 
          
Outcome   P=0.02*   P=0.007*   P=0.001* 
   No progression (n=63) 52 11  50 13  44 19  
   Progression (n=24) 13 11  12 12  7 17  
* significant P-value; NS= non-significant P-value. Abbreviations: CR, Chromosome Ratio between chromosomes 
7 and 1; Normal CR 0.84≤CR≤1.16; PAN, Percentage of Aberrant Nuclei (nuclei showing other than 0,1 or 
2 signals for chromosome 1 and/or 7); HP, hyperplasia, MD, mild dysplasia, MDD, moderate dysplasia. 
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Histopathological diagnosis of premalignant laryngeal lesions and 
malignant progression 
Histopathological diagnosis was dichotomized and the lesions were divided in 
two categories: hyperplasia and mild dysplasia (n= 64) versus moderate 
dysplasia (n=23). No significant differences between both groups were found 
for age and gender.  
The lesions classified as moderate dysplasia showed significantly more often 
malignant progression than the lower grade lesions (hyperplasia + mild 
dysplasia); (P=0.02; Table 6.2).  
CI detection in FFPE tissue sections and application to premalignant 
laryngeal lesions 
a) Definition of cut-off values for CI assessed by CR-FISH in normal head and 
neck  squamous epithelium 
Randomly selected normal head and neck squamous cell epithelium samples 
from 35 healthy, non-cancer related patients were used as a control population 
and were subjected to CR-FISH analysis. All epithelia showed nuclei containing 
a maximum of 2 signals per chromosome per nucleus (Figure 6.1A), which is 
expected in normal tissue and in line with our previous findings17. The mean 
CR was 0.97 (range 0.84-1.07; SD 0.05). As the hypothetical CR between 
chromosome 7 and 1 would be 1.0, we used for statistical reasons the 
“distance to 1” as a parameter, which resulted in a mean of 0.045 (range 0.01-
0.16; SD 0.04). Based on the mean distance to 1 +/- 3 x SD we defined the 
range for a non-aberrant CR as 0.84≤CR≤1.16. 
b)  Assessment of CR-FISH  in premalignant laryngeal lesions and the 
association with malignant progression 
CR-FISH analysis performed in 87 premalignant laryngeal lesions showed an 
aberrant CR in 25 lesions. In most cases (21 out of 25; 84%) we found a 
CR≥1.16 indicating a relative gain of chromosome 7, which is in agreement 
with previous studies17. 
A representative image of a premalignant lesion with an aberrant CR is 
displayed in Figure 6.1B. 
Aberrant CRs were found in all histopathological stages, including hyperplasia, 
which demonstrates that the morphology of low-grade premalignant lesions 
does not reflect  underlying genetic changes (Table 6.2, Figure 6.1D). There 
were no significant differences in clinical features including age, gender and 
histopathology between the group with a normal CR and the group with an 
aberrant CR (Table 6.2).  
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Figure 6.1 Representative images of tissue sections of premalignant laryngeal lesions, analyzed 
by FISH 1/7 with centromere probes for chromosome instability (CI) detection showing 
disomy for chromosomes 1 (green) and 7 (red) (no CI) (A), trisomy for chromosome 1 
and polysomy for chromosome 7 (CI) resulting in an aberrant CR and PAN≥10% (B) 
and a lesion with only few aberrant nuclei, resulting in a normal CR but PAN≥10% (C). 
(D-E): percentage of CI in premalignant laryngeal lesions (hyperplasia, mild and 
moderate dysplasia) as determined by CR-FISH (D) and PAN-FISH (E). 
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An aberrant CR was associated with malignant progression (12 out of 25) 
(P=0.007; Table 6.2). However, 12 lesions with a normal CR did progress 
towards malignancy (12 out of 62), of which 5 lesions showed a trisomy for 
both chromosomes (n=3), or a relatively low number of nuclei with a trisomy for 
chromosome 1 (n=2). The remaining seven lesions showed a disomy for 
chromosomes 1 and 7, indicating a diploid status. On the other hand 13 lesions 
with an aberrant CR did not progress towards malignancy.  
c) PAN-FISH in premalignant laryngeal lesions and the association with 
malignant progression 
PAN-FISH analysis performed on 87 premalignant laryngeal lesions showed a 
PAN≥10% in 36 lesions, thus identified 11 additional lesions with chromosome 
alterations as compared to CR-FISH. A representative image with a PAN≥10% 
(and normal CR) is shown in Figure 6.1C.  
The group of lesions with a PAN≥10% contained significantly more lesions with 
moderate dysplasia and the percentage of lesions with a PAN≥10% increased 
with advancing histopathological stage (Table 6.2, Figure 6.1E). There were no 
significant differences in age and gender between the group with a PAN<10% 
and PAN≥10% (Table 6.2). Furthermore, a PAN≥10% was strongly associated 
with malignant progression (17 out of 36) (P=0.001; Table 6.2). Seven out of 87 
lesions did not contain aberrant nuclei and were nevertheless progressive. On 
the other hand 19 out of 36 lesions with PAN ≥ 10% did not undergo malignant 
transformation within 5 years and were considered as non-progressive. 
However, four of these patients showed malignant transformation after more 
than 5 years.  
Logistic regression analysis for histopathology, CR and PAN  
Odd’s Ratio’s for individual parameters are displayed in Table 6.3. 
PAN≥10% showed the strongest association with malignant progression 
(OR=5.6; (2.0-15.8); P=0.001), followed by dichotomized histopathological 
diagnosis, comparing moderate dysplasia with the combined group of 
hyperplasia and mild dysplasia (OR=4.0; (1.42-11.24); P=0.009), and aberrant 
CR (OR=3.8 (1.41-10.52); P=0.009). 
 
Table 6.3 Odds Ratios for individual parameters to predict malignant progression.  
Parameter  OR (95% Confidence Interval) P-value 
Histopathology 4.0 (1.42-11.24)  0.009* 
HP and MD vs MDD    
CR 3.8 (1.41-10.52)  0.009* 
PAN (≥10%) 5.6  (2.0-15.8)  0.001* 
* significant P-value. OR, Odds Ratio; CR, Chromosome Ratio; PAN, Percentage of Aberrant 
Nuclei; HP, hyperplasia; MD, mild dysplasia; MDD, moderate dysplasia. 
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Kaplan Meier progression-free survival analysis 
Patients with moderate dysplasia showed a significantly shortened 5-years 
progression-free survival as compared with lesions containing hyperplasia or 
mild dysplasia (P=0.009). No significant difference in survival was found 
between lesions containing hyperplasia or mild dysplasia (Figure 6.2A.). 
Kaplan Meier survival analysis showed a significantly shortened 5-years 
progression-free survival for patients with lesions harboring CI (P=0.003) 
(Figure 6.2B), and even more pronounced with lesions harboring a PAN≥10% 
(P=0.0001; Figure 6.2C), in which PAN-FISH outperformed CR-FISH analysis. 
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Figure 6.2 Kaplan Meier survival analyses for histopathology, CR-FISH and PAN-FISH. 
A) Progression-free survival according to histopathological diagnosis, patients with 
moderate dysplasia show a significantly shortened progression-free survival as 
compared to the patients diagnosed with hyperplasia or mild dysplasia; (P=0.009). 
The diagnosis of hyperplasia or mild dysplasia does not provide additional information 
on progression-risk. B) Progression-free survival according to CR-FISH. Patients with 
an aberrant CR show a significantly shortened progression-free survival (P=0.004). 
C) Progression-free survival according to PAN-FISH. Patients with PAN≥10% show a 
significantly shortened progression-free survival (P=0.0001) 
 
Multivariate predictive model, ROC curves  
In order to evaluate the prognostic information provided by dichotomized 
histopathological diagnosis, CR-FISH and PAN-FISH a multivariate regression 
analysis was performed and Receiver Operating Curves (ROC) were 
calculated. The combination of PAN-FISH with dichotomized histopathological 
diagnosis resulted in a slightly larger area under the curve (AUC=0.75; 
sensitivity 71% and specificity 70%) (Figure 6.3A) as compared to the 
combination of CR- FISH with dichotomized histopathological diagnosis 
(AUC=0.73; sensitivity 75% and specificity 66%) (Figure 6.3B). 
Histopathological diagnosis alone resulted in an AUC of 0.64. 
 
 Evaluation criteria for chromosome instability detection by FISH  
103 
6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.3 A) Receiver Operating Curve (ROC) for dichotomized histopathological diagnosis only 
(black line a) and in combination with PAN≥10% (upper dotted line b), AUC=0.75, 
optimal sensitivity 71%, specificity 70%. B) Receiver Operating Curve (ROC) for 
dichotomized histopathological diagnosis only (black line a) and in combination with 
CR (upper dotted line b),  AUC=0.73, optimal sensitivity 75%, specificity 66%. 
 
Discussion 
In previous studies we have shown that the analysis of CI in premalignant head 
and neck lesions by detection of CNVs of chromosomes 1 and 7 using FISH 
contributes to a more reliable risk assessment for cancer outgrowth.8,14,17,18 CI 
detection can be particularly useful in low-grade lesions (hyperplasia, mild and 
moderate dysplasia), because in these lesions the gold standard of 
histopathological assessment does not provide sufficient prognostic 
information.17 This poses the clinician for the diagnostic dilemma which lesions 
require treatment and which do not.  
The aim of this study was to determine objective and easily applicable 
evaluation criteria for CI detection by FISH in a new, independent patient 
population of low-grade premalignancies. For this purpose, two CI detection 
methods were compared, i.e. 1) determination of the ratio between 
chromosome 7 and 1 copy numbers (CR) counted in 100 nuclei (CR-FISH) and 
2) the determination of the percentage of aberrant nuclei (showing >2 signals 
for one or both chromosomes) in 100 nuclei (PAN-FISH). We found that CI 
detected by CR-FISH and especially PAN-FISH (cut-off ≥10% aberrant nuclei) 
was strongly associated with malignant progression (OR 3.8 and 5.6, 
respectively). A multiparameter model with ROC curves combining respectively 
PAN-FISH with dichotomized histopathological diagnosis (hyperplasia and mild 
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dysplasia vs. moderate dysplasia) resulted in an AUC of 0.75, which was 
slightly higher than when combining CR-FISH with histopathology (AUC 0.73).  
PAN-FISH is more favorable than CR-FISH for CI detection 
The CR-FISH approach is suitable for an objective, quantitative analysis of 
chromosome 1 and 7 copy number variations. However, if only few aberrant 
nuclei are present in a lesion, as a consequence, the CR may not exceed the 
defined range for normal squamous cell epithelium. The same issue is 
encountered in case of a numerically balanced chromosome status (trisomy/ 
tetrasomy), resulting in a potentially false negative test result (no CI detected). 
In both examples thus CR-FISH will not detect CI while PAN-FISH will (if ≥ 10% 
aberrant nuclei). In addition, scoring of a minimal amount of abnormal nuclei 
(PAN-FISH) in between a large amount of normal nuclei is easier to perform 
than assessing the CR in such a situation (CR-FISH). Indeed, PAN-FISH is 
also often used for the diagnostics of CNVs and gene rearrangements in other 
tumors (see Table 6.1.). 
FISH not always correctly predicts outcome 
Despite the strong correlation between CI and malignant progression, both 
FISH approaches did not always correctly predict outcome. For example, 
lesions with CI did not always progress to cancer, which can be explained by a 
possibly radical excision of a small laryngeal lesion containing CI, during the 
primary biopsy. Seven patients with a premalignant lesion containing CI 
showed malignant progression >5 years after biopsy (range 63-208 months). 
Because a 5-year follow-up is generally considered as an endpoint for outcome 
we considered these cases as non-progressive in this study, although 
malignant progression of lesions after a relatively long period (>5 years) has 
been reported earlier8. Statistical analysis taking into account the clinical 
outcome of patients with or without the 5-years endpoint of follow-up however, 
showed comparable results in terms of prognostic values of the tested 
parameters (data not displayed).  
On the other hand, lesions without CI and harboring a disomy for chromosome 
1 and 7 sometimes show malignant progression, as has been previously 
reported. Also the recent ATCG sequencing study reported a subgroup of 
HNSCC with a stable genome.20 In diploid precursor lesions carcinogenesis 
may be induced by other factors e.g. oncogenic viruses, methylation or LOH at 
9p21, which may not always result in numerical aberrations of chromosome 1 
and/ or 7.22,31-33 In order to recognize this particular group of diploid, 
progressive lesions, probably the supplementary application of other markers, 
such as LOH for 9p21, could be useful.  Particularly PAN-FISH will determine 
lesions with tri-or tetrasomies as well as lesions with only small groups of 
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aberrant nuclei, in contrast with CR-FISH. Finally, a false-negative (non-
representative) tissue biopsy should always be considered.7,17,18 
The role of histopathological diagnosis 
The histopathological classification of laryngeal biopsies remains the gold 
standard for the risk assessment of malignant outgrowth. The evaluation of 
squamous cell epithelium may lead to diagnoses varying from e.g. hyperplasia 
to CIS, according to the WHO criteria. Severe dysplasia and CIS are 
classifications which are in general univocally posed by different pathologists 
and correlate strongly with the presence of CI and malignant progression of a 
lesion. However, this is not the case for the lower-grade histopathological 
classifications (hyperplasia, mild and moderate dysplasia), which do not always 
reflect the underlying genetic changes.34 In this study histopathology 
contributed only positively to the risk-assessment if applied in a dichotomized 
way, (hyperplasia and mild dysplasia v.s. moderate dysplasia), resulting in a 
better OR than expected on the basis of our previous results.17 This might be 
explained by the study design, in which inter-observer variability was reduced 
by the assessment of the lesions by two experienced head and neck 
pathologist (PJS and CJP), which is not the case in daily clinical practice.  
 
In conclusion, our data provide evidence that CI in premalignant lesions 
predicts malignant progression. CI analysis based on FISH analysis for the 
detection of chromosomes 1 and 7 CNVs can best be performed using a cut-off 
value of ≥10% nuclei with aberrant chromosome copy numbers.  
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General discussion 
The development of HNSCC is a multistep process in which the head and neck 
mucosa undergoes molecular and histomorphological changes which finally 
result in cancer. In this process, precursor lesions are often encountered and 
the clinical management of these lesions comprises local treatment (surgery 
and/or radiation therapy) or a wait and see policy.1,2 The gold standard for risk 
assessment is histopathological classification of these lesions, which however 
remains a major challenge. The main aim of the studies in this thesis was to 
identify reliable molecular indicators for malignant outgrowth. For this purpose 
we investigated three approaches i.e. FISH for copy number analysis of 
chromosome 1 and 7, Image Cytometry (ICM) to detect DNA aneuploidy and 
immunohistochemistry (IHC) to evaluate expression of proteins involved in the 
cell cycle and apoptosis. 
First, we investigated which histopathological classification method for 
premalignant laryngeal lesions provides the most uniform diagnosis, and which 
level of uniformity can be reached (Chapter 2). We found a large interobserver 
variability for all 3 investigated classification systems. A reduction of the 
grading systems towards a 2 or 3-grade system resulted in a better 
concordance between observers. Nevertheless, only moderate agreement was 
achieved. Simultaneous assessment of lesions by three pathologists did also 
result in an improvement of the concordance level.  
In the next chapter (Chapter 3), we compared the value of chromosome 
instability (CI), detected by FISH and defined as CNV for chromosome 1 and 7, 
with immunohistochemical analysis of p53, FADD, pFADD and Cyclin D1 
expression for the prediction of malignant progression in premalignant 
laryngeal lesions. CI detection proved to be a strong prognostic marker of 
malignant progression. In addition, detection of p53 and FADD overexpression 
can be helpful in the identification of progressive, CI-negative lesions. 
In Chapter 4 we compared the prognostic value of CI determined by FISH and 
aneuploidy by ICM in oral premalignant lesions. The presence of CI/ 
aneuploidy detected by both methods was strongly associated with malignant 
progression.   
In Chapter 5 we found that CI detection by FISH also can be of value for the 
prediction of tumor recurrence in histopathologically tumor free resection 
margins of Oral Squamous Cell Carcinoma (OSCC). In this follow-up study 
resection margins with CI showed to be associated with tumor recurrence. The 
presence of p53 overexpression as detected by IHC was unreliable for this 
purpose.   
In order to establish objective evaluation criteria for CI detection by FISH, two 
approaches were compared and applied on a new series of premalignant 
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laryngeal lesions in Chapter 6. The first approach determined the chromosome 
7:1 copy number ratio in 100 nuclei (CR-FISH), whereas the second assessed 
the number of CI-containing nuclei in 100 nuclei, with a cut-off value of ≥10% 
for CI-positivity (PAN-FISH). The latter approach provided the most reliable 
prognostic information in the risk-management of these lesions.  
Interpretation of study findings 
The role of histopathology in risk-assessment of head and neck 
premalignancies 
Different histopathological grading systems have been developed for 
premalignant head and neck lesions. The most commonly used systems 
include the WHO-, SIN-, and Ljubljana classification. The reported percentages 
of lesions that show malignant progression for each classification-subclass 
however differ substantially in literature.3-5 
In this thesis we evaluated the value of histopathological assessment to predict 
malignant progression of premalignant head and neck lesions. In chapter 2 we 
compared the WHO, SIN and Ljubljana classification systems on premalignant 
laryngeal lesions. Disappointing κ-values for interobserver agreement were 
found for each classification system, and no significant differences between the 
κ-values of the three systems were found. A reduction of the grading systems 
to a 2 or 3-grade system resulted in an improvement of the κ-values and the 
percentage of concordance between pathologists. However, only a moderate 
(and clinically insufficient) agreement between observers was achieved. 
Simultaneous assessment of lesions by three pathologists resulted in an 
improvement of the concordance level. This underlines the fact that the 
histomorphological assessment of premalignant lesions remains difficult and 
subjective, which makes a prediction of the malignant progression risk based 
on the histomorphological features hazardous. Thus, histopathological 
diagnoses of one head and neck precursor lesion posed by different 
pathologists are inconsistent. 
In Chapter 3, 4 and 6 we have analyzed the prognostic value of 
histopathological diagnosis, including all different degrees of dysplasia, based 
on the WHO criteria. We found that for both laryngeal and oral lesions 
histopathological diagnosis was not able to reliably differentiate between 
progressive and non-progressive lesions, especially in the lower-grade lesions 
(hyperplasia, mild and moderate dysplasia). Only the diagnosis severe 
dysplasia distinguished clearly between progressive and non-progressive 
lesions, i.e. a significant difference in disease-free survival was found. For the 
lower-grade lesions statistical significance could only be reached by the use of 
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a two-degree dichotomization (hyperplasia + mild dysplasia versus moderate 
dysplasia). This underlines the fact that the grade of dysplasia does not 
accurately predict the risk for progression of premalignant head and neck 
lesions.  
On the basis of our data we would like to propose regular training of head and 
neck pathologists as well as pathology residents for the assessment of head 
and neck precursor lesions. Furthermore, histopathological assessment of 
premalignant head and neck lesions by more than one pathologist and the 
introduction of a two-degree classification system for the category of lesions 
comprising hyperplasia, mild and moderate dysplasia should be considered. 
Finally, it is highly recommended to combine histopathological assessment with 
the application of molecular biomarkers to improve the risk assessment of head 
and neck premalignancies,2 Chapter 3,4,6.  
The role of molecular biomarkers in risk assessment of head 
and neck premalignancies 
In this thesis we focused on FISH analysis to detect CI and ICM to detect 
aneuploidy, as well as overexpression of p53, cyclin D1, FADD and pFADD 
proteins, all being potential biomarkers for progression of head and neck 
premalignancies.6-8 
Chromosome instability detection by FISH  
FISH using chromosome 1 and 7 centromere probes to detect CNVs for one or 
both chromosomes is a relatively straight-forward approach, which can be 
easily implemented in a clinical diagnostic setting. It has been earlier applied in 
a pilot study on premalignant laryngeal lesions, which showed an association 
between chromosome 1 and 7 CNVs and malignant progression.9 Analogue to 
this study, in this thesis we applied FISH for chromosome 1 and 7 centromeres 
in premalignant laryngeal and oral lesions to detect CI  and studied its value as 
a prognosticator (Chapter 3 and 4). The FISH approach showed to be ideal for 
premalignant head and neck lesions, especially for the larynx, where small 
biopsies are common. We found numerical aberrations of one or both 
chromosomes in hyperplasia, the different grades of dysplasia and CIS. Copy 
number gain was found for both chromosomes, however especially for 
chromosome 7.  
CI, including tri,- and  tetrasomy for both chromosomes (balanced 
chromosome-status), showed a strong association with malignant progression 
in both laryngeal and oral lesions.  
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Furthermore, in a minority of low-grade lesions an isolated trisomy for 
chromosome 1 with a disomic chromosome 7 status was observed. In the more 
advanced histopathological stages a majority of lesions with chromosome 
instability showed copy number gains for both chromosomes, which most 
probably reflects the occurrence of aneuploidy in the cell.  
In Chapter 5 we showed in a small retrospective study, that CI detection by 
FISH applied on resection margins of histopathologically radically resected 
OSCC (n=19) is able to predict local tumor recurrence. Four patients showed 
tumor recurrence and all cases showed CNVs for one or both chromosomes in 
at least one resection margin. Three out of these 4 lesions showed also p53 
overexpression. This pilot study shows that resection margins, which are 
considered as histopathologically tumor free, may contain (groups of) cells with 
CI, which may be associated with later tumor recurrence. In a subsequent 
study on 42 patients with resected OSCC, FISH analysis showed that in nine 
out of the eleven cases with tumor relapse within 5 years, CI could be detected 
in at least one of the surgical margins of the previously resected primary tumor. 
Thus, this study further underlines the prognostic value of CI detection to 
identify patients at risk for developing local recurrence, which has been further 
explored in a recent extended study on resection margins of OSCC.10 
Comparison of FISH results with DNA ploidy analysis by ICM 
In oral premalignant lesions (Chapter 4), in which larger tissue amounts were 
available, DNA ploidy detection by DNA image cytometry was performed in 
addition to the FISH approach, in order to compare both techniques. The 
presence of CI as detected by both FISH and ICM was strongly associated with 
malignant progression. While the assessment of chromosome instability by 
FISH is based on the analysis of CNVs of only two chromosomes, ICM 
comprises the whole DNA content and ploidy status. Both techniques have 
their merits and limitations, resulting in false positive and false negative results. 
For example, in case of an aneuploid lesion without CNVs for chromosomes 1 
and/ or 7 FISH results will show a disomy for both chromosomes, while ICM 
analysis will show an abnormal DNA content. On the other hand, small areas 
with aneuploid nuclei in lesions can be detected by FISH, while these lesions 
would be classified as normal by ICM. Nevertheless, the kappa analysis 
showed a “substantial” agreement between ICM and FISH. Multivariate 
analysis including both techniques showed a decrease of both Hazard Ratios, 
indicating that both techniques yield comparable information and that FISH 
gives a reliable indication of the ploidy status of the cell.  
Comparable with the results in laryngeal premalignant lesions, also in oral 
lesions the histopathological diagnosis did only have prognostic value if the 
different histopathological subclasses were pooled into low-grade vs. high-
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grade (hyperplasia and mild dysplasia vs. moderate dysplasia and severe 
dysplasia). This lead to a clinically relevant categorization of lesions in 1) 
lesions with a good prognosis (diploid low-grade), 2) lesions with an 
intermediate prognosis (diploid high-grade or aneuploid low-grade), and 3) 
lesions with a poor prognosis (aneuploid high-grade), the latter showing the 
poorest disease-free survival.  
CI detection in precursor lesions over time 
The ploidy status of oral precursor lesions and the subsequent tumor lesion 
was investigated in 9 patients who had undergone several tissue biopsies 
(Chapter 4). In five cases all precursor lesions as well as the tumor were 
aneuploid. In 3 out of 9 patients a diploid precursor lesion and diploid tumor 
was found (detected by both FISH and ICM analysis). This indicates that in 
order to identify this special entity of diploid, progressive lesions, other 
additional markers are required. In diploid precursor lesions carcinogenesis 
may be induced by other factors e.g. oncogenic viruses, methylation, Micro 
Satellite Instability (MSI) or LOH at 9p21, which may not always result in 
numerical aberrations of chromosome 1 and/ or 7.11-15 In order to recognize this 
particular group of diploid, progressive lesions, probably the supplementary 
application of other markers, such as LOH for 9p21, could be useful. 
One case showed an aneuploid precursor lesion, followed by a diploid 
precursor lesion and a diploid SCC. This might be explained by the existence 
of field cancerization, in which several genetically different clones may develop 
in a cancerous lesion.16 On the other hand, the localization of tissue biopsies 
might differ slightly, which may result in the detection of precursor lesions with 
a genetically different profile (biopsy bias).  
The role of cell-cycle and apoptosis related genes as markers 
of progression 
P53 
P53 is probably the most frequently mutated tumor suppressor gene in 
smoking and alcohol induced HNSCC.17,18 However, the role of p53 as an 
indicator of progressing premalignancies remains issue of debate.19-22 P53 
overexpression can even be found in non-cancerous lesions, e.g. Reinkes 
oedema of the larynx,23 which may also be induced by non-cancer related 
factors or simply be a sign of cellular stress.24 P53 overexpression in 
(pre)cancerous lesions is generally the result of gene mutation, but the 
interpretation and clinical relevance of p53 overexpression remains difficult.24 
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Furthermore, gene mutation without detectable protein overexpression may 
occur in case of truncation of the protein, as well as p53 overexpression 
without detectable gene mutation.25 The p53 overexpression pattern we found 
in premalignant laryngeal lesions (Chapter 3) as well as in histopathologically 
tumor free oral squamous cell (OSCC) resection margins (Chapter 5) was not 
sufficiently powerful as an individual marker of progression or predictor of 
tumor recurrence, although other studies report the contrary.20 However, most 
other p53-studies were performed on oral lesions, in which TP53 mutation and 
overexpression is far more common than in laryngeal lesions.26 Additional 
mutation analysis for TP53 might differentiate between gene mutation induced 
p53 protein overexpression and non-oncogenic overexpression. Probably, 
additional events along with TP53 mutation are required to induce progression 
towards cancer.  
Cyclin D1, FADD and pFADD   
Amplification and overexpression of the 11q13-related genes and proteins of 
Cyclin D1, FADD and its phosphorylated isoform pFADD is frequently found in 
head and neck cancer and has also been described as a marker of progression 
for premalignant lesions.8,27 However, our study in Chapter 3 could not confirm 
this in premalignant laryngeal lesions. We observed Cyclin D1 and FADD 
overexpression in a minority of cases of the study population (32% and 15% 
respectively), which might reflect a situation of impairment of cell cycle control 
and apoptosis induction, which does not necessarily lead towards cancer. 
Nuclear pFADD overexpression was very commonly found (93%), however 
without clinical significance.  
A multi-parameter progression model combining CI, p53 and 
FADD detection and histopathology for the risk-assessment 
of premalignant head and neck lesions 
The individually tested markers P53, Cyclin D1, FADD and pFADD were not 
sufficiently powerful to be used as single predictors of malignant progression, 
which is in line with other reports.19 
p53 and FADD overexpression was only clinically relevant in a multiparameter 
model combined with histopathology and FISH, which reduced the false 
negative cases, including a part of the diploid precursor lesions which were 
progressive but were “missed” by FISH detection alone. FADD and pFADD 
overexpression is probably clinically less relevant in head and neck 
premalignancies than in HNSCC, where overexpression of this protein can be 
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used for therapeutic purposes and differentiate between tumors that are more 
sensitive to radiation therapy or chemotherapy.28,29 
Optimization of the evaluation criteria for CI detection by 
FISH in risk assessment of premalignant head and neck 
lesions 
The evaluation criteria for the assessment of CI by FISH were further 
investigated in Chapter 6, in order to achieve a maximum of objectivity, 
reliability and time efficiency. Based on the evaluation criteria used in FISH 
diagnostics for other tumors (Chapter 6, Table 6.1)30-37 we tested and 
compared the chromosome 7:1 ratio (CR), based on the total of FISH signals 
for both chromosomes in 100 nuclei, with the percentage of aberrant nuclei 
(PAN), defined as the percentage of nuclei harboring more than 2 signals per 
chromosome. The use of PAN with a cut-off value of ≥10% aberrant nuclei 
showed the best association with malignant progression. Furthermore, this 
assessment method can be easily implemented in tissue diagnostics and is 
less time-consuming than CR assessment. Aberrant nuclei are relatively easily 
detected because copy number gain is nearly always observed. In this study 
we combined PAN with dichotomized histopathological diagnoses (hyperplasia 
vs. mild and moderate dysplasia), which resulted in an improvement of the 
AUC of the ROC curve, e.g. a slightly better predictive model.  
The role of FISH in the risk-counseling of premalignant head 
and neck lesions: limitations of the studies of this thesis 
As has been shown by the studies on premalignant laryngeal and oral lesions, 
FISH is a strong additional prognostic tool in the risk counselling of these 
lesions. Although it has been shown to be much more reliable than the 
traditional histopathology, large prospective studies are required for validation. 
There are some weaknesses, which should be addressed in future. The 
genetic diversity of premalignant lesions makes that, in order to identify also 
those lesions that have a diploid DNA status, it might be necessary to assess 
additional molecular markers, such as p53 and FADD overexpression and/ or 
3p and 9p deletion analysis.  
The results of our studies might, despite all efforts, be negatively influenced by 
1) biopsy bias (the biopsy of the precursor lesion has been not exactly taken 
from the same localization as the tumor lesion), 2) the biopsy that has been 
taken has radically resected all aberrant cells, 3) the tissue slices analyzed for 
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histopathology, FISH, ploidy assessment and immunohistochemistry possibly 
harbored slightly different regions (especially when only small areas of 
aneuploidy cells are present and 4) a lack of representative tissue which has 
reduced the number of eligible patients for the studies. 
However, based on the currently reported other markers of progression for 
premalignant head and neck lesions, which all give poorer predictive results, 
we believe that the introduction of FISH in the diagnostic management of these 
lesions may be of value and should be implemented in clinical practice.  
Future perspectives in the management of premalignant head 
and neck lesions 
The diagnostic dilemma of how to manage premalignant head and neck lesions 
remains an issue for further research. In this thesis we studied the value of 
other potential biomarkers for progression besides histopathological diagnosis. 
Numerical aberrations of chromosomes 1 and 7 have been shown to be useful 
as a strong marker of progression.  
To achieve better treatment results in terms of reduction of morbidity and 
mortality due to prevention of progression to HNSCC, early detection and 
appropriate treatment remain indispensable. 
Prevention should include awareness of individuals of the carcinogenic risks of 
especially smoking and alcohol consumption. Systematic screening for 
aberrant cells by cellular mouth-brushes could be done in individuals with an 
increased risk for the development of HNSCC, however, this would probably be 
cost-ineffective due to the relatively low incidence of HNSCC as compared to 
other types of cancer such as breast cancer, where population broad detection 
has been proved effective.  
For the early detection of asymptomatic oral lesions increased alertness of 
dentists, who carry out periodic dental controls could be helpful. In case of a 
mucosal lesion, which could require further investigation early referral to a 
specialist could then be established. Biopsies of a mucosal lesion could be 
(intra-operatively) guided by Narrow Band Imaging, which could better identify 
regions at risk in a lesion.38 
Once a biopsy has been taken, based on our data a dichotomized 
histopathological classification dividing lesions in low-risk and high-risk (which 
could comprise the WHO classifications hyperplasia and mild dysplasia vs. 
moderate dysplasia and severe dysplasia) should be applied. Additional 
assessment of chromosome instability by the detection of CNVs of 
chromosomes 1 and 7 by FISH in combination with FADD and p53 
immunohistochemistry may lead to a diagnostic model. In this light, also other 
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biomarkers, such as 3p and 9p loss and 8q gain might be relevant 
alternatives.12,39 
This approach could also be extrapolated to the assessment of resection 
margins of resected OSCC. A multi-center prospective study should provide 
final validation of these results and facilitate implementation of a new 
diagnostic protocol in the daily clinical practice.  
Conclusion 
CI detection by FISH is a powerful biomarker of malignant progression in 
laryngeal and oral premalignant lesions, which can also be applied on resection 
margins of OSCC to assess risk for local recurrence. This marker overrules the 
subjectivity of histopathological assessment and can detect those lesions which 
are at risk despite a normal histopathological appearance. However, the 
development of HNSCC is a complex process, in which different genetic 
pathways to cancer play a role. This makes a multiparameter approach for 
premalignant lesions indispensable in order to reduce false-negative cases and 
reduce patient morbidity and mortality. p53 and FADD may play a role as 
supplementary markers for the detection of diploid, progressive lesions, where 
FISH stainings may show chromosome 1 and 7 disomy. A prospective study 
design should provide data on the benefits in terms of a patients prognosis, 
cost-effectiveness and evaluation of future clinical implementation. 
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Summary 
In Chapter 1 a general introduction on the carcinogenesis of head and neck 
squamous cell carcinoma (HNSCC) and the etiological, clinical, epidemiological, 
histopathological and genetic features is given. HNSCC is a disease with a 
poor overall survival rate of approximately 50%. The factors that contribute to 
this disappointing survival rate are outlined. One of these is the existence of 
multiple precursor lesions in the head and neck mucosa or field cancerization, 
which may lead to tumor outgrowth. The importance of early detection and 
appropriate treatment of premalignant head and neck lesions is emphasized. 
The currently available diagnostic detection methods are described. 
Histopathological assessment of head and neck tissue biopsies remains until 
now the gold standard for the assessment of premalignant and malignant head 
and neck lesions. However, the histopathological approach, for which three 
internationally accepted classification systems do exist, has limitations due to 
inter observer variation in the assessment of lesions. This results in poor 
prognostic information in terms of an unreliable prediction of the risk of 
malignant progression for head and neck premalignancies. Due to the lack of a 
reliable prognostic tool for these lesions, the clinician may have difficulties in 
decision-making concerning the treatment or follow-up strategy of a lesion. The 
need for additional, more reliable, molecularly based and clinically applicable 
markers of progression, especially based on chromosome instability (CI) 
detection is highlighted, with a focus on clinically implementable diagnostic 
methods. The aims of the present thesis are described. 
 
The inter observer agreement between the three internationally accepted 
histopathological classification systems i.e. the WHO-, SIN- and Ljubljana 
classification in premalignant laryngeal lesions is compared in Chapter 2. We 
found a disappointing high interobserver variability for all three systems. A 
modification of the grading systems towards a 2 or 3 grade system resulted in 
an improvement of the agreement between observers, reflected in a 
“moderate” kappa value. Furthermore, an improvement of the inter-observer 
consensus was achieved when a lesion was simultaneously assessed by more 
than one pathologist. In order to achieve a maximum of interobserver 
agreement, a simplification of the existing histopathological grading systems 
towards a 2- or 3- degree profiling of lesions, i.e. low-risk, intermediate risk and 
high-risk as well as simultaneous histopathological assessment could lead to a 
more consistent histopathological diagnosis. 
 
In order to acquire more reliable prognostic information on the malignant 
potential of premalignant head and neck lesions, CI detection can be applied. 
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This principle is highlighted in Chapter 3, where we investigated the potential 
role of CI, defined as Copy Number Variations (CNV) of chromosomes 1 and 7, 
as a marker for malignant progression in laryngeal precursor lesions. Based on 
earlier reports by Veltman et al. on the presence of CNVs of chromosome 1 
and 7 in premalignant head and neck lesions, which showed to be associated 
with malignant progression, we further investigated this approach on a new 
series of laryngeal precursor lesions. Chromosome 1 and 7 CNVs were 
assessed by Fluorescent in Situ Hybridization (FISH) on centromere probes. 
Furthermore, the expression of the protein markers p53, Fass Associated 
Death Domain (FADD), pFADD and Cyclin D1 was immunohistochemically 
assessed. We observed that a large majority of the lesions with CI showed 
copy number gain, i.e. trisomy, tetrasomy or polysomy. Lesions with CI showed 
a strongly increased risk for malignant progression. Interestingly, CI was found 
in all histopathological grades, e.g. also in the WHO classification hyperplasia, 
however, more frequently in the more advanced histopathological degrees. 
None of the protein markers showed to be useful as an individual marker of 
progression. Histopathological diagnosis showed to be unable to differentiate 
between progressive and non-progressive lesions, especially when only lesions 
containing hyperplasia, mild and moderate dysplasia were analyzed. 
Dichotomization of the histopathological diagnosis to low-grade (hyperplasia 
and mild dysplasia) and high-grade lesions (moderate dysplasia) improved the 
prognostic value of histopathology. This findings lead to a proposed 
multiparameter prognostic model based on the markers CI, dichotomized 
histopathological diagnosis, p53 and FADD. The combination of these markers 
showed to be a useful prognostic tool for laryngeal premalignancies.  
 
In Chapter 4 we investigated the prognostic information provided by CI in oral 
premalignant lesions. CI detection was performed by both FISH analysis, 
based on the detection of CNVs of chromosome 1 and 7 and DNA Image 
Cytometry (ICM). The presence of CI as detected by both methods was 
strongly associated with malignant progression. Both ICM and FISH yielded 
comparable prognostic information in terms of malignant progression risk. This 
suggests that the analysis of CNVs of chromosome 1 and 7 by FISH can give a 
reliable impression of the general ploidy status of a lesion. Both techniques 
have their merits and disadvantages. The FISH approach is ideal for the 
detection of especially small lesions and visualizes small groups of aberrant 
cells, which are not always detected by ICM. Furthermore, FISH is also 
applicable on small tissue biopsies such as laryngeal biopsies, which do not 
contain sufficient DNA for ICM analysis. In this study, the prognostic 
information provided by histopathological examination of lesions was also 
analyzed. Only if dichotomization of the four included histopathological grades, 
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i.e. hyperplasia and mild dysplasia (low-grade) versus moderate and severe 
dysplasia (high-grade), was applied, a significant discrimination between non-
progressive and progressive lesions was found. This is comparable with the 
results found in premalignant laryngeal lesions, as reported in Chapter 3.  
Furthermore, in a series of oral premalignant lesions of which different, 
consecutive  tissue biopsies were available, we retrospectively analyzed the 
ploidy status over time (ICM and FISH 1c/7c). This analysis showed that almost 
all aneuploid tumors had an aneuploid precursor lesion and nearly all diploid 
precursor lesions resulted in a diploid tumor. Furthermore, in two cases an 
aneuploid tumor developed out of a aneuploid precursor lesion after a timespan 
of more than 9 years. On the basis of the information provided by CI detection 
(CI or no CI) and histopathological grade (low-grade or high-grade), a three 
steps risk-profile for premalignant lesions was proposed, containing 1)  diploid 
low-grade (low risk of malignant progression), 2) diploid high-grade and 3) 
aneuploid-low-grade (intermediate risk of malignant progression) and aneuploid 
high-grade (high risk of malignant progression). This subdivision of lesions 
could be useful to enable the discrimination of premalignant head and neck 
lesions that do not need follow-up, do require strict follow-up or do require 
immediate treatment.  
 
While the prognosis of HNSCC patients largely depends on whether tumor 
relapse occurs or not, we analyzed the potential role of CI detection in the 
search for residual, potentially malignant (groups of) cells in resection margins 
of oral squamous cell carcinomas (OSCC). In Chapter 5 we retrospectively 
analyzed resection margins in a set of 19 histopathologically radically resected 
OSCC for the presence of CI, assessed by FISH analysis, based on the 
detection of CNVs of chromosome 1 and or 7, and p53 protein overexpression 
assessed by IHC. We correlated these data to the clinical outcome in terms of 
(loco)regional tumor recurrence. CI in resection margins showed to be 
associated with tumor recurrence. Also long term recurrences, up to eleven 
years after primary resection, were found. P53 was not significantly associated 
with malignant progression. This pilot study indicates that additional CI analysis 
should be considered in resection margins of histopathologically radically 
resected OSCC to minimalize the risk of tumor relapse. This has been recently 
confirmed in an extended study on OSCC resection margins (Pierssens et al. 
2017). 
 
In order to develop a maximum of objectivity in the CI analysis in premalignant 
head and neck lesions, we described in Chapter 7 the definition of objective, 
clinically applicable evaluation criteria for CI detection. We performed dual-
target FISH for chromosomes 1 and 7 centromeres on 4 µm formalin-fixed, 
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paraffin embedded tissue sections of 87 laryngeal premalignancies (severe 
dysplasia and carcinoma in situ (CIS) excluded) to detect CNVs. A set of 
normal head and neck squamous cell samples was used as a control 
population. Two approaches, derived from generally accepted tumor 
diagnostics based on CNV detection, were compared. First, the chromosome 
7:1 ratio (CR), based on the objective count of chromosome signals of both 
chromosomes per nucleus in 100 nuclei was assessed. Second, the 
percentage of aberrant nuclei (PAN), based on the amount of aberrant nuclei 
(containing more than 2 signals per chromosome) in 100 analyzed nuclei, was 
established in each lesion. Based on the CRs found in the control population, 
we defined a normal range of CRs (≥0.84≤1.16), furthermore, the cut-off value 
for abnormal PAN was set at ≥10%. Data were correlated with the clinical 
outcome of patients. Both evaluation methods were reliable for the prediction of 
malignant progression, however, PAN showed the strongest correlation with 
malignant progression especially in combination with dichotomized 
histopathological diagnosis. These evaluation criteria for CI detection based on 
PAN, with a cut-off value of ≥10% aberrant nuclei, are also recommendable 
because of the possibility of a relatively quick, easy to perform assessment of 
lesions. This study provides information for a standardized, clinically applicable 
protocol for FISH-based CI detection in premalignant head and neck lesions.  
 
Chapter 8 comprises the general discussion and the conclusion of the results 
described in this thesis. Future perspectives are discussed. 
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Samenvatting 
Hoofdstuk 1 bevat een algemene introductie in de carcinogenese van hoofd-
hals kanker (HNSCC) en de etiologie, klinische presentatie, histopathologische 
en genetische kenmerken van deze aandoening. HNSCC kenmerkt zich door 
een slechte 5-jaars overleving van circa 50%. Factoren die bijdragen aan deze 
slechte prognose worden toegelicht. Een van de belangrijkste hiervan is de 
frequente aanwezigheid van multiple mucosale laesies die voorstadia van 
HNSCC bevatten (dysplasie), en zich kunnen ontwikkelen tot HNSCC. Het 
belang van vroege detectie van deze potentieel maligne laesies wordt 
toegelicht, alsmede een overzicht van de huidige, meest frequent gebruikte 
detectie methoden hiervoor. Histopathologische beoordeling van weefsel 
coupes uit biopten is tot op heden de gouden standaard voor de analyse van 
premaligne en maligne hoofd-hals laesies. Echter, histopathologische 
beoordeling, waarvoor drie internationaal geaccepteerde classificaties bestaan, 
kenmerkt zich door een hoge variabiliteit in diagnoses indien een coupe door 
verschillende onafhankelijke pathologen wordt beoordeeld (inter-observer 
variabiliteit). Dit resulteert in een onbetrouwbare diagnose met betrekking tot 
het risico op maligne ontaarding en leidt tot onduidelijkheid voor de 
behandelend arts omtrent welke beslissing hij/zij dient te nemen ten aanzien 
van eventuele behandeling of follow-up van de betreffende laesie. De 
noodzaak voor het aan de diagnostiek van premaligne hoofd-hals laesies 
toevoegen van additionele, meer betrouwbare, moleculaire markers wordt 
benoemd. Een belangrijke potentiele marker voor het voorspellen van maligne 
progressie van een laesie is Chromosomale Instabiliteit (CI), welke gebaseerd 
is op de genotypische kenmerken van een laesie, losstaand van fenotypische 
veranderingen. De verschillende methoden om CI aan te tonen, waaronder de 
detectie van veranderingen in kopie aantal (CNV) van de chromosomen 1 en 7 
door middel van Fluorescente In Situ Hydridizatie (FISH), worden belicht, met 
de nadruk op klinische toepasbaarheid. Ten slotte volgt een nadere toelichting 
op de doelen van dit proefschrift. 
 
De inter-observer variabiliteit bij het toepassen van de drie internationaal 
geaccepteerde histopathologische classificatie systemen, te weten de WHO-, 
SIN- en Ljubljana classificatie, wordt in Hoofdstuk 2 geanalyseerd en 
onderling vergeleken in een groep premaligne larynx laesies. Het blijkt dat de 
drie classificatie systemen zich alle kenmerken door een hoge inter-observer 
variabiliteit. Een vereenvoudigende modificatie van deze classificatie systemen 
naar een twee of drie-graads indeling resulteert in een verbetering van de 
overeenkomst tussen de beoordelingen van de verschillende pathologen, 
uitgedrukt in een “redelijke” Kappa-waarde. Daarnaast blijkt dat er meer 
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consensus ten aanzien van de diagnose wordt bereikt indien meerdere 
pathologen tegelijk een weefselcoupe beoordelen. Door het introduceren van 
een histopathologische indeling voor premaligne hoofd-hals laesies, bestaande 
uit twee of drie keuzemogelijkheden, kan de inter-observer variabiliteit worden 
gereduceerd, een positief effect zal hebben op de prognostische informatie 
geleverd door histopathologische beoordeling.   
In Hoofdstuk 3 wordt CI detectie, gebaseerd op de detectie van CNV’s van 
chromosoom 1 en 7 door middel van FISH met behulp van chromosoom 1- en 
7- specifieke centromeer DNA-probes (FISH 1c/7c) op een serie premaligne 
larynxlaesies beschreven. Deze techniek werd reeds eerder toegepast in een 
eerdere pilot-studie op premaligne larynxlaesies door Veltman et al. (2000). De 
betrouwbaarheid van deze potentiële marker in het kader van voorspelling van 
maligne progressie werd retrospectief geanalyseerd. Daarnaast werd 
immunohistochemisch aangetoonde overexpressie van de eiwitten p53, FADD, 
pFADD en Cycline D1 gecorreleerd met eventuele maligne progressie op basis 
van de beschikbare klinische patiëntendata. De laesies waarin CI werd 
gedetecteerd, vertoonden vrijwel alle een verhoogd kopie aantal van 
chromosoom 1 en/of 7 (gain), te weten trisomie, tetrasomie en polysomie. 
Laesies met CI bleken een sterk verhoogde kans te hebben op maligne 
ontaarding. Een opvallende bevinding was dat in alle voorloper stadia, 
variërend van hyperplasie tot ernstige dysplasie, CI werd gedetecteerd, in een 
min of meer oplopende mate, al naar gelang de ernst van de histo-
pathologische diagnose. Geen van de onderzochte eiwit-markers bleek 
significant geassocieerd met maligne progressie in de univariate analyse. Ook 
histopathologie (WHO-classificering) bleek geen significante voorspeller van 
maligne progressie, met name voor de lagere histopathologische 
classificeringen, te weten hyperplasie, geringe en matige dysplasie. De 
prognostische betrouwbaarheid van histopathologie nam toe door een 
gedichotomiseerde indeling toe te passen, bestaande uit twee keuze-
mogelijkheden, waarbij hyperplasie en geringe dysplasie versus matige en 
ernstige dysplasie respectievelijk werden beschouwd als laesies met “laag 
risico” en “hoog risico”. Logistische regressie analyse toonde aan dat de 
combinatie van CI, gedichotomiseerde histopathologische diagnose, p53 en 
FADD samen gebruikt kan worden als een bruikbaar, betrouwbaar model voor 
de voorspelling van maligne progressie in premaligne larynx laesies. De laatste 
twee eiwit-markers dragen positief bij aan de reductie van het aantal fout-
negatieven. 
De waarde van CI bepaling in het kader van het voorspellen van maligne 
progressie in premaligne mondholtelaesies werd onderzocht in Hoofdstuk 4. 
CI detectie vond hier plaats door middel van FISH 1c/7c alsmede door analyse 
van de DNA ploidie status door middel van DNA Image Cytometrie (ICM), 
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waarbij alle ploidie configuraties buiten de normale diploide status werden 
beschouwd als CI. Met beide methoden kon CI worden aangetoond en was 
significant geassocieerd met maligne progressie. Beide methoden toonden 
maligne progressie-kans aan met een vergelijkbare Hazard Ratio (HR), 
hetgeen aanduidt dat beide technieken vergelijkbare prognostische informatie 
leveren. Dit geeft aan dat CI detectie met FISH 1c/7c, waarbij er slechts twee 
chromosomen worden geanalyseerd, een betrouwbare indruk geeft van de 
algemene ploidie status van een laesie. Beide methoden kennen voor- en 
nadelen. FISH 1c/7c kan bijvoorbeeld kleine groepjes celkernen met CI 
detecteren, welke niet zouden leiden tot een afwijkende ploidie status bij ICM 
analyse. Daarnaast is deze techniek geschikt voor kleine weefselbiopten (zoals 
van de larynx) waarbij vaak te weinig materiaal bestaat voor ICM bepaling.   
De prognostische informatie van de histopathologische diagnose bleek niet 
afdoende om te discrimineren tussen progressieve en niet progressieve 
laesies, met name in de WHO classificaties hyperplasie, geringe en matige 
dysplasie. Dichotomisatie, waarbij hyperplasie en geringe dysplasie werden 
gebundeld tot een “laag risico” groep en matige en ernstige dysplasie tot een 
“hoog risico” groep, leidde tot een betere prognostische waarde van 
histopathologie als parameter, uitgedrukt in een significant slechtere ziekte-
vrije overleving voor de laatste groep. Deze uitkomst was vergelijkbaar met de 
bevindingen in premaligne larynx laesies, zoals beschreven in Hoofdstuk 3. 
Vervolgens werden van 12 patiënten verschillende weefselbiopten, afkomstig 
van dezelfde localisatie, door middel van FISH 1c/7c en ICM geanalyseerd, 
met als doel de ploidie status in de voorstadia in de tijd tot aan maligne 
ontaarding te meten. Het bleek dat vrijwel alle aneuploide tumoren aneuploide 
voorlopers hadden en het merendeel van de diploide tumoren diploide 
voorlopers. Tevens werden enkele gevallen gezien waarbij een aneuploide 
status werd gevolgd door een diploide status en vice versa. Ook werd een 
uitzonderlijk lange tijdspanne tot maligne ontaarding van meer dan 9 jaar 
waargenomen in twee gevallen.  
Op basis van de gegevens verkregen door middel van CI detectie (FISH 1c/7c 
en ICM) en histopathologische beoordeling werd een risicoprofiel-indeling 
gemaakt bestaande uit drie categorieën: 1) diploid-laag risico (lage 
ontaardingskans), 2) diploid-hoog risico en  aneuploid-laag risico (intermediaire 
ontaardingskans) en 3) aneuploid-hoog risico (hoge ontaardingskans). Deze 
indeling van premaligne laesies zou de basis kunnen zijn voor een klinische 
indeling met betrekking tot de behandeling van laesies respectievelijk: geen 
follow-up, strikte follow-up en (chirurgische) behandeling.   
 
De prognose van patiënten met HNSCC wordt sterk negatief beïnvloed door 
het wel of niet optreden van een (loco)regionaal recidief door de aanwezigheid 
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van achtergebleven tumorcellen (minimal residual disease) of premaligne 
cellen, die potentieel kunnen uitgroeien tot HNSCC. In dit kader werd in 
Hoofdstuk 5 retrospectief een kleine groep mondholtetumoren geanalyseerd, 
welke histopathologisch radicaal waren gereseceerd. Klinische gegevens met 
betrekking tot tumor recidief werden verzameld. Door middel van FISH 1c/7c 
werd onderzocht of er in de resectievlakken van de betreffende preparaten CI 
aanwezig was en of dit geassocieerd was met later tumor recidief. Daarnaast 
werd door middel van immunohistochemie p53 eiwit overexpressie gemeten in 
de resectievlakken en de associatie met maligne progressie bepaald. CI bleek 
significant geassocieerd met het optreden van tumor recidief. P53 was niet 
significant geassocieerd met tumor recidief. Op basis van deze gegevens en 
naar aanleiding van de bevestiging van deze resultaten in een recent 
gepubliceerde vervolg studie over CI in resectieranden (Pierssens et al. 2017), 
dient CI detectie in resectieranden te worden overwogen.   
 
Hoofdstuk 7 bevat een nadere analyse van de evaluatie criteria voor FISH 
1c/7c in het kader van CI detectie in premaligne hoofd-hals laesies. Deze 
criteria dienen maximaal objectief te zijn en goed klinisch toepasbaar. FISH 
1c/7c werd toegepast op 4 µm formaline-gefixeerde paraffine coupes op een 
groep premaligne larynxlaesies (ernstige dysplasie en carcinoma in situ 
werden geëxcludeerd), met als doel het aantonen van veranderingen in kopie 
aantal van één of beide chromosomen (CNV). Voor het bepalen van CNV’s 
wordt in het algemeen in de diagnostiek van diverse soorten kanker gebruik 
gemaakt van 1) het bepalen van een chromosoom ratio tussen de twee 
chromosomen in een bepaald aantal te beoordelen celkernen, of 2) het 
objectief aantal afwijkende celkernen (die CNVs bevatten voor een of beide 
chromosomen) per vastgesteld aantal celkernen. Hierbij wordt gebruik gemaakt 
van een afkappunt, uitgedrukt in een percentage afwijkende celkernen. 
In de studiepopulatie werd de chromosoom 7: chromosoom 1 ratio (CR) 
berekend op basis van het totaal aantal getelde signalen per 100 celkernen. 
Normaalwaarden voor de CR (≥ 0.84 ≤ 1.16) werden berekend vanuit de CRs 
gevonden in een serie van 25 coupes van normaal plaveiselcelepitheel. 
Vervolgens werd volgens de tweede gangbare methode het percentage 
afwijkende celkernen (geteld per 100 celkernen) vastgesteld per laesie (PAN). 
Het optimale afkappunt werd vastgesteld op ≥10% afwijkende celkernen. De 
uitkomsten werden gecorreleerd met de klinische patiëntendata en de 
associatie met maligne progressie werd berekend. Hieruit bleek met name bij 
het gebruik van PAN een sterke associatie met maligne progressie. CR en 
PAN werden ook gebruikt in combinatie met gedichotomiseerde 
histopathologische diagnose (hyperplasie versus geringe en matige dysplasie 
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samengevoegd) in een multivariate regressie analyse, waarbij de 
betrouwbaarheid van de test toenam.  
Voor de beoordeling van FISH 1c/7c lijkt op basis van deze data PAN de meest 
betrouwbare en minst complexe beoordelingsmethode voor weefselcoupes.  
De gedichotomiseerde histopathologische diagnose in combinatie met PAN 
(met een afkappunt van ≥10%) levert een positieve bijdrage in de zin van een 
toename van de sensitiviteit van de test.  Deze studie is de basis voor verdere 
toekomstige implementatie van CI detectie door middel van FISH 1c/7c in de 
diagnostiek van premaligne hoofd-hals laesies en/ of resectieranden van 
hoofd-halstumoren. 
 
Hoofdstuk 8 bevat de algemene discussie en conclusie van de resultaten van 
dit proefschrift toekomst perspectieven worden besproken.   
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Valorisation addendum 
Early detection of head and neck cancer is of utmost importance for prognosis 
and preservation of function. In an ideal scenario, progressive premalignant 
lesions will be detected before malignant progression has taken place. 
Especially in the field of head and neck cancer, possibilities for early detection 
are given for a number of subsites: e.g. mucosal alterations of the oral cavity 
can be visualized at ENT-examination and mucosal alterations of the vocal 
cords can give early complaints of hoarseness. If mucosal alterations are 
detected, tissue biopsies will guide the clinician in the decision whether 
treatment, i.e. surgical excision or radiation therapy, is necessary. In case of 
malignancy there is no doubt about the need of treatment. However, in case of 
premalignant lesions that harbor a risk of malignant progression to head and 
neck squamous cell carcinoma (HNSCC), decisions are more complex. Until 
now, the risk of malignant progression for different precursor lesions remains 
unclear. Furthermore, histopathological classifications of these lesions are 
variable and greatly observer dependent.  
The same is the case for resection margins of malignant head and neck 
tumors: not only (minimal) residual disease, but also groups of premalignant 
cells in resection margins of tumors can lead to an increased risk of (local) 
recurrence. 
Reliability and clinical value of histopathological diagnosis 
The tissue analysis of mucosal biopsies is generally performed by histo-
pathological assessment. However, the in literature reported malignant 
progression risks for the different grades of dysplasia differ largely1,2 and no 
internationally accepted guidelines exist for the therapeutic management of 
these precursor lesions. 
Therefore, the studies in this thesis have been performed in order to 1) analyze 
the reliability of today’s histopathologic classification systems in terms of inter 
observer concordance and prognostic information concerning malignant 
progression risk and 2) to identify additional markers of malignant progression 
in premalignant laryngeal and oral lesions. Furthermore, markers for tumor 
recurrence in resection margins of oral squamous cell carcinomas were 
investigated.  
Our studies showed that the histopathological assessment of premalignant 
head and neck lesions on the basis of the existing histopathological 
classifications, leads to an inconsistent diagnosis, related to inter-observer 
variability. Furthermore, the WHO classifications hyperplasia, mild and 
moderate dysplasia do not discriminate between progressive and non-
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progressive lesions. An improvement of the reliability can be achieved by the 
introduction of a two-grade scale modification of the used histopathological 
WHO-criteria, i.e. a division of premalignant lesions in “low-grade” (hyperplasia 
and mild dysplasia) and “high-grade” (moderate dysplasia).  
Chromosome instability detection and its additional value 
above the available markers of progression 
While the histopathological diagnosis of a premalignant lesion does not provide 
reliable prognostic information on the malignant potential of a lesion, the 
clinician may have difficulties in the decision-making on the therapeutic 
management of a lesion. Therefore, additional molecular markers for the 
discrimination of progressive lesions are needed to solve this issue. In this 
thesis, we applied chromosome instability (CI) detection as an additional 
marker of progression in premalignant laryngeal and oral head and neck 
lesions. Chromosome Instability detection was performed by Fluorescent in 
Situ Hybridization (FISH) on chromosome 1 and 7 centromere probes. CI was 
defined as the presence of copy number variations (CNVs), e.g. trisomy of 
polysomy of one or both chromosomes. We proved that CI detection can be 
performed by the count of aberrant cell nuclei in 100 nuclei, with a cut-off value 
of ≥10% aberrant nuclei (PAN). This approach improves the objectivity of the 
assessment as compared to histopathological assessment. We combined the 
information provided by the histopathological diagnosis, which was converted 
to a two-degree classification, with CI and immunohistochemically assessed 
protein overexpression of p53 and Fass Associated Death Domain (FADD). 
This lead to a multi-parameter progression model based on the previously 
mentioned markers, which improved the prognostic value compared to the 
routine histopathological assessment. This predictive model could be 
considered as a new tool for clinicians that need a more reliable tool for the 
discrimination of potentially progressive head and neck precursor lesions.  An 
improvement of the counseling and therefore a more appropriate treatment of 
head and neck premalignancies will probably lead to a long-term decrease of 
patients morbidity and mortality, which is in general high in HNSCC.3,4 
Clinical applications of CI detection and additional molecular 
markers 
The main proposed molecular marker of this thesis is chromosomal instability 
(CI), defined as copy CNVs of chromosomes 1 and 7, which can be easily 
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assessed by dual target, centromere probe FISH. The relative low complexity 
of this detection method makes it very attractive for application in the daily 
clinical setting of ENT-surgeons, maxillofacial surgeons and other clinicians 
who encounter patients with potentially malignant head and neck lesions. CI 
detection by FISH can be implemented in a two-day diagnostic procedure and 
provides a quick and reliable diagnosis, especially if combined with a simplified, 
two-degree histopathological assessment scale and additional p53 /FADD 
immunostaining. The application of a quick CI-detection procedure on fresh-
frozen intra operative tissue samples is in development.  
Cost-effectiveness of the suggested new diagnostic model 
CI detection by FISH and immunohistochemistry can be performed with 
relatively low costs especially if compared to other, more complex molecular 
detection methods. 
There are no data available on the total costs related to the diagnostic 
procedure, treatment and follow-up of HNSCC patients. However, it is clear 
that the health-care related costs of a patient who is treated for HNSCC are 
high and often include a surgical procedure, hospitalization of the patient, 
radiation therapy, revalidation, (years of intensive) medical follow-up and 
sometimes specialized supportive extramural health care in case of 
progressive and non-curable disease. Secondary costs related to a short-term 
or long-term decrease of work-productivity should also be taken into account. A 
global comparison of the costs made in our clinic for the surgical treatment of a 
premalignant vs. a malignant oral lesion showed that the costs are 
approximately 10 times higher for the latter (i.e. 1700 euro vs. 17000 euro). 
The implementation of CI detection and immunostainings in the diagnostic 
procedure will lead to a slight increase of the diagnostic costs which, however, 
are non-significant as compared to the amount that can be potentially saved by 
the prevention of the development of HNSCC. However, yet to perform cost-
effectiveness studies could provide more information on this issue. 
Future perspectives- prospective study design 
Today, there is no generally applied diagnostic and treatment protocol for 
premalignant head and neck lesions, except for lesions containing severe 
dysplasia or CIS (based on the WHO classification), which are in general 
treated by radical surgical (laser)excision or radiation therapy5 Based on the 
results of this thesis, future research should focus on the development of a 
standardized, uniform and validated treatment protocol for premalignant head 
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and neck lesions. Currently, we are working on the development of a 
prospective, clinical multi-center study on the diagnostic and therapeutic 
approach of head and neck premalignancies with implementation of CI 
detection. Also patient related parameters such as the quality of life in 
relationship to potential loss of functionality (i.e. voice quality, swallowing) and 
discomfort after a performed surgical treatment as well as the cost-
effectiveness of this new approach of head and neck premalignancies will be 
subject of investigation. This prospective study may finally lead to the definition 
of the optimal moment for (surgical) intervention in head and neck 
premalignancies.  
Last but not least, it would be of great interest to perform further research 
based on the same principles, on other premalignant lesions found in the aero-
digestive tract, for which comparable diagnostic issues do exist. 
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Dankwoord 
Het ei is gelegd! Trots ben ik dat na een jaren durend onderzoekstraject het 
eindresultaat -dit proefschrift- nu een feit is. Wat begon als enkele losse A4-tjes 
met hierop handgeschreven de namen van patiënten die moesten worden 
geïncludeerd is uitgegroeid tot diverse onderzoekslijnen rondom het 
hoofdthema chromosomale instabiliteit in (voorstadia van) hoofd-hals kanker. Ik 
ben trots dat ik aan het begin van dit project heb mogen staan. Mooi is te zien 
hoe in dit kader een steeds nauwere samenwerking is ontstaan tussen de 
basale wetenschap, te weten de Moleculaire Celbiologie met de klinische 
geneeskunde, zijnde de Keel- Neus en Oorheelkunde en in het midden de 
Klinische Pathologie. Geen van deze drie entiteiten kan floreren zonder de 
ander.  
 
In de afgelopen jaren hebben velen bijgedragen aan de voortgang van het 
onderzoek en hiervoor ben ik zeer dankbaar. Enkelen wil ik hierbij in het 
bijzonder danken. 
 
Als eerste wil ik bedanken Professor Kremer. Beste Bernd, jij bent naast mijn 
(tweede) opleider in het MUMC een ontzettend toegewijde, integere en altijd 
enthousiaste persoon. Jouw pragmatische visie op het onderzoek heeft 
bijgedragen tot het tot stand komen van praktische handvatten waarmee dit 
onderzoek een duidelijke klinische relevantie heeft gekregen. Ik denk met veel 
plezier terug aan de vele avonden waarop we, met name in de eindfase van 
het proefschrift, met de nodige gezelligheid en humor bij jou thuis hebben 
doorgewerkt richting de afronding. Ik hoop dat we onze goede samenwerking 
in de toekomst mogen voortzetten.  
 
Professor Speel, beste Ernst-Jan, we hebben er heel wat jaartjes samen 
opzitten! Wat begon op je kamer op de Moleculaire Celbiologie, werd later de 
Pathologie. Je hebt mij de kern van het basaal wetenschappelijk onderzoek 
bijgebracht. Het voelde soms als een detective: het in het donker bekijken van 
de microscopische coupes, waar ik dan iets meende te zien, en jou vervolgens 
enthousiast erbij riep. Je bent een enorme duizendpoot en hebt een overvolle 
agenda, wat onze afspraken soms in de weg stond, maar ik ben je dankbaar 
dat je in deze drukte toch tijd vrij hebt kunnen maken voor het samen schrijven 
aan de papers in dit proefschrift, wat ook altijd weer gezellig was. 
 
Professor Ramaekers, beste Frans, je hebt altijd de afgelopen jaren over mijn 
schouder meegekeken. Ik ben je dankbaar voor je helikopter-visie op het 
onderzoek. Ondanks het feit, dat je je met zoveel andere projecten bezighoudt, 
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kon je feilloos de draad oppakken als je weer eens een definitieve versie onder 
je neus kreeg. Je ziet altijd de rode draad in het verhaal en streeft naar een 
tijdsplanning voor afronding, wat zeker beslissend is geweest voor de 
voortgang van het promotietraject, dank daarvoor! 
 
Professor Manni, beste Hans, mijn eerste opleider Keel-, Neus en 
Oorheelkunde. Via jou ben ik in dit onderzoeksproject gerold. Zonder jouw rol 
als initiator was het er niet geweest. Je bent de “oervader” die aan het begin 
stond van dit onderzoek en had al vele ideeën voordat we er überhaupt aan 
begonnen. Je bent – ook in je werk als Keel-, Neus- Oorarts- en oncoloog- 
altijd hard geweest voor jezelf en een enorme doorzetter: “ook na tegenslagen 
niet opgeven”! Een grondhouding waar ik zeker veel van heb geleerd. Ondanks 
je pensionering bleef je altijd zeer betrokken en geïnteresseerd in het 
onderzoek, wat ik enorm waardeer. 
 
Stijn Fleskens en Theke Siebers, dank voor de prettige samenwerking die heeft 
uitgemond in twee gezamenlijke papers.  
 
Annick en Andrea hartelijk dank voor jullie hulp bij de analyses. 
 
Dr. Chenault, beste Mickey, je hebt mij geweldig geholpen in methodologisch 
en statistisch opzicht. Je heldere kijk op de data in combinatie met veel humor 
zijn zeer waardevol.  
 
Dr. Voogd, beste Adri, je hebt onze eerste FISH studie op larynxlaesies vanaf 
het allereerste begin statistisch begeleid, waarvoor mijn hartelijke dank.  
 
Graag wil ik de leden van de manuscriptcommissie en de corona danken voor 
hun beoordeling en hun aanwezigheid tijdens de verdediging van het 
proefschrift.  
 
De stafleden en assistenten KNO gedurende mijn opleidingstijd in het MUMC.  
We hebben naast een leerzame tijd ook ontzettend veel plezier beleefd samen, 
dank daarvoor!  
 
Kenneth, ik ben je dankbaar voor alle mooie en humorvolle momenten die we 
samen hebben beleefd, onder andere als kamergenoten in het Oxford gebouw. 
Ik ben blij dat je over bent gekomen uit Frankrijk om mijn paranimf te zijn!  
 
Secretaresses van het Oxford gebouw: Edith, Ester, Marèse en Nicole, jullie 
hebben gezorgd voor de noodzakelijke gezelligheid gedurende de vele uren 
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die ik de afgelopen jaren op jullie afdeling heb mogen doorbrengen om het 
proefschrift af te schrijven, waarvoor dank.  
 
Tiny Wouters, dank voor jouw vliegensvlugge afwerken van dit proefschrift 
 
Mijn maten van de huidige maatschap KNO in het Zuyderland MC: dank voor 
jullie vertrouwen, geduld en flexibiliteit de afgelopen jaren. Zonder deze 
factoren was het niet gelukt dit project af te ronden. Jullie zijn mij dierbaar.  
 
Margreet, mijn hardloop-maatje: je relativerende en inspirerende woorden 
tijdens de vele kilometers die we er op hebben zitten met Juulke onze 
(leen)hond zijn goud waard! 
 
Mijn tweelingzus Alina, ondanks de reisafstand zijn we nog steeds net zo close 
als in onze kindertijd. Jouw promotie is al jaren geleden afgerond, waar ik best 
jaloers op ben. Heerlijk dat jij nu mijn paranimf bent. 
 
Mijn lieve ouders, het doet mij verdriet dat jullie niet meer aanwezig kunnen zijn 
om mijn promotie mee te maken. Ik ben jullie intens dankbaar voor alles wat 
jullie mij hebben meegegeven. Doorzettingsvermogen, altijd verdieping zoeken, 
liefde voor cultuur en wetenschap. Ik hoop dat jullie toch vanuit die andere 
wereld meegenieten. 
 
Kochana Rodzino z Polski! Grunt to rodzinka! Bardzo cieszę się, że będziecie 
uczestniczyć w ceremonii obrony mojego doktoratu, serdecznie Wam dziekuję! 
 
Mijn lieve man en kinderen, Hans, Emilia, Josephine en Titus, zonder jullie 
steun, geduld en acceptatie van de offers waarmee dit gepaard is gegaan, was 
het zeker niet gelukt dit werk af te maken. Ik ben er weer voor jullie! 
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